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Abstract 
 
Antimicrobial resistance is a challenge facing the world in the twenty-first century with an 
estimated 10 million deaths by 2050 if no actions are taken. Microbial resistance to drugs is 
a natural consequence when bacteria develop and adapt genetically to face new challenges 
including antibiotics. Currently, this development occurs at a higher rate than drug discovery. 
Hence there is a need for a new generation of antibiotics that kill pathogenic bacteria.  
Nature itself provides inspiration for such new antibiotics. For example, our immune system 
secretes antimicrobial peptides (AMPs), which have been successful agents in killing 
pathogens with no reported bacterial resistance. Compared with conventional antibiotics, 
these peptides are larger and more sophisticated biological molecules, which disturb the 
bacterial membrane, leading to cell lysis.  
It is currently costly to extract AMPs from natural resources to be used for fighting infections. 
Alternatively, synthetic AMPs that mimic natural ones could provide a sustainable cheap 
weapon against such thread. This also provides a unique opportunity to understand the 
structure–function relationships of such molecules to optimise these effective, non-toxic 
antimicrobial properties.  
Our collaborators at National Physical Laboratory have designed and synthesised new 
AMPs from their essential building blocks (amino acids). This thesis describes the use of 
atomic force microscopy (AFM) as a nanoscale imaging technique for characterising and 
imaging membrane poration mechanisms of four new AMP systems.  
Two of these systems are helical peptides, explained in chapter 3. The third system, 
explained chapter 4, is a triskelion with three arms of antimicrobial β-sheet peptide that co-
assemble to form a hollow antimicrobial capsules. The latter has two possible functions: 
gene delivery and bactericidal effects. The fourth system, explained in chapter 5, contains 
two peptide monomers that are designed to co-assemble and form antimicrobial hollow 
capsids, inspired by the natural viral capsids. 
Finally, chapter 6 is a plan for taking these AMPs a step closer to commercialisation, 
including a business plan for one potential application.  
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Chapter 1 
Introduction 
1.1 Antimicrobial Resistance - a Global Challenge 
Antimicrobial resistance is considered one of the global challenges facing the world in the 
twenty first century. The World Health Organization (WHO) has raised this issue as one of 
its main priorities to be worldly discussed and fought. Many governments, institutions and 
organisations are getting more engaged to face this major problem. The issue is that many 
pathogenic microorganisms that used to be killed by the available antibiotics to treat the 
infections, have become resistant [23]. This resistance shows a real possibility for very 
common infections and minor injuries to be a cause of death, which is referred to as an entry 
to a “post-antibiotic era”. In 2012 for instance, it was reported that 480,000 new cases of the 
multidrug-resistant tuberculosis (MDR-TB) have been identified in more than 100 countries 
[24]. The WHO and its worldwide partners have set a surveillance platform to track the 
antimicrobial effectiveness and any potential emergence of resistant microorganisms. The 
report shows that there are seven multi-drug resistant bacterial stains with global concerns 
and they are under a constant surveillance. These strains have been reported in more than 
60 countries in the world [25].  
In fact, microbial resistance to antibiotics is a natural occurrence acquired over time. 
Resistance against every single antibiotic drug, regardless of the drugs’ mechanisms of 
action, was reported very soon after the introduction of these drugs to clinical use [26]. 
Traditional antibiotics are small molecules that inhibit the growth of pathogens by blocking a 
key (bacterial) cellular pathway in order to prevent infections.  The microbial immune system 
develops and adapts genetically to encounter these challenges. The acquisition of this 
resistance has been exacerbated due to the misuse and overuse of antibiotics in humans 
and animals. Some examples are the over-prescribing or the non-completion of the 
necessary prescribed antibiotic dosage for humans, animals or for farming. In addition, low 
hygiene standards contribute to spreading resistance to other bacterial strains and to other 
geographical areas. According the WHO, antimicrobial resistance is now increasing at a 
higher rate than the discovery of antimicrobial drugs. 
The WHO has proposed a plan to tackle and control antimicrobial resistance. This includes 
a reduction of unnecessary prescriptions of antibiotics. It has also set a worldwide 
educational programme to eliminate antibiotics misuse by the lay public. In addition, a 
solution of this problem can be via two main strategies: (1) developing new antimicrobial 
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agents and (2) searching for smart strategies that can restore or preserve the efficacy of 
existing antimicrobial agents. Therefore, the WHO urges governments and responsible 
bodies to stimulate researches to promote antibiotic development.  
There is a considerable responsibility on industry and pharmaceutical companies to invest 
and increase the pace of antibiotic research and discovery. Unfortunately however, 
antimicrobial development is still an unattractive investment [27]. One reason is that the 
antibiotics market is not stable and that alternative, commercially more interesting 
investment opportunities are available [28]. The unstable market of antibiotics, as mentioned 
in chapter 6, is associated with the waves of infections that target particular areas and the 
rapid cure of these infections with no continued treatment required. In contrast, chronic 
diseases and disorders such as hypertension require therapeutic drugs to be used (i.e., 
implying a continued demand) for decades. Furthermore, the nature of the antibiotic 
research, the uncertainty of the life cycle for new drugs, the regulatory issues that limit the 
pace of exploitation, all reduce the commercial attractiveness of the investment in antibiotic 
development [29].  
For this reason, it is believed that the quickest developments of antimicrobial researches will 
be initiated from the academic and small-to-medium size research laboratories [30]. 
Consequently, the WHO has suggested a plan to include new ways for stimulating new 
researches and developments, as we are currently in a race between drug development and 
microbial evolution [24].  
1.2 Bacterial Types and General Structures 
Notwithstanding the threat from the pathogenic bacteria, some bacteria play a very useful 
role in maintaining the health of our planet. According to reported studies, probably only 1% 
of bacterial species are known and their morphologies vary in shape and size [31]. The most 
common two shapes are the rod shape and cocci shape. Mycoplasmais is a bacterium with 
a size near the lower end of the spectrum, with ~ 0.3 µm diameter [32]. On the other hand, 
Oscillatora, which is a photosynthesis bacterium, has a 7 µm width and a ~500 µm length 
[33]. Escherichia coli (E coli) is a rod shape bacterium with a typical width of 0.5 µm and 
length of 2 µm [34]. 
These bacteria are protected by a cell envelope, which is a quite complex multilayer 
structure that protects the organism from the external unpredicted environment. In 1884 
Christian Gram developed a staining method for bacteria [35]. He found that most bacteria 
fall into one of the two categories according to the staining of their envelope, Gram-positive 
or Gram-negative [36].  
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1.2.1   Gram-negative Bacteria 
In Gram-negative bacteria such as E coli, the membrane consists of three main layers; the 
outer membrane (OM), the peptidoglycan cell wall and the cytoplasm inner membrane (IM) 
[37], figure 1.1. The two membranes are separated by an aqueous space which is called 
periplasm [38].  
The Outer Membrane 
The OM in Gram-negative bacteria consists mainly of lipid bilayer like any other biological 
membrane. However, the study shows that phospholipids only construct the lower leaflet of 
the bilayer, while upper leaflet is composed of glycolipids, principally lipopolysaccharide 
(LPS) [39] figure 1.1. The phospholipids making the lower leaflet of the OM are mainly 
phosphatidyl ethanolamine (PE) and phosphatidyl glycerol (PG). 
At physiological conditions, PE is neutral while PG is anionic (i.e., negatively charged at 
neutral pH). Additionally, LPS is excessively anionic at neutral pH comparing with 
phospholipids because of the exposed phosphoryl and carboxyl groups, which can readily 
be ionised [40]. 
This causes the overall charge of the OM in the gram-negative bacteria to be negative. In 
addition, the OM includes enzymes [41] and other proteins that are broadly classified into 
two categories, lipoproteins and β-barrel proteins, figure 1.1.  
LPS plays a vital role in the OM as a functional barrier. It has been reported that LPS 
molecules bind each other avidly and tightly due to the large saturation of the acyl chains. 
The OM in the Gram-negative bacteria forms an effective and selective permeability barrier 
[42]. This is due to the role of the tightly packed LPS as a barrier for the hydrophobic 
molecules, coupled with the fact that proteins limit the diffusion of hydrophilic molecules 
larger than about 700 Dalton.  
The Periplasm and Peptidoglycan Layer 
Just underneath the OM, in the periplasm, there is a thin layer of one or two sheets thick 
called peptidoglycan. This peptidoglycan is composed of repeating units of the disaccharide 
N-acetyl glucosamine-N-actyl muramic acid cross-linked by pentapeptide side chains figure 
1.1 [43] . Because of it rigidity, peptidoglycan has role in maintaining the cell shape. Overall, 
the periplasm has a higher viscosity than the cytoplasm [44], and it has a role in hiding away 
any potential harmful degradative enzymes from reaching the IM. 
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The Inner Membrane 
Phospholipids also constitute both leaflets of the IM in Gram-negative bacteria. Similar to 
the OM, the two main phospholipids making the IM In E.coli are PE and PG figure 1.3. 
Lipopolys-
accharides 
OM 
Periplasm 
IM 
Peptido-
glycan 
 
Figure 1.1: Diagram showing the structure of a Gram-negative bacterium with a 
magnified area on its cell wall. The magnified cell wall diagram highlights the main 
parts and components which are the outer membrane (OM), the periplasmic space, 
the inner membrane (IM), the lipopolysaccharides, and the peptidoglycan. Note that 
the yellow balls on the upper leaflet of the OM are either the phospholipids 
headgroups or the saccharide rings as parts of the lipopolysaccharides. Image was 
adapted from Wikipedia (author: Jeff Dahl). 
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The composition of these two phospholipid types can respectively vary in the mass ratio 
(PE:PG) from 1:1 to 4:1 [45].  
Bacterial cells lack many of the intracellular organelles that are present in eukaryotic cells. 
For this reason, membrane-associated functions in bacterial cells are performed in the IM. 
For example, membrane proteins that function in energy production, lipid biosynthesis, 
protein secretion, and transport are located in the IM [36]. 
1.2.2   Gram-positive Bacteria 
Gram-positive bacteria differ from the Gram-negative by some key aspects. First and 
foremost, the cell envelope of Gram-positive bacteria only contains a single lipid bilayer. In 
addition, these bacteria protect themselves from the surrounding environment by a layer of 
peptidoglycan that is thicker than that found in the periplasmic space of Gram-negative 
bacteria figure1.2. However, the contents of the peptidoglycan layer in the Gram-positive 
bacteria B. subtilis, for example, is very similar to that found in E.coli [46].  
Furthermore, there are long anionic polymers, called teichoic acids penetrating through 
these layers of peptidoglycan, figure 1.2. These are repeats of glycerol phosphate, glucosyl 
phosphate, or ribitol phosphate [47]. These anionic polymers give the overall anionic charge 
of the Gram-positive bacterial surface. Finally, the surfaces of Gram-positive 
microorganisms are decorated with a variety of proteins, some of which are analogous to 
proteins found in the periplasm of Gram-negative bacteria [48]. 
The cytoplasmic membrane in the Gram-positive bacteria is also a bilayer, with both leaflets 
formed mainly by phospholipids [49]. However, here the major phospholipids are 
phosphatidyl glycerol (PG) and cardiolipin (CL), the headgoups of which are anionic, giving 
an overall negatively charge to the membrane, figure1.3 [50, 51].    
 
1.2.3   Pathogenic Bacteria 
Pathogenic bacteria are highly adapted microorganisms that cause disease. This is due to 
their ability to survive, multiplicate and colonise host cells or tissues. Pathogenicity can be 
attributed to common factors, namely the entry, the finding a niche and the avoiding of host 
defence mechanisms [52]. For the entry, there is a belief that it is a matter of probability for 
pathogenic bacteria to enter the host, over which it has a little control. 
Successful pathogen must find a suitable niche and multiply or at least survive there. There 
are many mechanisms employed by the bacteria for different environments and host 
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surfaces [53]. Host defence mechanisms are considered the most difficult for the pathogen 
to overcome. These mechanisms employ natural immune responses by the hosts to 
encounter any dangerous microorganism trying to invade or localise [54]. 
 
Pathogenic bacteria therefore possess a counterstrategy for these responses to avoid, 
disrupt or reverse these protective secreted agents. The longer the bacteria can protect itself 
to reach their niche and multiply, the more probable they are to succeed in multiplying and 
ultimately causing the disease. Some of the best known mechanisms for countering the host 
defences are antiphagocytic capsules, toxins that target host immune cells [52], and the 
synthesis of immunoglobulin-specific proteases [53]. 
Lipoteichoic 
Acid 
Peptidoglycan 
Cytoplasmic 
membrane 
Teichoic acid 
Wall-associated 
protein 
Periplasm 
Figure 1.2: Diagram showing the structure of a Gram-positive bacterium with its cell 
wall magnified. The main parts and components of the cell wall are the peptidoglycan 
layer, the periplasmic space, the cytoplasmic membrane, lipoteichoic acids, teichoic 
acids and wall-associated proteins. Image reproduced from Pearson Education, Inc. 
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DLPG 
DLPE 
Figure 1.3: The chemical structure of the neutral and anionic phospholipids. 
DLPE and DLPC are neutral while DLPG and CL are anionic. Structures were 
taken from lipids catalogues of Avanti® Polar Lipids, Inc. 
CL 
DLPC 
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1.3 Antibiotics Targets and Mechanisms of Bacterial Resistance 
In 1904, Paul Ehrlich started a screening program to find a drug against syphilis, which was 
a widespread and almost incurable disease at that time.  
The disease is caused by a bacterium called Treponema pallidium. In 1910, Ehrlich 
successfully discovered an effective drug to treat syphilis, called Salvarsan. Antibiotic 
discoveries then carried on with Josef Klarer and Fritz Mietzsch synthesising Prontosil in 
1930s, followed by Penicillin in 1940s [55]. 
The discovery of these first three effective antimicrobials, Salvarsan, Prontosil and Penicillin, 
inspired for further discoveries of antibiotics between the 1950s and 1970s. However, no 
new classes of antibiotics have been discovered since then [55]. 
Generally, antibacterial therapeutics act upon bacteria by targeting a process that is 
essential for the bacterial cells survival or the growing cycle. Based on the effect on these 
functions, antibiotics can either kill bacteria (bactericidal drugs) or inhibit its growth 
(bacteriostatic drugs). 
Figure 1.4: Mechanistic modes of action for antibiotics in bacterial cells. 
(A) Disruption of cell membrane. (B) Inhibition of DNA synthesis. (C) 
Blocking of RNA synthesis. (D) Inhibition of enzymes necessary for 
linking of structural proteins in the cell wall. (E) Inhibition of ribosomal 
function and protein synthesis. (F) Blocking of chaperone proteins 
necessary for proper folding of proteins. (G) Targeting of mitochondria. 
Figure was reproduced from reference [14].  
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Most of the current bactericidal antimicrobials work by inhibiting DNA, RNA, cell wall or 
protein synthesis which are necessary for the bacterial cell life cycle [56]. In addition, peptide 
based antibiotics such as polypeptides or lipopeptides target the cell membrane leading the 
cell lysis [57]. Figure 1.4 summarises these antimicrobial targets within the bacterial cells. 
In addition, a list of the common classes of available antibiotics and their mode of actions 
are summarised in table 1.1 [58].  
Bacteria are living and genetically dynamic organisms that have the ability to overcome new 
challenges caused by antibiotic treatment. In fact, resistant bacterial stains were found even 
before the antibiotics era, when heavy metals were used to treat infections [59]. Figure 1.5 
shows a proposed resistance mechanisms employed by a Gram-negative bacterium to 
protect itself from antimicrobial attacks [6]. Whether the antimicrobial target is on the 
bacterial membrane or in the cytoplasm, bacteria have developed ways to deactivate such 
threats. For example, bacteria can change the composition of their membranes to make 
them more rigid or impermeable [60]. 
In addition, bacteria can develop a multidrug resistance efflux pumps. These pumps secrete 
antibiotics from the cell, figure 1.5b. For antibiotics that target organelles in the cytoplasmic, 
bacteria can make resistant mutations of the targeted receptors, which deactivate the 
antibiotic, figure 1.5c. Finally, bacteria can disable antibiotics by covalent modification to 
lose their active sites, figure 1.5d.   
What exacerbates the bacterial resistance challenge is that these resistance genes are 
found to be horizontally transferable. This means that these genes can mobilise in between 
bacteria of the same or different species [61]. 
1.4 Alternatives to Traditional Antibiotics 
It is clear that, with the rise of bacterial resistance, long-term alternative therapies to combat 
antibiotic-resistant bacteria are needed. These alternatives could be defined as non-
compound approaches (products other than classic antibacterial agents) that target bacteria. 
There has been progress in developing approaches like antibodies, probiotics, and 
vaccines, which are currently in phases 2&3 clinical trials [62]. In addition, antimicrobial 
peptides (AMPs) which are also termed “host defence peptides” hold a great promise to 
counter the resistant bacteria. AMPs are produced by every living organism [63] and 
considered important natural defence strategy against invading pathogens [64, 65]. 
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Antibacterial classes Mode of action 
Penicillins, cephalosporins, 
carbapenems, monobactems, 
glycopeptides, polypeptides 
Cell-wall construction inhibitors of 
peptidoglycan synthesis or cross-linking 
functions, resulting in osmotic lysis 
Lipopeptides, polypeptides Cell-membrane disrupters altering the 
structure and function of the cell membrane, 
thus causing cellular leakage. 
Aminoglycosides, 
tetracyclines 
Protein synthesis inhibitors binding to the 
30S ribosomal subunit, thus preventing 
translation initiation and tRNA binding 
Macrolides, oxazolidinones, 
streptogramins, phenicols 
Protein synthesis inhibitors binding to the 
50S ribosomal subunit, thus disrupting 
translocation and peptidyl transferase activity 
Rifampin RNA synthesis inhibitors preventing the 
synthesis of mRNA by binding to DNA-
directed RNA polymerase 
Quinolones DNA synthesis inhibitors preventing DNA 
replication by binding to the topoisomerase IV 
or DNA gyrase 
Trimethoprim Folic acid metabolism inhibitors preventing 
the synthesis of nucleotide bases by blocking 
the synthesis of tetrahydrafolate 
Sulfonamides Folic acid metabolism inhibitors inhibiting 
nucleic acids synthesis by preventing the 
synthesis of folate 
            Table 1.1: Antibiotics classes and their modes of action [58] 
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1.5   Antimicrobial Peptides 
In 1980, two cationic AMPs, cecropin A and B, were isolated and identified in hemolymph of 
silk moths. They were considered as the moths’ primary weapons of defence against 
pathogens. Over the last three decades, researchers have identified more than 2000 AMPs 
from animals, fungi, plants and bacteria [66]. 
Although these AMPs share a number of common features and a limited number of structural 
motifs, their sequences, activities, and targets differ considerably. In general, natural AMPs 
are ribosomally expressed and typically range from 12 to 50 amino acid residues [67]. They 
are often produced as an inactive form that can next be converted into an active antibacterial 
form [67]. While the majority of these peptides are characterised as cationic or amphipathic, 
Figure 1.5: proposed mechanisms employed by bacteria to resist 
antibiotics. (a) Impermeable barriers. (b) Multidrug resistance 
efflux pumps. (c) Resistance mutations. (d) Inactivation of the 
antibiotic. Figure was reproduced from reference [6].  
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anionic peptides were also reported with a considerable antimicrobial activity under specific 
conditions [68].  
All AMPs have an abundance of the cationic amino acids such as arginine (R) and lysine 
(K) [69]. These residues are responsible for the net positive charge on these molecules at 
neutral pH [70]. In addition, AMPs usually contain a high proportion (up to 50 % or more) of 
hydrophobic amino acids [71]. These two features (positivity and hydrophobicity) direct 
AMPs to fold into amphipathic secondary structures upon interaction with bacterial 
membranes. Their folded structures are characterised by the segregation of the hydrophobic 
residues into one face of the molecule and the cationic and polar ones into the opposite face 
[72]. 
AMPs are typically unstructured in aqueous solution, but they adopt the intended secondary 
structure when interacting with bacterial cell membranes or their mimetic [72]. As shown in 
figure 1.6, typical secondary structures of AMPs could be α-helical, β-sheet, extended and 
looped structures [4]. 
The adopted secondary structure of AMPs can be investigated by various techniques. The 
most frequently employed are circular dichroism (CD) [73], oriented circular dichroism 
(OCD) [74], linear dichroism (LD) [75] and solution state NMR [76, 77].  
 
 
A C 
B D 
Figure 1.6: Structural classes of antimicrobial peptides: (A) β-
sheet, tachyplesin I. (B) α-helical, magainin 2. (C) Extended, 
indolicidin. (D) Loop, thanatin [56]. Disulfide bonds are indicated in 
yellow. Figure reproduced from reference [4] 
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AMPs have been reported act in numerous, different ways, implying that there is no common 
mechanism for all AMPs. A common feature, however, is that cationic AMPs are 
electrostatically attracted to the anionic LPS and lipoteichoic acids found on the surface of 
Gram-negative and Gram-positive bacteria, respectively. Such interactions are considered 
the first contact which could lead AMPs to pass through this external cell walls and to reach 
the cytoplasmic membrane. Once AMPs pass though the external cell wall, they 
preferentially interact with the anionic phospholipids that form the cytoplasmic membrane, 
such as phosphatidylglycerol and cardiolipin [78]. 
When AMPs reach the bacterial cytoplasmic membrane, and due to their amphipathic 
structures, they are able to insert and disrupt the membrane via different mechanisms, as 
shown in figure 1.7. The common models describing such mechanisms are the “barrel-stave 
model” [79], the “toroidal-pore model” [79], the “aggregate model” [80] and the “carpet 
model” [81].  
Toroidal and barrel-stave for example, are both pores forming models as shown in figure 
1.7. The toroidal model differs from the barrel-stave model in that the peptides are always 
associated with the lipid headgroups even when they are perpendicularly inserted in the lipid 
Figure 1.7: Events occurring at the bacterial cytoplasmic membrane 
following initial antimicrobial peptide (AMP) adsorption. Figure 
reproduced from reference [11] 
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bilayer. In forming such a pore via the toroidal model, the lipid monolayer bends continuously 
from the top to the bottom in the fashion of a toroidal hole. This makes the pore lined by both 
the peptides and the lipid headgroups. 
Although AMPs commonly interact with and damage the bacterial external wall and 
cytoplasmic membranes of bacteria, it is yet not fully clarified how these interactions lead to 
bacterial cell death. Recently, there has been speculation that transmembrane pore 
formation is not the only mechanism of microbial killing. In fact, several observations suggest 
that translocated peptides can alter cytoplasmic membrane formation, inhibit cell-wall 
synthesis, inhibit nucleic-acid synthesis, inhibit protein synthesis or inhibit enzymatic activity 
[82-84]. In this context, it is worthwhile to note that, in bacteria, these activities take place 
on the membrane, as discussed earlier.  
The diversity in membrane disrupting mechanisms and intracellular targets causes AMPs to 
be a rather generic threat for bacteria, not relying on too specific interactions that would 
facilitate evasion by few mutations [85]. For this reason, AMPs are considered to be 
excellent candidates for further development as a new class of antimicrobials to combat the 
emerging threat of multidrug-resistant bacteria [86]. 
1.7   Engineered and Synthesised Antimicrobial Peptides  
Early studies of AMPs relied on the extraction and purification of peptides from natural 
sources, and then testing their antibacterial activity. The drawback of this approach is that it 
requires a large amount of raw biological sample to obtain modest quantities of peptides 
[87]. In addition, natural AMPs are usually translated as larger proteins which then are 
cleaved to  produce the peptide in its active form [88, 89]. This post-translational process in 
secreting the natural AMPs makes it very challenging and costly to purify from natural 
sources as the desired peptide may not be present in a unique and/or active form. 
Fortunately, chemical synthesis of peptides has quickly become an alternative method for 
obtaining AMPs at high purity and yield. As will be explained in chapter 2, solid-phase 
peptide synthesis (SPPS) is now widely employed to produce large quantities of peptide 
[90].  
Since the antimicrobial action of these peptides is directly associated with its amino acid 
sequence, the effectiveness of synthetic peptides should be identical to the natural ones 
when the sequence is the same. In fact, this chemical synthesis enables the production at 
reasonable price. 
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In addition, chemically synthesised peptides have many additional advantages. Since the 
synthesis occurs gradually by sequentially adding amino acids to the growing peptide chain 
(as explained in chapter 2), the method allows researchers to precisely modify AMP 
sequences. Such modifications can lead to AMPs with modified antibacterial activity and 
more importantly, they help in investigating the structure-activity relationships that may guide 
the development of more potent antibiotics. 
Such modifications are not limited to the use of the 20 naturally occurring amino acids; non-
natural amino acids can also be added into the AMP sequence to improve the activity and 
stability. Furthermore, it is possible to include synthetic peptidomimics such as sequences 
consisting of β-amino acids [91] or D-forms of AMPs [92]. These peptidomimics retain the 
intended antimicrobial activity of the parent AMP molecule with additional imperviousness 
to proteolytic degradation by enzymes [93]. 
Over the last two decades, there has been significant progress in engineering and designing 
nanostructured materials with a clear potential for commercialisation [94]. Self-assembling 
peptides provide flexible solutions to devise such materials with programmed biological 
functions [95]. One function, beside antimicrobial action, could be gene and drug delivery as 
a promising solution to counter diseases and promote the longevity of human life [96]. 
Scientists revealed the possibility to program two functions such as gene delivery and 
bactericidal activity within one finely devised nanostructure [2]. 
1.8   Atomic Force Microscopy for Studying AMPs Mechanisms 
As mentioned above, there are a number of tools to characterise the modes of action of 
AMPs. In that context (and in the context of this thesis), a particularly interesting 
characterisation tool is atomic force microscopy (AFM), as it can visualise the effect of AMPs 
on the  bacterial or model membranes with ~1 nm spatial resolution. Compared to other 
imaging techniques, it also has the advantage of being able to image the biological samples 
in liquid, i.e. in similar conditions to their native environments, facilitating the study of AMPs 
in action. 
1.8.1   Imaging AMPs and their Effects on Bacterial Cells by AFM 
To date, AFM investigations of AMPs effect on bacterial cells have largely been conducted 
in air [10, 16, 97, 98]. The AFM images in such studies revealed changes in bacterial cell 
height and surface roughness upon incubation with AMPs. Figure 1.8 shows an example of 
a study conducted to investigate the effect of AMPs called Sushi peptides (S3) on P. 
aeruginosa bacterial cells [10].  In this study, different samples were prepared by mixing the 
cells with the S3 AMP at different concentrations or incubation times.  
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Figure 1.8: AFM images in air of P. aeruginosa bacterial cells treated with 
S3 AMP. (A) Image of untreated bacteria. (B) Indentations and outer 
membrane debris of P. aeruginosa treated with 0.25 μM of S3 for 15 min. 
(C) Small amount of leakage of periplasmic fluid of P. aeruginosa treated 
with 0.25 μM of S3 for 30 min. (D) Extensive leakage of cytoplasmic fluid 
of P. aeruginosa when exposed to 5 μM of S3 for 1 min. Figure 
reproduced from reference[10]. 
Figure 1.9: Time dependence of AMP effects on E. coli imaged by AFM. A–I, 
three-dimensional orthogonal projection images (derived from the height data) 
of untreated E. coli cells (top row), and E. coli cells treated with 3 μM BP100 
(middle row), and 5 μM pepR (bottom row). Images were acquired following the 
treatment of the bacterial cells for 0.5 h (first column), 2 h (second column), and 
5 h (third column). Total scanning area for each image: 4 × 4 μm. Figure 
reproduced from reference [16] 
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Next, bacterial cells were dried on the substrate to be imaged by AFM. In another study, 
shown in figure 1.9, an investigation of the effect of two AMPs (BP100 and pepR) was 
conducted on E. coli bacterial cells. Although the AFM images in both studies have revealed 
defects in the bacteria membranes and changes in the cells morphologies as the results of 
AMPs exposure, they only provided limited insight into AMP mechanisms. This is because 
sample drying can also affect the morphology of the bacterial cells and because in air AFM 
does not allow to track the effect of the AMPs while they attack the bacteria. 
AFM has also been used to image bacterial cells in liquid [13, 99, 100]. Provided that such 
imaging is done as sufficient spatial and temporal resolution, this may answer many 
questions about the effect and mechanisms of AMPs and other antibacterial agents. 
However, high resolution in liquid AFM of bacterial cells is challenging. This is due to the 
difficulty in immobilising live bacteria on the AFM substrate, due to the large variation in 
morphology of the bacterial cell and due to the risk of contamination of the AFM tip during 
the imaging process or artefactual differences in bacterial height due to differences in the 
adhesion forces between the AFM tip and the bacterial surface [101].  
Several methods have been used to immobilise and fix bacterial cells for imaging in liquid 
[102]. These include using glutaraldehyde, formalin, paraformaldehyde, methanol/acetone 
(1:1) and ethanol/acetic acid (3:1). It was reported that these agents can effectively preserve 
the bacterial cell morphology but they  are also likely  to change the cell wall structure [102]. 
As explained in section 1.2.1, the outer membrane of Gram-negative bacterial cells is an 
asymmetric bilayer composed of two leaflets. The inner leaflet is formed by phospholipids 
and the outer leaflet mainly by LPS which is the first target for antimicrobial agents. It was 
reported that the LPS layer can form phase separations as it exists in liquid-expanded (LE) 
and liquid-condensed (LC) domains.  
Figure 1.10 shows time-lapse AFM imaging of P. aeruginosa in liquid to monitor the 
morphology change as a result of incubation with the antimicrobial aminoglycoside agent 
(neamine) [13]. The cell’s height was reduced 50% over the course of experiment (35 min), 
shown in the lower panel of figure 1.10. However, the spatial resolution was insufficient to 
reveal information about the membrane disruption mechanism.  
In 2010, Fantner et al. used high-speed AFM imaging to study the kinetics of cell death of 
individual E. coli bacterial cell after the exposure to the pore-forming and membrane-
disrupting AMP CM15 figure 1.11 [12]. 
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Figure 1.10: In liquid AFM imaging of single P. aeruginosa cell following 
incubation with 3′,4′,6-tri-2NM neamine at 0.5-fold MIC. Deflection 
images (3 μm × 3 μm) recorded in real time for a single cell prior and 
after treatment is shown. The lower panel compares vertical cross-
sections.Figure was reproduced from reference [13] 
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The images show the gradual change in the bacterial membrane from smooth to corrugated. 
Their results suggested that the process of E. coli cell death is a combination of an 
incubation phase (taking seconds to minutes) and a more rapid execution phase. This 
mechanistic information is unattainable in traditional AFM imaging studies and is an exciting 
new approach to the study of AMPs. However, the spatial resolution again was not high 
enough to demonstrate details about the pores formed by the peptide such as the depth and 
whether they are static or expanded literally over time. 
Recently on the other hand, Alice Pyne et al. acquired a better resolution imaging of live 
bacteria incubated with an AMP (tilamin) [22]. Figure1.12 shows time-lapse AFM images 
over ~ 10 min on E. coli bacterial surface when incubated with tilamin. The AFM images 
indicate local removal of the bacterial outer membrane over larger areas, and suggest the 
presence of few-nanometre diameter holes with 2 nm depth, consistent with poration of the 
upper leaflet of the lipid bilayer in each membrane [22]. 
 
Figure 1.11: AFM imaging of E.coli incubated with CM15 antimicrobial peptide. 
CM15 injected at t = −6 s and images recorded every 13 s, with a resolution of 
1,024 × 256 pixels and a rate of 20 lines s
−1
. The surface of the upper bacterium 
(1) starts changing within 13 s. The lower bacterium (2) resists changing for 
78 s.  Images were recorded in liquid in tapping mode with a tapping frequency 
of 110 kHz. Phase images are shown here for high contrast. Figure was 
reproduced from reference [12].  
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The results were consistent with the effect of the same peptide on a supported lipid bilayers 
(bacterial model membrane) as will be explained in chapter 3.  Taken together with data 
obtained by other techniques, the AFM images indicated a poration mechanism in which 
helical peptides adopt a tilted orientation within the membrane [22].  
 
 
Figure 1.12: AFM imaging of progressive membrane removal in live bacteria 
incubated with tilamin AMP. (A) Topographic (height) and phase AFM 
images of live E. coli in water taken during the first 780 s of incubation with 
tilamin. Inset in height image: a height profile taken along the black dotted 
line on the back of the bacterium, showing 8 nm-deep steps from the outer 
cell-wall layer to the inner membrane. (B) High resolution topographic and 
phase images of the areas marked by white boxes in (A). (C) Height profiles 
taken along the highlighted lines in (B) (top), and after additional local 
background subtraction (bottom). These data show the depth profiles of 
individual pores. (D) High resolution phase images of E. coli during 
incubation with tilamin, as a function of time. Two different areas are shown. 
Time-point labels indicate time since injection. Colour scale for height data, 
see (A) 140 nm (A) and 19 nm (B). Incubation conditions: 3.5 μM, pH 7.4, 
room temperature. Figure reproduced from reference [22]. 
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1.8.2    AFM Imaging of AMPs on Bacterial Model Membranes  
As mentioned above, it is challenging to acquire high resolution AFM images in liquid on 
bacteria, and due to the complex composition of the bacterial cell wall, the interpretation of 
such images can be non-trivial. Hence model membranes can be useful alternative 
experimental systems, the composition of which can be tuned to mimic membranes of  
prokaryotic cells (such as bacterial cells) and eukaryotic cells (such as human cells).  
The ideal mimetic membrane would have the same compositions of the material making up 
the real one. In addition, the location of these components within the membrane has to be 
the same as in the real one. In fact, scientists are still far from reaching this level of similarity 
in mimicking natural cell membranes. The challenge is mainly in characterising, synthesising 
and inserting the structurally complicated natural components of the membrane such as the 
membrane proteins and lipids, and controlling their precise position within the artificial 
membrane.  
Such model membranes are often reconstituted from lipids alone. However, for example, it 
was mentioned before that LPS is the major component of the outer leaflet of the OM in 
gram-negative bacteria. To form a more realistic reconstituted bacterial membrane, 
membranes have also been formed by bacterial phospholipids (BPL) and LPS with a 
proportion (1:1) and (1:2) respectively [103]. The AFM images of such membranes, shown 
in figure 1.13, present the resulted membranes with phase separation, roughness and non-
flat bilayer surfaces at two different temperatures 20 Co and 40 Co. Here, the height 
difference across the bilayer is due to the thickness difference between the two formed 
separated bilayers (LPS and BPL).  The two temperatures 20 Co and 40 Co were chosen as 
LPS is either in gel or fluid phase respectively while BPL is in liquid crystalline phase in both 
temperatures [103]. At present, it is unclear how well these more complex model membranes 
represent the properties of bacterial membranes. In addition, natural bacterial membranes 
are asymmetric having LPS only on the outer leaflet, which further complicates the 
preparation of suitable biomimetics. On the other hand, lipid-only model membranes are 
readily prepared and have become very common model systems to at least represent lipid-
related properties of bacterial (and eukaryotic) membranes. 
Natural phospholipid extracts are now commercially available. For example, E .coli natural 
polar lipids extracts are available from Avanti® which are produced as a harvest from 
bacteria at specified growing phase. The datasheet specifies the lipids composition of this 
natural extract as PE 67%, PG 23.2%, CL 9.8% [104, 105]. This extract includes only the 
natural phospholipids making E. coli membranes and not the other contents like LPS or the 
membrane proteins. 
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Gram-positive natural lipid extracts are also available commercially. For example, B. subtilis 
extract contains PE, PG, CL, lysyl-PG in addition to neutral lipids (mostly diacylglycerol) 
[106-109]. One resource specify the percentages of these as 30%, 35.7%, 12.1%, 22.1% 
respectively [108].  
These percentages of phospholipids contents, however, can change with bacterial growth 
phase and conditions. For example, it was reported that CL levels rise, at the expense of 
PG when cells enter the stationary phase [110]. 
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Figure 1.13: AFM images of Rd LPS/BPL supported membranes. 
(A) 1:1 Rd LPS/BPL* and (B) 2:1 Rd LPS/BPL formed on PEI-
coated mica scanned in water at 20°C. (C) 1:1 Rd LPS/BPL and (D) 
2:1 Rd LPS/BPL bilayers formed on PEI-coated mica, scanned in 
water at 40°C. The cross section profiles shows a non flat bilayer 
Image size, 2 μm2; z-scale, 20 nm.* BPL= Bacterial Phospholipids. 
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Nevertheless, collective studies confirm that PE and PG are the two major phospholipids 
making up the membranes for both Gram-positive (B. subtilis) and Gram-negative (E.coli) 
bacteria [106-110] . 
PC and PE headgroups are chemically very similar with choline instead of ethanolamine 
group (methyl groups instead of hydrogen in the amine group) as shown in figure 1.3. They 
both are the major phospholipids making up the membranes of the eukaryotic cells including 
human cells [111]. Because both PE and PC are neutral phospholipids, they are not the first 
target of the cationic AMPs. This would in principle allow researchers to use both of them to 
represent the neutral content of the bacterial phospholipids. 
However, the function of the membrane is not only related to the chemistry of the 
phospholipids headgroup, but also to the length and type of the hydrocarbon chain making 
up the hydrophobic tail of the phospholipid. There are many types of phospholipids tails in 
nature. They are identified by the number of the carbon atoms and the unsaturation (double 
bonds) within the chain.  For example, a PC headgroup with saturated hydrocarbon tail of 
12 carbon atoms is 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC) while 14 carbon 
atoms is 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 16 carbon atoms is 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 18 carbon atoms is 1,2-distearoyl-sn-
glycero-3-phosphocholine (DSPC). In addition, unsaturated hydrocarbon chains are 
common in nature. For example, 18 carbon atoms with one (cis) double bond is 1,2-dioleoyl-
sn-glycero-3-phosphocholine (DOPC).  
Many researchers have used different lipid composition to mimic bacterial membranes. For 
instance, Balhara et al, compared the interaction of a 13 amino acids AMP (GL13K) with 
liposomes and supported lipid bilayers (SLBs) of DOPC and DOPG lipids as models for 
eukaryotic and bacterial membranes, respectively [112]. 
Lopes et al, on the other hand, characterised and compared two bacterial model 
membranes; POPE/POPG with the mass ratio of 0.6:0.4 and POPE:POPG:CL with the mass 
ratio of 0.67:0.23:0.1 respectively. They found that this later system is closer to the E. coli 
natural extracts in thermotropic terms which explain the phase transitions when changing 
the temperature. Cardiolipin (CL) has been shown to have a strong influence on membrane 
organization which in turn affects protein–lipid interactions [113]. AFM images of both 
systems revealed that the bilayer thickness was reduced by 0.8 nm due to the addition of 
CL lipid. 
Finally, Ryan et al and Jascindra et al, among others have used a vesicles mixture of 
DLPC:DLPG 3:1 mass ratio to study the interactions with different types of AMPs [114, 115]. 
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In this thesis, we have followed the latter work in using DLPC:DLPG 3:1 mass ratio as a 
bacterial model membrane. The PG gives the overall anionic charge expected in the 
bacterial membranes. PC was chosen for consistency with all other experiments performed 
on the same AMPs by our collaborators at NPL. Supported lipid bilayers of this composition 
were prepared as described in chapter 2.   
In chapter 3 of this thesis, two synthetic helical AMPs were studied as they attack the 
bacterial model membranes. The results demonstrated that a small change in the amino 
acid sequence induced a change in the mechanism of membrane degradation, leading to 
better understanding of the structure-function relationship for AMPs. In chapter 4, a de novo 
triskelion with three arms of antimicrobial β-sheet peptide motifs is characterised. The design 
was meant to co-assemble to form hollow antimicrobial capsules that can be used as 
antimicrobials as well as for intracellular gene delivery. Time lapse AFM imaging was used 
to monitor the attack of these capsules on the bacterial model membrane.  In chapter 5, 
another de novo antimicrobial capsid system was studied. The design was inspired from the 
viral capsids and modified to have antimicrobial properties. AFM images revealed the 
poration kinetics and characterisation. Finally, chapter 6 is an overview of a possible 
commercialisation plan for of such materials (in line with departmental guidelines for PhD 
theses) with a business plan for antimicrobial wound dressing as a possible application.  
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Chapter 2 
Materials and Methods 
This chapter is divided into three main parts. The first part is describing the methods used 
for preparing the antimicrobial peptides studied in this research. The second part is 
describing the preparation of supported lipid bilayers (SLBs) as well as other sample 
preparation techniques for AFM. Finally, the third part describes AFM itself.  
2.1   Antimicrobial Peptides Preparation 
All antimicrobial peptides studied in this research were synthesised chemically and prepared 
in laboratories at the sponsoring company of the project (NPL). The synthesis and 
preparation of one batch of peptide could take up to 2-3 weeks. This involves many steps 
as mentioned below which usually performed by a team in NPL. I have been shadowing my 
colleagues in NPL during these preparation steps and performed them myself entirely for 
one peptide which was not one of those mentioned in this thesis. 
2.1.1   Solid Phase Peptide Synthesis 
All peptides studied in this project were synthesised via solid phase peptide synthesis 
(SPPS). This technique was introduced by Merrifield in the early 1960s. In addition to 
synthesising peptides [116], it is also used to synthesise other organic molecules and 
oligonucleotides. This method uses a solid support (polymer-based resin), which is usually 
polystyrene, as a platform to facilitate and accelerate reactions between reactants. The resin 
is modified by attaching a cleavable linker (a chemical group) which provides an active 
centre to initiate the reactions of attaching the first amino acid to the resin. The amino acids 
used in the synthesis must have a protected N-α amino groups. This protection is temporary 
to allow only one possible reaction on the peptide chain. The protecting groups can then be 
selectively removed during the synthesis to allow the coupling of a next amino acid and thus 
the assembly of the peptide sequence happens in a step-wise fashion as illustrated in figure 
2.1. 
There are many advantages of SPPS over in-solution peptide synthesis [117]. Firstly, 
generally no post-coupling purification step is needed.  In addition, it enables the use of 
excess reagents driving each coupling reaction to the completion. Moreover, the synthesis 
can be automated and optimised to shorten synthesis cycles. 
The limitations of SPPS, however, are the difficulty of monitoring each synthesis step as it 
requires additional set-ups (e.g., UV monitoring or Kaiser test). 
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In addition, it typically requires an excess amount of (potentially expensive) reagents and 
solvents used. However, these disadvantages can be offset by the high quality of the final 
product. 
2.1.1.1   The Solid Support: Polystyrene Resin 
Since SPPS was introduced by Merrifield using polystyrene-based polymer as a support, a 
great number of other materials have been introduced. Nevertheless, polystyrene resin is 
still the most commonly used support in solid phase chemistry [118] and is obtained by a 
co-polymerization reaction of styrene and divinylbenzene (figure 2.2).   
 
Figure 2.1: Solid phase peptide synthesis cycle. The synthesis of a peptide using N- 
protected (PG) amino acids. 
Styrene  divinylbenzene  
CH2Cl2 
Figure 2.2: Synthesis of polystyrene resin with divinylbenzene cross-
linking. 
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Divinylbenzene is used to a small concentration (1-2 %) in the reaction to cross-link 
polystyrene chains, figure 2.2. The degree of cross liking is directly related to the ability of 
resin to swallow when solvating, which has an effect on the reaction kinetics. 
Polystyrene resins are insoluble in organic solvents, but when solvated in aprotic solvents 
such as toluene, DMF, and DCM they become swollen and mesh-like. The more the resin 
swallows, the larger the diffusion rate of the reactants toward the resin matrix [119]. Since 
the reaction kinetic is a diffusion controlled, higher diffusion will make the reaction time 
shorter. 
2.1.1.2   Linkers 
Achieving a covalent bond of organic molecules directly into the polystyrene support is 
difficult. A more efficient approach is to modify the polystyrene support with different linkers. 
A large number of linkers have been developed and are commercially available and each 
has an advantage for a particular synthesis.  Figure 2.3 shows the chemical structure of 
MBHA linker used in synthesising all peptides studied in this project [9]. When cleaving the 
peptide at the end of the synthesis, this linker gives an amide group at the carboxylic end. 
 
2.1.1.3   Boc and Fmoc Protected Amino Acids for Solid Phase Peptide Synthesis 
Peptide synthesis happens through steps in which the amino acids forming the peptide 
sequence are added one by one. For this stepwise SPPS to happen, two types of protecting 
groups are necessary to avoid undesired reactions and side products. The first one is a 
protecting group on the α-amino group of each new amino acid added to the reaction which 
is also called orthogonal protecting group. This protecting group will prevent the same amino 
acid to form a chain with itself; instead, it only allows the carboxylic acid side to form a 
peptide bond with the α amino group at the end of the peptide chain. This protecting group 
is then removed after each coupling (linking an amino acid to the chain) to allow chain 
Figure 2.3: Chemical structure of MBHA linker attached to resins (grey 
balls) used for SPPS [9]. 
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elongation. The second protecting group is a side chain protecting group which is necessary 
to prevent reactions that could happen on the side chains of the amino acids. 
 
These protecting groups are usually removed at the end of the synthesis during the peptide 
cleavage (detaching from the resin). Hence, the removal of these two protecting groups 
should happen via two different mechanisms.  
Amino acids that already have their groups protected are commercially available. There are 
two main types of protected amino acids according to the N-α protecting groups. Boc (tert-
butyloxycarbonyl) and Fmoc (9H-fluoren-9-ylmethoxycarbonyl) protected amino acids, 
figure 2.4. The removal of the Fmoc protecting group is achieved by adding a very mild base, 
usually piperidine, leaving an exposed neutral amine group. Therefore, no neutralisation of 
the peptide-resin is require after each deprotection, figure 2.4 (blue box). The Boc protecting 
group on the other hand is removed by adding acid which is usually TFA, figure 2.4 (yellow 
box). 
The choice of Boc or Fmoc as an orthogonal protecting group depends on the nature of the 
resin linker and the synthesised peptides. For example acid sensitive resins can be used 
Figure 2.4: Orthogonal protection using Fmoc as Nα-protection group and 
acid labile side-chain protecting groups. Fmoc groups are removed only using 
basic conditions (blue box). Low TFA concentrations are sufficient to remove 
highly acid labile trityl groups (Red box), whereas high TFA concentrations 
remove all acid-labile groups including Boc and Trityl groups (red and orange 
rectangle). Figure reproduced from [5].  
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only with Fmoc orthogonal protecting group [120]. All the peptides in this study were 
synthesised using Fmoc as orthogonal protecting group and Boc as a side chains protecting 
group.   
2.1.1.4   Coupling Principle 
In order to form a peptide bond, the carboxyl group of the amino acids needs to be activated 
to couple with the amino group of another amino acid. This activation is necessary to speed 
up the reaction. Figure 2.5 shows the coupling reaction using a general activating group.  
 
There are many different activation agents available. There are activating groups such as 
phosphonium salts and uronium salts. The two activating groups used in this study are 
HBTU, TBTU. Both are uranium salts with a chemical structure illustrated in figure 2.6. For 
the coupling reaction to be activated, it usually needs specific conditions suitable for the type 
of activating group used. For these activating groups, a basic medium is necessary and 
usually achieved by using DIPEA (Diisopropylethylamine). 
 
2.1.1.5   Peptide Synthesis Protocol  
All peptides studied in this project were synthesised by a Liberty-1 microwave peptide 
synthesizer (CEM Corp) as peptide amides using solid phase Fmoc/tBu protected amino 
acid. HBTU/DIPEA are used as coupling reagents and Rink amide 4-
Figure 2.5: Formation of amide bonds via activating the carboxylic 
acid group of one amino acid. 
Figure 2.6: Chemical structures of the two activating groups HBTU and 
TBTU [7] . 
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methylbenzhydrylamine (MBHA) resin (Novabiochem, UK) was used throughout. For the 
synthesis of capzip monomers, Fmoc-Lys(Mtt)-OH was used to enable orthogonal 
conjugation via a tri-functional dendritic hub – βA-KK-am. While allyl-based orthogonal 
protocols were used for the synthesis of the C 3 (+) -triskelion on resin. Fmoc-Lys(Alloc)- 
OH was used to generate the C 3 -dendrimer hub. The C 1 (-) strand was acetylated using 
a solution containing acetic anhydride (5%, v/v) and pyridine (5%, v/v) in DMF. 
2.1.2   Peptide Purifications 
Once the peptide is synthesised, the resin is thoroughly washed with DMF and DCM and 
then cleaved and deprotected using an acidic mixture containing 95% TFA, 2.5% TIS, 2.5% 
water. The resin is then separated from the peptide solution by filtration followed by peptide 
precipitation using cold diethyl ether. The pellet (containing the peptides) is re-suspended in 
di-water to be purified by RP-HPLC.  
2.1.2.1   RP-HPLC  
All peptides were purified by semi-preparative gradient reversed-phase high performance 
liquid chromatography (RP-HPLC). RP-HPLC was performed on a JASCO HPLC system 
using Vydac C18 semi-preparative (5 μm 10 mm i.d x 250 mm) column.  
The semi-preparative HPLC was run using a 10-60 % buffer B gradient over 50 min at 4.5 
mL/min with detection at 280 nm, 230 nm and 220 nm. The mobile phases used are: buffer 
A – 5% aqueous CH3CN, 0.1% TFA and 95% Water, buffer B – 95% aqueous CH3CN, 
0.1% TFA and 5% water. 
2.1.3   Peptide Characterisation 
The identity of the peptide was confirmed by analytical reversed-phase high performance 
liquid chromatography (RP-HPLC) and matrix-assisted laser desorption/ionization time-of-
flight (MALDI-ToF) mass spectrometer. Similar to semi-preparative, analytical RP-HPLC 
was performed on a JASCO HPLC system but using Vydac C18 analytical (5 μm, 4.6 mm 
i.d x 250 mm) column. It was again run using same buffers but with a gradient of 10-60 % 
buffer B over 50 min at 1 mL/min. Analytical RP-HPLC was employed to determine the 
peptide purity. As the eluted peptides from the chromatography column are represented by 
peaks on the micrographs, the sharpness of these peaks indicates the purity. The integrated 
area of these peak is a measure of the purity. All the peptides produced for this study had a 
purity of at least 98%.  
The final peptides constructs were also identified by MALDI-ToF mass spectrometry with α-
cyano-4-hydroxycinnamic acid as the matrix to help ionisation of the sample. Mass spectra 
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show peaks of mass/charge ratio of the positive ions resulted from sample ionisation. As 
MALDI-MS is considered a soft ionisation technique, the full peptide structure is expected 
to be ionised without fragmentation. Hence the calculated mass/charge ratio of the peptide 
should appear experimentally in the spectrum as a sharp peak. The purity of the peptide 
could also be identified from MALDI-MS spectra. The peaks that are not related to the 
peptide must be attributed to the impurities. Ideally, the pure peptide sample should show 
only peaks that are attributed to the full structure of the synthesised peptide. 
2.1.4   Peptides Drying and Storage 
Once the peptides were purified, they were freeze dried and stored in their powder form at 
-80 Co freezer. 
2.1.5   Peptides Sample Preparation  
In order to prepare the liquid sample used for experiments, the peptide powder was 
dissolved in DI water and the molar concentration was determined using the UV:VIS 
spectroscopy, employing the Beer-Lambert Law explained in the next section [121]. Once 
the concentration of the stock solution was determined, peptide solutions of lower 
concentrations were prepared by simple dilution with DI water. The entire amount of solution 
then was divided into small volumes (200 µL each) and kept separately in small Eppendorfs 
tubes in the freezer (– 4C). In this way, frosting-defrosting of the peptides was avoided to 
minimise the risk of peptide deformations. 
2.1.5.1   Determining the Molar Concentration 
The Beer-Lambert Law given in the equation 2.1 relates the total absorbance of the material 
to its concentration in the solution. Two constants are involved in this equation. First, the 
extinction coefficient (𝜖) which is directly related to the chemical bonds and chemical 
structure of the absorbents. Second, and the path length (𝑙) which is the cell width through 
which the light passes. 
𝐴 = 𝜖𝑙𝑐 2.1 
 
𝐴: The Absorbance 
𝑙: The length of the cell path (cm) 
𝑐: The concentration of the absorbent (mole L-1) 
𝜖: The extinction coefficient (L mole-1 cm-1) 
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The cell used in the studies has a width of 0.1 cm, a value which can be substituted in the 
equation. The extinction coefficients of the peptides were determined by summing up all the 
extinction coefficients of every amino acid and chemical bond that absorbs at the selected 
wavelength [121]. By measuring the absorbance of the peptide solution at the selected 
wavelength, and by substituting the extinction coefficients and the length of the cell used in 
the equation 2.1, the concentrations of the peptide solutions were determined. 
2.1.5.2   Peptides Extinction Coefficient Calculations 
Table 2.1 shows the amino acid sequences of each peptide studied in this project with their 
calculated extinction coefficients at the selected wavelengths. Appendix 1 includes a list of 
the amino acids with their abbreviation and chemical structure. 
 
2.1.5.3   Peptides Sample Preparation for AFM 
Starting from the peptides stock solutions of determined concertation, amhelin and tilamin 
peptides were considered ready for AFM experiment. The required concentration of the 
peptide for AFM experiments was achieved with simple dilution of the peptide stock in DIi-
water or in the relevant buffers.  
Peptide  Amino Acid Sequence 
Wavelength 
λ 
Calculated 
 𝝐 
Amhelin KQKLAKLKAKLQKLKQKLAKL-am 214 19621 
Tilamin KARLAKLRARLYRLKARLARL-am 280 1280 
Capzip 
monomer 
(RRWTWE)-βA-K(RRWTWE)-
K(RRWTWE)-am 
280 34140 
C3 (+) 
 
214 71241 
C1 (-) ac-CβAEISALEQEIASLEQEISALEQ 214 22848 
 
Table 2.1: The studied peptides with their amino acid sequences, the calculated 
extinction coefficient at the specific absorbance wavelength 
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However, capzips (explained in chapter 4) and capsids (explained in chapter 5) require more 
preparations for the peptide monomers to co-assemble into antimicrobial spherical shells.  
For capzip, the monomers stock solution was used to prepare a solution of 100 µM in MOPS 
buffer pH 7. The sample then was left overnight at room temperature prior AFM experiments.  
Capsids on the other hand, was prepared by mixing two peptides C1 (-) and C3 (+) with the 
molar ratio of 3:1 respectively. The overall monomers concentration in the sample was 100 
µM (75 micromoles C1 (-) and 25 micromoles C3 (+)). To achieve the required concentration 
of the monomers, the peptide stock solutions were diluted in MOPS buffer pH 7. To induce 
the assembly, the sample requires the addition of the reducing agent TCEP to a 
concentration of 0.147 M in the sample. Prior to mixing TCEP with the peptides monomers, 
TCEP was neutralised to pH 7.4 using 1 M NaOH. After mixing all the three components, 
C1 (-), C3 (+) and neutralised TCEP, the sample was tleft to self-assemble over night at 
room temperature. 
2.2   AFM Sample Preparations 
2.2.1   Substrates for AFM Imaging 
Choosing the suitable substrate is essential to immobilise the biological sample during 
scanning. Muscovite mica has been demonstrated as a suitable substrate for biological 
samples. It consists of layers of silicate minerals sheets. The top sheets are easily cleavable 
by an adhesive tape leaving a clean and atomically flat layer [122]. For most experiments in 
this study, sample supports were made using ⌀ 15 mm steel SPM specimen discs (Agar 
Scientific), topped by a layer of self-adhesive, fluorinated ethylene propylene (FEP) coated 
Bytac laminate with a thickness of 0.254 mm (Saint-Gobain Performance Plastics). On the 
Bytac laminate, a ⌀ 9.9 mm muscovite mica disc (Agar Scientific) was glued using two 
component Araldite rapid epoxy adhesive (Huntsman Advanced Materials) with a 5 min 
working time. The sample supports were cured overnight before use. 
The hydrophobic (FEP) layer clued in between the metal disc and the mica is to make a 
hydrophobic edge around the mica disc, to prevent the liquid from leaking off the mica. 
Before using the substrate, mica discs were cleaved using Scotch Magic tape (3M). In this 
process, several layers of the mica crystal are removed from the surface, leaving a flat and 
clean substrate suitable for lipid bilayer deposition and AFM experiments. 
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To facilitate the immobilisation of the molecules of interest on mica, it is often beneficial to 
add covalent cross-linking agents or certain cations such as calcium or magnesium. These 
link the constituents of the sample to each other and/or to the mica.  
In this study, and for immobilising the negatively charged lipid bilayers on mica, mica discs 
in all samples were treated with buffer including ~10 mM of both CaCl2 and MgCl2. 
2.2.2   Buffer Solutions 
Two buffer solutions were used to prepare all the samples in this study. It was either 20 mM 
HEPES with 150 mM NaCl or 10 mM MOPS with 150 mM NaCl. The required amounts of 
HEPES, MOPS and NaCl powders were weighed and dissolved in DI water to get the 
concentration needed. Then the pH was adjusted to 7.4 by adding 1 M NaOH. 
2.2.3   Phospholipids 
As discussed in chapter 1, supported lipids model membranes were employed in this work 
to study the peptides antimicrobial mechanisms.  
This was achieved by using two types of lipids, namely DLPC (1,2-dilauroyl-sn-glycero-3-
phosphocholine) and DLPG (1,2-dilauroyl-sn-gly-cero-3-phospho-(1-rac-glycerol)) with a 
mass ratio of 3:1 (W:W). The chemical structures of these two lipids are shown in figure 2.7. 
This composition was chosen as a good mimic of the bacterial membrane [123, 124] and it 
was the same lipid composition used in other complementary experiments that were carried 
out at NPL.  
DLPC is considered as neutral lipid and DLPG is negatively charged under the experimental 
conditions at pH 7. In addition, both lipids have transition temperatures below zero Celsius, 
which means they stay in the fluid phase and not in the gel phase at room temperature.  
 
Figure 2.7: The chemical structure of both DLPC and DLPG lipids. 
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2.2.4   Formation of Bacterial Model Membranes 
The bacterial model membranes were prepared fresh before every experiment following the 
same protocol which includes three main steps explained below. 
2.2.4.1   Formation of Small Unilamellar Vesicles 
The weighed amounts of the lipid powder (usually 3 mg DLPC and 1mg DLPG) are mixed 
and dissolved in 1 mL organic solvent to obtain a homogeneous mixture. This solvent was 
chosen to be Chloroform:Methanol 2:1 (V:V). The lipid powder and the solvent are mixed 
together in a glass vial until a clear solution is achieved. The organic solvent is then 
evaporated by a gentle steady nitrogen stream to form a dry lipid film deposited at the bottom 
of the glass vial. This film is then hydrated by 1 mL deionised water to achieve a lipid solution 
with a concentration of typically 4 mg/mL. The lipid suspension is vortexed for 2-4 minutes 
at room temperature to mix the lipids. At this stage, the lipids form large multilamellar 
vesicles (LMVs) in solution. These must be dispersed and reduced to single unilamellar 
vesicles (SUVs) via sonication and extrusion. The cloudy suspension of LMVs is sonicated 
at room temperature, well above the transition temperature of the lipids for sixty minutes in 
a bath sonicator. The use of the 80 kHz sonication frequency allows the large vesicles to be 
ruptured and broken down into SUVs. To ensure a uniform size distribution of vesicles in 
suspension, extrusion is performed [125]. Extrusion is the process by which the lipid 
suspension is forced through a polycarbonate membrane with pre-defined pore sizes. In this 
study, the lipid suspension is chosen to pass through a 50 nm pore membrane to form 
vesicles with 50 nm diameter.  The process was performed a minimum of twenty times to 
ensure a uniform size distribution using an Avanti mini-extruder. 
2.2.4.2   Absorption of Lipids Vesicle to form the SLB 
The preparation of supported lipid bilayers is performed via the vesicle fusion method, 
described fully in reference [126]. The vesicle fusion method cannot be used to form 
asymmetric bilayers or closely regulate the packing density of the lipids in the bilayer as can 
be achieved via the Langmuir-Blodgett technique, but the vesicle fusion technique allows 
bilayers to be assembled relatively easily and quickly.  
In the vesicle fusion method, SUVs in suspension are allowed to adsorb onto the sample 
substrate over a period of 30-60 minutes. If the transition temperature of the lipids is above 
room temperature, the process can be completed at room temperature [127]. 
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As the lipids reach the surface the spherical vesicles deform onto the surface as they adsorb, 
becoming ellipsoidal in form, before rupturing to form a bilayer fused to the mica surface 
[128]. A schematic of the vesicle fusion process is shown in figure 2.8. 
The substrate used in this research is mainly muscovite mica, which has a negatively 
charged surface under the here applicable buffer conditions [129]. In addition, the vesicles 
prepared to form the bacterial model membranes are negatively charged because of the 
presence of the negatively charged lipid DLPG.  
Therefore, it is essential to add bridging positive cations to attract the negatively charged 
vesicles and immobilise the formed bilayer on mica [130]. In this study, we employed two 
cations, calcium and magnesium each with a concentration of 10 mM in the buffer. This 
cations-contained buffer is used to hydrate the mica substrate before letting the 
(DLPC:DLPG) lipid vesicles to absorb onto the mica surface.   
This technique has been successfully used to form a continuous bilayers with both full and 
partial coverage on the mica. There are a number of parameters that can influence this 
process, including temperature, time of incubation and the amount of added lipid vesicles 
on the mica [131].  
Model membranes were typically prepared at room temperature by adding 2 µL lipids 
vesicles solution (4 mg/ml) onto clean and freshly cleaved mica, which was pre-hydrated by 
50 µL buffer containing 10 mM cations. The samples then were incubated for about 30 
minutes in room temperature, well above the transition temperature of the lipids. The mica 
was then washed about 10 times with the same buffer except for the calcium and 
Figure 2.8: A schematic showing the deformation of a vesicle as it fuses onto 
the mica substrate forming the SLB. Illustration prepared by Dr Carl Leung 
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magnesium cations. This washing stage removes any lipids remaining in the fluid that were 
not adsorbed to the substrate, to prevent later aggregation on the model membrane. 
2.3   AFM Imaging 
As explained in chapter 1, AFM can be used to image the peptides in action, or at least their 
effects, as they attack bacterial membranes. Here I am explaining the principle of AFM 
technique, the main components of atomic force microscope and the common modes of 
operation. In addition, I explain the methods for optimising the imaging on SLB.  
In this project, I employed three atomic force microscopes, namely Multimode 4, Multimode 
8 and FastScan Bio systems (Bruker, CA, USA). As explained below, different AFM 
operation modes and cantilevers were employed. 
2.3.1   AFM Principles of Operation 
AFM generates images by feeling the sample surface. This happens via tracing a sharp tip 
attached to a flexible lever over the surface of interest, as illustrated in figure 2.9. The surface 
could be a hard sample or a soft biological specimen, which in this case requires more care 
in applying lower forces to avoid sample deformation. Three dimensional images are 
recorded by scanning the sample surface by the AFM tip in a two dimensional (xy) plane 
with the ability to move in the third dimension (z dimension) when the tip senses features on 
the surface. As the tip is raster scanned over the surface, the topography of the sample 
surface is reconstructed from these traces. The movement of the sample or the tip in the z-
direction is in response to the tip-sample interactions. When the tip encounters a feature on 
the scanned surface, a tip-sample interaction will arise. This then will change the force 
applied between the tip and sample. Usually, 
AFM is operated by keeping these tip-sample 
interactions or force gradient constant, via 
adjustment of the z position of the tip.  
AFM can be operated in several modes. Each 
mode has different way to monitor and control 
the tip-sample interaction. In addition, AFM 
experiments can be performed in a vacuum, 
air or fluid. AFM operations in fluid are 
arguably the most relevant for imaging 
biomolecules.  
Figure 2.9: Description of the principle 
operation of an AFM. The tip follows 
contour B to maintaining a constant 
force between tip and sample. Figure 
reproduced from reference [11]. 
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The change of tip-sample interactions induces bending of the cantilever or changes in a 
cantilever oscillation. In the majority of AFM setups, the cantilever bending or changing in 
the oscillation is monitored optically via the optical lever method pioneered by Alexander in 
1989 [132]. This is achieved by focusing a laser on the back side of the cantilever and 
reflected on a position-sensitive detector (PSD), which is usually a quadrant photodiode. 
The quadrant photodiode measures the bending of the cantilever through the displacement 
of the laser signal. 
The optical lever method reads the deflection of the cantilever on the quadrant photodiode 
by converting the incident light on each quadrant into a voltage as shown in figure 2.11. The 
vertical displacement or deflection of the cantilever can therefore be measured by the 
difference between the upper and lower quadrants of the photodiode. In the same manner, 
the voltage differences between the left and right quadrants can be used to determine the 
torsional motion of the cantilever, such as can be induced by frictional forces. The optical 
lever method amplifies the movement of the cantilever purely by path length, as the 
measured displacement on the photodiode (D) is proportional to the cantilever movement 
(z) multiplied by the path length from the cantilever to the photodiode (S) over the cantilever 
length (l) as shown in equation 2.2 [133]. 
D= 
3
2
𝑆
𝑙
z 2.2 
 
The applied force in an experiment (𝐹) can be calculated by Hooke's law shown in equation 
2.3 from the deflection of the cantilever which gives the cantilever displacement (𝑥) and the 
stiffness of the cantilever (𝑘). 
𝐹 = −𝑘𝑥 2.3 
 
The applied force is therefore strongly dependent on the stiffness of the cantilever, as will 
also be discussed in section 2.3.5, and to the minimum detectable cantilever bendin. 
Alternatively or complementarily, force gradients and dissipation can be derived from 
changes in the oscillation of the cantilever when it is modulated vertically during the (lateral) 
scanning over the sample surface as described in section 2.3.4.2. 
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2.3.2   Tip-Sample Interaction Forces 
Since the surface topography is determined from contours of constant tip-sample interaction 
(at least on average), it is worthwhile to understand the forces acting on the tip. Relevant 
forces in liquid and vacuum operations are long range attractive van der Waals, 
electrostatics and short-range repulsive interactions, figure 2.10. However, in air operation, 
capillary forces and the resultant adhesive forces should also be considered. The long range 
van der Waals forces and electrostatic forces can act over tens of nanometres and are 
caused by dipole interactions between atoms, and by Coulomb interaction between surface 
charges, respectively. At the Ångström range, the strong repulsive force originating from the 
overlap of atomic orbitals begins to dominate. At this point the tip is considered to be in 
contact with the sample. In air, the water meniscus formed between the tip and the sample 
causes an attractive capillary force between the tip and the sample. In aqueous salt 
solutions, van der Waals forces and electrostatic forces are usually screened for tip-sample 
distances larger than a few A, and there are no capillary forces. 
 
2.3.3   AFM Imaging in Liquid 
One of the main advantages of using the AFM for imaging biomolecules is the ability to work 
in fluid and thereby visualise and probe biomolecules in conditions similar to their natural 
Figure 2.10: A representation of forces that can act on the AFM tip at various 
tip-sample separations with ignoring electrostatic interactions. At high 
separations the attractive van der Waals dominate, with the repulsive short-
range repulsive forces dominating at lower separations. Figure was 
reproduced from [3]. 
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state. Additional advantages of AFM operation in liquid are the avoidance of the tip-sample 
capillary forces experienced in air, as explained above. These forces increase the contact 
area between the tip and the sample and tend to reduce the spatial resolution [134]. Another 
advantage of the operation in liquid is the use of buffer solutions. These buffer solutions 
permit tuning the long range electrostatic forces between the tip and the sample. This control 
of electrostatic forces can increase the spatial resolution [135]. 
The distance over which the long range electrostatic force decays is defined as the Debye 
screening length (𝐾−1) which is given by equation 2.4. This equation shows that (𝐾−1) is 
dependent on the permittivity of vacuum and the dielectric constant of the medium (𝜖0 and 
𝜖𝑟, respectively). It also depends on the absolute temperature (𝑇), the ionic strength of the 
solution (𝐼), the electron charge (𝑒) and Boltzmann's constant (𝑘𝑏). Under typical conditions 
for AFM imaging of biomolecules, 𝐾−1 is a few Å. 
 Figure 2.11 shows the standard setup of an AFM in liquid. The principle is the same as in 
air but without immersing the sample and cantilever in fluid. For imaging in fluid, a fluid cell 
(not shown) is used to hold the cantilever and contain the liquid. 
 
𝐾−1  =  √
𝜖0𝜖𝑟 𝑘𝑏  𝑇
2𝑒2𝐼
 2.4 
Figure 2.11: A schematic showing the operation of the AFM in fluid. Image 
courtesy of Prof Bart Hoogenboom. 
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There are some disadvantages to AFM imaging in fluid related to viscous damping. This is 
more pronounced for imaging in dynamic modes since the damping force exerted by the 
viscous liquid causes the resonant frequency 𝑓0 and the quality factor, 𝑄, of the cantilever 
to decrease. This issue will be discussed more in section 2.3.4.2. All AFM experiments in 
this project were carried out in fluid under buffer conditions with near-physiological pH and 
salt concentrations. 
2.3.4   AFM Imaging Modes 
As mentioned previously, AFM can function in a number of imaging modes, the most 
common of which are contact and tapping mode. Contact mode, elaborated in next section, 
is the simplest and fastest mode. However, its use for imaging biomolecules is limited 
because of the relatively high lateral forces exerted on the specimen. Tapping mode, 
elaborated in section 2.3.4.2, operates by oscillating the tip vertically above the sample. This 
makes the tip continuously coming into and out of contact with the sample in a `tapping' 
motion. This vertical modulation reduces the lateral forces that the tip exerts on the sample 
making it widely used for imaging biomolecules in liquid with lower risk of distortion or 
destruction of the specimens under study. Peak force tapping, elaborated in section 2.2.4.3, 
is a relatively recent mode for high resolution imaging of biomolecules and has been used 
extensively throughout this project along with tapping mode. 
Other popular modes which have not been used in this project and not explained here are 
frequency-modulation AFM and multi-frequency AFM. 
2.3.4.1   Contact Mode AFM in Liquid 
In contact mode AFM, the tip is kept constantly in contact with the surface while moving 
across the sample. The cantilever deflection is directly proportional to the interactions arise 
between the tip and the molecules on the surface. In most commercially available AFMs, 
this deflection is simultaneously probed by the optical detector and translated by the 
feedback loop to the scanner. Typically, the feedback loop directs the scanner to adjust the 
z position (vertical position) of the cantilever or the sample to maintain a predefined constant 
force or cantilever deflection known as the setpoint. This assure a constant interaction force 
between the tip and the sample [133].  
Contact mode AFM is the simplest in term of operation but it has its drawbacks of applying 
the large lateral force on the sample leading possibly to damage of soft biological specimen. 
In addition, the deflection of the cantilever drifts over time, even without contact with the 
sample, which results in a change in the applied imaging force as the setpoint is maintained. 
This can result in much larger forces than intended being applied to the sample. For this 
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reason, relatively soft cantilevers with less than 0.1 N/m spring constant are recommended 
to be used in this mode for scanning soft surfaces.  
Dynamic imaging modes were subsequently developed and introduced to reduce the lateral 
force applied to a biomolecule [134],[136]. 
2.3.4.2   Tapping Mode AFM in Liquid 
Tapping mode AFM, also known as amplitude modulation (AM-AFM) or intermittent contact 
mode, is one of the many dynamic modes evolved to minimise the drag force applied on the 
sample while scanning. This is achieved by oscillating the cantilever vertically while 
scanning the surface with maintaining constant frequency or amplitude. Hence, the time 
spent by the tip applying force on the surface while scanning is lessened. This technique is 
particularly useful for imaging biological molecules loosely bound to a substrate where the 
use of contact mode AFM would result in sample damage or sample movement. The 
movement of the sample/molecules during imaging could also irreversibly blunt the tip which 
results in reducing the resolution. 
Hence, in this operational mode we can use stiffer cantilevers with up to 0.6-1 N/m spring 
constant without a significant damage of the sample. The cantilever is oscillated while 
scanning at its resonance frequency to get the maximum oscillation amplitude. The 
resonance frequency of the cantilever, 𝑓0 , is (approximately) the frequency at which the 
driven cantilever amplitude response is largest. This can be calculated using the equation 
(2.5) knowing the cantilever’s effective mass 𝑚 and the stiffness 𝑘. 
 
This is usually achieved by driving the tip (the cantilever) to oscillate sinusoidally above the 
sample at a frequency 𝑓 close to the natural resonance of the cantilever, 𝑓0 , while the 
cantilever raster scans the surface.  
The cantilever is usually driven mechanically by a piezoactuator in the fluid cell. The 
amplitude of oscillation is monitored as the root mean square (RMS) value of the deflection 
readout on the detector. When the tip approaches the sample surface while oscillating at 
frequency 𝑓, the attractive or repulsive tip-sample forces will change the resonance 
frequency of the tip that is driven and the energy is dissipated during the oscillation. 
𝑓0 = 
1
2𝜋
 √
𝑘
𝑚
 (2.5) 
59 
 
Figure 2.12 shows an example of a cantilever resonance curve when it is away from the 
sample and when interacting with the sample. The cantilever resonance decreased by Δ𝑓, 
when the repulsive tip-sample interaction increases. 
 
As shown in figure 2.10, changing the tip-sample distance affects the type and strength of 
forces raised between the tip and the sample. Hence, the topography changes of the surface 
when scanning will alter the strength of the interactions between the surface and the 
cantilever tip and this alteration will lead to changing the oscillation amplitude. The level of 
the amplitude change across the sample is probed by the optical detector. Usually the tip-
sample interaction induces a reduction 𝛿𝐴 in the amplitude oscillation. The feedback loop is 
used to maintain the amplitude of oscillation A of the cantilever by adjusting the position of 
the cantilever with respect to the sample (or vice versa). This (approximately) will yield to 
traces of a constant tip-sample distance.  
In tapping mode, additional information about the sample properties can be inferred from 
the change in the phase of the oscillation. Phase imaging monitors the phase lag between 
the signal that drives the cantilever to oscillate and the measured cantilever oscillation. 
Variations in a number of surface properties including elasticity, adhesion and friction can 
cause change in the phase of the oscillation and therefore affect the phase lag. Additional 
characteristics of a biomolecular surface can therefore be probed simultaneously to the 
topographic features. This can be used for example, to distinguish variations in the lipid 
composition of a bilayer which appears perfectly flat in topography but contains two phases 
of lipids. 
Figure 2.12: Amplitude versus frequency curves for a cantilever driven near 
resonance away from the sample (dotted line) and interacting with the sample 
(solid line) [3]. 
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On the other hand, the major drawbacks for tapping mode imaging in fluid are: (i) the 
reduction of the quality factor of the cantilever 𝑄 by the viscous damping of the fluid. This 
reduces the sensitivity of the method in changing the amplitude because a small shift in 𝑓0 
in liquid produces a much smaller 𝛿𝐴 comparing with in air. (ii) The cantilever is usually 
driven by a piezo actuator as explained in section 2.3.6.1. This actuator drives the entire 
fluid cell, or cantilever holder leading to the production of mechanical resonances in the fluid 
cell, in addition to the cantilever. This results in an excitation spectrum that is commonly 
denoted as a `forest of peaks' as shown in figure 2.13. This forest of peaks varies while 
imaging as the fluid changes within the fluid cell. This can result in large changes to the 
amplitude of the cantilever resonance peak as the forest of peaks moves [137]. Changes to 
the free amplitude of oscillation of the cantilever will result in changes in the load force and 
the resolution.  
 
These are the major drawbacks for the imaging of biomolecules in fluid using tapping mode. 
Although the lateral forces in tapping mode are reduced, the applied force is in fact less-
defined and can vary. The large changes in applied force can result in a loss of resolution, 
or damage to the sample or to the tip, which is another key for high resolution imaging using 
the AFM. 
2.3.4.3   Peak Force AFM in Liquid 
Peak force is a relatively new technique developed by Bruker (Bruker, Santa Barbara, USA) 
where the topographical image coupled with information about the mechanical properties of 
the surface are gathered simultaneously [138]. This is achieved by applying a series of force 
curves at a frequency significantly lower than the resonance frequency of the cantilever 
Figure 2.13: A plot of actuation amplitude versus frequency for a cantilever with  𝑓0 
~ 550 kHz showing the forest of peaks introduced by the actuation of other 
mechanical resonances [3]. 
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[139]. For imaging in fluid, the tip is `tapped' on the surface in a sinusoidal motion at 
amplitudes that are typically less than 10 nm, at frequencies of 1-8 kHz. The tip-sample 
interaction is controlled by maintaining the maximum force, or `peak force', between the tip 
and the sample constant.  
The force curves taken at each point on the surface allow precise control of the tip-sample 
interaction force, enabling imaging at peak forces of less than 200 pN, and as low as 30 pN 
in fluid environments. This helps protect both the AFM probe and the sample from potential 
damage and is a key factor in enabling high-resolution imaging.  
Peak force tapping also allows to probe mechanical properties of the sample, including 
adhesion, dissipation, deformation and elastic modulus [140] [141]. The typical force curves 
are acquired by vertically approaching the tip from the sample, pressing on it with a set force 
causing a deflection of the cantilever and then retract from the sample. The force curve, 
shown in the figure 2.14.iv, is highlighting the way of calculating these mechanical properties 
of the surface. In the peak force tapping mode, the surface is scanned and represented in 
different ways. It could be represented in height so the topographical image is generated. 
The image could alternatively be generated to represent any of the mechanical properties 
mentioned above. 
 
Figure 2.14: A schematic showing the data collected from an instantaneous Peak 
Force Tapping force curve, reproduced from reference [15]. Plot (i): Force (blue-
approach and red-retract) and z-piezo (dotted) position as a function of time, 
where B is the jump to contact, C is the Peak Force, D is the Adhesion force. (ii) 
A force versus time plot with small peak force. (iii) A force versus z position plot. 
(iv) Force versus tip sample separation plot showing the different parameters 
calculated in Peak Force QNM. 
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2.3.5   Cantilevers 
Cantilever properties as well as the tip shape have a vital role in increasing the imaging 
resolution. This is because force sensitivity is a key for increasing the imaging spatial 
resolution, which is directly related to the mechanical properties of the cantilever. In other 
words, the cantilever stiffness determines the sensitivity for force applied to the sample while 
imaging. The stiffer the cantilever, the less the force sensitivity, which could lead to sample 
deformation and/or less responsiveness to track the small topographical changes of the 
sample leading to poor resolution [1, 142]. 
2.3.5.1   Mechanical Properties of the Cantilever 
For imaging of biomolecules in fluid in contact mode, tapping mode and peak force tapping 
mode, soft cantilevers are used to obtain high force sensitivity, minimising the load force on 
the sample. 
In the contact mode for instance, usually soft cantilevers are used with ~ 0.01 N/m spring 
constant to be as soft as possible on the sample to avoid any damage. In tapping modes 
however, it is recommended to use stiffer cantilevers with 0.05-0.5 N/m spring constant.  
There is on-going research to improve the cantilever properties. For example, smaller 
cantilevers allow for higher resonance frequencies while maintaining a low spring constant, 
facilitating faster or more sensitive measurements.  
2.3.5.2   Small Levers 
 Small cantilevers have been predicted to yield 
improvement in image stability, imaging speed 
and reduction of  the thermal noise. Compared to 
conventional cantilevers, small cantilevers show 
up to 5 times improvement in force sensitivity 
[143]. Much work on these cantilevers has been 
done in the context of high-speed AFM using 
tapping mode [144].  
Traditionally, small cantilevers have been difficult 
to manufacture, however, they are now 
commercially available with high resonance 
frequencies [145-147]. Figure 2.15 shows the size 
difference between a conventional cantilever 
(100's of µm) and a small cantilever (~20 µm). 
Figure 2.15: Scanning electron 
microscopy image of a small 
cantilever compared to a 
conventional NCH cantilever. Image 
reproduced from [1]. 
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There are however a number of drawbacks for small cantilevers that might limit their use. 
Usually when the cantilever approaches the sample surface, the resonance frequency  𝑓0 
does not stay constant and this is more pronounced with small cantilevers. This is because 
of the interaction between the cantilever beam and the sample surface leading to 
hydrodynamic damping of the cantilever. This results in a less clearly defined force baseline 
above the sample [1].  
In addition, it is difficult to fabricate a sharp tip at the end of a small cantilever. Larger tips 
however have masses that contribute more heavily with respect to the overall weight of the 
cantilevers which reduces the resonance frequency 𝑓0 [133], but more importantly, it is 
harder to align the tip to the end of the cantilever in a batch fabrication process. Alternatively, 
carbon tips can be grown on the end of these cantilevers. This alteration largely increases 
the cost of manufacturing, and it has been shown that in some cases such tips reduce the 
resolution by affecting the interaction strength with the sample [148].  
2.3.5.3   Tip 
The cantilever tip also has a large effect on image resolution. By definition, each image is a 
convolution of the tip shape and the sample topography. For this reason, tip sharpness has 
been identified as a key component to increase the imaging resolution. The smaller the 
radius of the tip, the finer topographical details of the scanned surface can be resolved [149]. 
In addition, tip apex and aspect ratio are relevant to imaging resolution for larger 
biomolecules [1]. The convolution with the tip apex is responsible for the broadening effects 
that are observed in most AFM images, and that lead to an overestimation of the lateral 
dimensions of measured objects [150]. 
In addition, the higher the aspect ratio of the tip, the less the 
interactions are allowed between the tip’s walls and the 
sample. This will minimise the extra forces arise that can 
alter the real topography of the scanned surface. 
Ideally, the tip is preferred to be a sharp needle with a radius 
of less than a nanometre. Indeed a carbon nanotube with 
such narrow diameter mounted on a flexible cantilever was 
achieved. However, the manufacturing of carbon nanotube 
tips has considerable obstacles which results in high cost 
[151].  
The most commonly used cantilevers are silicon with silicon 
tips or silicon nitride with silicon tips as shown in figure 2.16.  
Figure 2.16  SEM image of the 
silicone nitride tip of a 
conventional the MSNL 
cantilever manufactured by 
Bruker (image taken from the 
company website) 
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Table 2.2 shows the specifications of the cantilevers mainly used in this project, and the 
operational mode they were used for. 
 
Cantilever Type 𝒌 (𝑵/𝒎) 𝒇𝟎 (𝒌𝑯𝒛) 𝑹 (𝒏𝒎) Mode Used 
MSNL-C 0.01 1.5 2 Contact 
MSNL-D 0.03 4 2 Contact 
MSNL-E 0.1 6 2 Tapping/PFT 
MSNL-F 0.6 40 2 Tapping/PFT 
Fastscan DX 0.25 110 8 Tapping/PFT 
 
 
Table 2.2: Nominal specifications for spring constant 𝑘, resonance frequency 
in fluid 𝑓0, tip radius 𝑅 and mode of imaging employed, for the cantilevers used 
in this project. 
 
2.3.6   Cantilever Actuation 
As mentioned in section 2.3.4.2, AFM imaging using tapping mode requires oscillating the 
cantilever at a particular frequency above the surface of the sample. This is also called 
cantilever actuation and is performed by an actuator. This actuator has to facilitate a stable 
and reproducible cantilever signal for measuring the tip sample interaction.  
There are two cantilever actuation methods employed in this project: (piezo)mechanical 
actuation and photothermal or optical actuation. 
2.3.6.1   Cantilever Mechanical Actuation 
In the (piezo)mechanical method of actuating the cantilever, it is typically driven by a 
piezoactuator in the fluid cell. However, this has drawbacks in liquid where the cantilever 
resonance is convoluted with the other mechanical resonances of the fluid cell causing a 
`forest of peaks' as discussed previously. This affects imaging because the force exerted by 
the cantilever on the surface cannot be easily and precisely monitored during experiments, 
a problem the drifting of the `forest of peaks'.  
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2.3.6.2   Cantilever Optical Actuation 
The optical method for actuating the cantilever was developed to solve the `forest of peaks' 
problem associated with the piezomechanical method, leading to more clearly defined 
cantilever resonance and more stable actuation. In the optical method, the cantilever is 
directly actuated without exciting the support chip or the fluid cell, thus avoiding the spurious 
resonances that are typical of piezomechanical actuation. This is achieved by focusing a 
modulated actuation laser on the cantilever surface. Due to the composite nature of most 
AFM cantilevers (silicon or silicon-nitride lever covered with a metallic coating) and their 
resulting propensity to bend [152], they can be actuated and brought to resonance by laser 
heating [153, 154].  
The advantages of this optical actuation method over the other non-mechanical ones is that 
it does not require any electrical connections or any corrosive coatings for cantilevers and 
fluid cells, making it a convenient technique for use in fluid. In addition, the laser modulation 
allows the use of both small cantilevers with a range in ~MHz resonance frequencies, [148, 
155], as well as the standard cantilevers. 
The drawback however of optical actuation is that the achievable range of tapping 
amplitudes is usually small [153].  
In this project, we have employed optical actuation for fast scan imaging using small 
Fastscan DX cantilevers with a spring constant of ~0.25 N/m. The cantilever actuation 
performed via a modified AFM head designed for the photothermal actuation of miniaturised 
cantilever [156, 157]. 
2.3.7   Optimising AFM Parameters for Imaging Model Membranes 
As discussed in section 2.2.4, supported lipid bilayers were formed on a mica substrate to 
mimic bacterial membranes. These supported membranes are considered soft biological 
samples and imaging it by AFM requires careful operation. This is mainly due to the risk of 
damaging the membrane by the AFM tip while imaging.  
As stated in equation 2.3, in order to calculate the precise force applied by the tip on the 
sample, the cantilever spring constant has to be measured. In addition, it is essential to 
calculate the precise spring constant of the cantilever, if one wishes to determine the 
mechanical properties of the sample surface. Usually, the theoretical spring constant of a 
cantilever is provided by the manufacturer of the cantilever. However, the precise spring 
constant could vary from one cantilever to another. There are different ways to measure the 
spring constant of the cantilever. The method usually employed in this research is the 
thermal fluctuations method [158]. 
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Our imaging is usually aimed to be performed with forces lower than or approximately equal 
to 100 pN. The imaging starts by approaching the tip to the sample surface with an approach 
setpoint slightly higher than the imaging setpoint, to avoid an erroneous detection of a tip-
sample contact (‘false engage’). To assure an optimum minimum force is applied, after the 
tip is engaged with the sample surface, the force again was gradually reduced until a total 
dis-engage occurred. Finally, the force was increased again very slowly until the tip engaged 
again with a reasonable minimum force. This force was determined from the quality of the 
imaging, which can be monitored by the “trace” (left to right) and “retrace” (right to left) line 
profiles. Regardless the typical noise level of ~few Å, an optimum force should result in a 
stable and overlapped trace and retrace spectra. Once an optimum force is found, a larger 
scan area 1-3 µm can be set. 
 2.3.8   Characterisation of Bacterial Model Membranes  
The prepared model membranes were subject to characterisation process before using 
them for testing and studying the mechanisms of antimicrobial peptides.  
To achieve a clean flat membrane surface, it was essential to assure that all the materials 
and equipment used are clean and free of contaminations. This includes the lipid, the 
buffers, the mica discs, the fluid cell and the cantilevers.  
Clean bilayers formed using (DLPC:DLPG) lipids are expected to be flat with no topographic 
features [2, 159]. This flatness is because both lipids have the same length and they have 
similar transition temperature, hence they mix well. The flatness of the membranes was 
often investigated by AFM at different areas across the sample. 
To assure that the imaged flat surface is a lipid bilayer and not the (nearly equally flat) mica 
disc surface, force curves were recorded with minimum force load and then at gradually 
increasing force load until the tip penetrates the bilayer, showing a step down within the 
force curve. Figure 2.17 shows a verification of the presence of a lipid membrane on a mica 
surface. Figure 2.17.A displays a flat surface imaged by peak force tapping mode. A force 
curve was performed on the area highlighted by the white circle. Figure 2.17.B shows the 
approaching and retracting curves of the performed force curve. The approach curve shows 
the breakthrough event highlighted by the black circle. This breakthrough is a typical event 
when the cantilever tip penetrated the soft lipid bilayer to reach the solid surface of the mica 
substrate. 
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This verification process via applying force curve was avoided if not necessary as it can 
cause tip contamination and thus affects the spatial resolution. By following exactly the same 
protocol for membrane preparation, the same clean and flat membrane was achieved 
without the need to check it every time.  
DLPC:DLPG membranes have a thickness of about ~ 3.2 nm [159, 160]. This thickness 
could slightly be influenced by the temperature [161], pH and the salts exist in the buffer 
[162].   
In order to measure the depth of this bilayer, we need to know what we call the (sensitivity 
calibration of the cantilever) to convert the deflection of the cantilever from volt to distance. 
This sensitivity value varies from cantilever to another and the calibration must be performed 
every time we need this value. Once this calibration is done, We find, by measuring the little 
step in the middle of the deflection curve that the bilayer depth is about 3 nm, matching the 
value of the expected depth of DLPC:DLPG lipid bilayers. 
A non-complete coverage of the mica by the SLB is also possible. This would result in step-
wise changes of ~3 nm height. It usually happens when the amount of the lipid vesicles 
injected on the mica is not enough to cover entirely the mica surface, leaving the mica partly 
uncovered. Such phenomena were avoided by injecting enough lipid vesicles to completely 
cover the mica.  
 
 
400 nm 
A B 
Figure 2.17: Force curve verification of the presence of a lipid bilayer 
on a mica surface. A)  A peak force tapping AFM image of a 
supported lipid bilayer. B) A force curve taken on the DLPC:DLPG 
(3:1) lipid bilayer surface with a breakthrough event (marked by the 
black circle) confirming the presence of the lipid bilayer. 
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To test the effect of antimicrobial peptides on the formed lipid membranes, we also need to 
verify that imaging itself does not alter or change the membrane topography. 
To confirm that AFM imaging does not deform the lipid model membrane, continued imaging 
on the same area of the membrane surface was performed over a course of an hour as 
shown in figure 2.18. The images show no considerable change in the topography or flatness 
of the membrane surface. This confirms that the membrane is immobilised well on the 
substrate and that the imaging operation is soft enough to avoid any deformation.  
This confirms that under the same conditions, and after injecting the studied peptides on the 
membrane, any topographical change or deformation of the membrane can be attributed to 
the peptides. 
2.3.9   Image Processing 
NanoScope Analysis (1.5), (1.7) and Gwyddion (2.34) are the software items used in this 
thesis to process the AFM images. Often, the first tool employed to process all AFM images 
is 1st or 2nd order plane subtraction, to remove background tilt of curvature. 
0 min 10 min 
25 min 34 min 
16 min 
43 min 
500 nm 
2 nm 
- 2 nm 
Figure 2.18: AFM images of a DLPC:DLPG (3:1) lipid bilayer surface 
imaged in buffer solution over the course of an hour. 
69 
 
In addition, we use line by line background subtraction, often called flattening, which aims 
to correct any remaining tilt or curving in the scan lines and to compensate for sudden line-
to-line changes in the imaging process. 
This plane subtraction and flattening tools can be applied on the whole image or on a 
selected area of the image that requires correction. As the images could include features 
like holes or aggregations, flatting was usually applied while a mask tool is performed to 
eliminate these features from the background fitting procedure.  
Once the image is process, the analysis tools were used to study the features shapes and 
dimensions.  
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Chapter 3 
Alpha Helical Antimicrobial Peptides 
3.1   Introduction: 
As discussed in chapter 1, many natural antimicrobial peptides adopt α-helical structure on 
bacterial membranes [163]. Natural helical AMPs include cathelicidins, cecropins, 
magainins, dermaseptins and buforins [164]. Helical AMPs interact with the bacterial 
membranes and many of them form pores causing cell lysis. The poration mechanisms, 
however, vary between the different peptides. While relatively few are studied in detail [165], 
it is still not obvious to understand the relation between the peptide sequence/structure and 
the mechanism by which the helical AMPs attack the bacteria. This chapter aims to provide 
an insight into this relation. Combined with the known structures and mechanisms of some 
natural AMPs, such an insight can facilitate the design of improved AMPs based on modified 
sequences of well understood peptides. Here, we will compare two synthesised peptides 
each with a sequence of 21 amino acids. They are both designed to form α-helices when 
interacting with the bacterial membranes. The only difference is that in the first one, called 
amhelin, all the positively charged amino acid used in the sequence are lysines (L), while in 
the second one, called tilamin, only three of them are lysines and the other six are arginines 
(R). Our collaborators in NPL have prepared both peptides and determined their structure 
using different techniques and investigated their biological activity against bacteria, as 
published in references [22, 159] and briefly reviewed below. The next sections then 
describe the AFM experiments carried out as part of this PhD research to determine their 
mechanism of action. 
3.2   Amhelin Peptide 
3.2.1   Amhelin Design and Structure 
Amhelin is a de novo amino acid sequence designed according to the heptad model 
(PPPHPPH) [166] where (P) corresponds to a polar amino acid and (H) corresponds to a 
hydrophobic amino acid, with the sequence containing three PPPHPPH repeats. Figure 
3.1.A shows the amhelin amino acid sequence highlighting the polar (P) and the hydrophobic 
(H) residues (top) and the cationic (C) and the neutral (N) residues (bottom) at neutral pH. 
As a unique feature of helical AMPs, the positively charged peptide is expected to 
preferentially interact with the negatively charged bacterial membranes and to fold into an 
amphipathic helical structure. 
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Thus targeting bacterial membranes, the peptide is antimicrobial against a wide range of 
bacteria. The expected secondary structure of the peptide is represented in figure 3.1.B, 
showing a top-down schematic view. It is presented like a wheel with the amino acids side-
chains protruding out of the peptide cylinder. This representation is highlighting the 
hydrophobic side along the peptide (located within the acute angle), attributed to leucines 
(L). All the other amino acids are aligned on the other side of the peptide cylinder (located 
around the reflex angle) and are hydrophilic. The length of the folded helix is about 3.15 nm 
attributed to 0.54 nm per turn. 
To confirm the helicity of the peptide, circular dichroism (CD) spectroscopy [167] was carried 
out on three different samples. The first sample is a control consisting of amhelin peptide in 
Figure 3.1:  Amhelin peptide sequence and secondary structure characterisation. (A) 
Amhelin amino acid linear sequence (middle) with the tokens of polar (P) and 
hydrophobic (H) amino acids (top), and the tokens of cationic (C) and neutral (N) 
amino acids (bottom). (B) Amhelin peptide as a helical wheel showing an 
amphipathic helix spanning ~3.15 nm (in blue, 2ZTA PDB entry [21], rendered with 
PyMoL). (C) CD spectra of amhelin (20 μM) in 10 mM phosphate buffer, in the 
absence (red line) and presence of ZUVs (blue line), both red and blue spectra are 
overlapped, and in the presence of AUVs (green line). (D) LD spectra of amhelin 
(solid line) and the non-AMP (dashed line) (both at 20 μM) in AUVs. 
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buffer solution. The second sample is amhelin peptide with the presence of zwitterionic 
unilamellar vesicles (ZUVs) formed by the neutral lipid (DLPC). This lipid composition 
mimics eukaryotic cell membranes [111]. The third sample is amhelin peptide in the 
presence of anionic unilamellar vesicles (AUV) formed by a mixture of two lipids; 
(DLPC:DLPG) with the mass ratio of (3:1) respectively. As mentioned in chapter 1, this lipid 
composition mimics prokaryotic (bacterial) cell membranes. The CD spectra of the control 
sample (amhelin in buffer) and the second sample (amhelin in buffer with neutral vesicles) 
are hardly distinguishable and show a negative signal near 195 nm confirming the 
disordered peptide structure [168], figure 3.1.C. On the other hand, the spectrum of the third 
sample (amhelin in buffer with negatively charged vesicles) shows a positive signal at 193 
nm and negative signals at 208 and 222 nm. These features are signatures for peptides with 
helical structure [168]. The CD data therefore confirms that amhelin folds into the 
amphipathic helical structure only when interacting with the negatively charged bacterial 
membrane.  
To understand the mechanism by which antimicrobial peptides interact with the bacterial 
lipid membrane and eventually disrupt it, it is important to know the orientation of peptide 
helices with respect to the membrane. To probe this, linear dichroism (LD) [167] 
spectroscopy was used for two different samples.  The first sample is the amhelin peptide 
and the second sample is a control that includes a peptide that is not antimicrobial (non-
AMP), both measured in the presence of anionic unilamellar vesicles (AUV). The LD data 
shows that the spectrum of amhelin presents peaks at 190-195 nm and 220-230 nm, and a 
minimum at 205-210 nm. These bands are indicative that the peptide is inserted in the lipid 
vesicles figure 3.1.D solid line; the spectrum of the non-AMP peptide shows no signals 
meaning that it cannot bind and orient itself in any specific direction with respect to the 
membrane, figure 3.1.D dashed line [169]. 
 
 3.2.2   Biological Activity of Amhelin 
As mentioned above, amhelin was designed as an antimicrobial peptide. To determine its 
activity against bacterial cells, a live/dead-stain (propidium iodide, PI) assay [170] was 
performed on two samples. The first sample was a control consisting of E.coli bacteria 
incubated with a non-AMP. The second sample was E. coli incubated with amhelin. The 
fluorescence data figure 3.2.B, show that for the control experiment and over 50 minutes of 
incubation, the number of the dead cells (red spots) has not considerably increased.  
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On the other hand, many dead cells appeared after 20 minutes of incubating E. coli with 
amhelin. A quantitative analysis of these results shows that amhelin can reach up to a 100 
% efficiency in killing E. coli within 60 minutes incubation, compared with the non-AMP 
peptide, which showed no significant effect, figure 3.2.A. 
To verify that amhelin shows similar antimicrobial activity against different bacteria, the 
standard minimum inhibitory concentration (MIC) assay [171] was performed on different 
types of bacteria, shown in table 3.1. E. coli and P. aeruginosa are Gram-negative bacteria, 
while the other three, B. subtilis, S. aureus and M. luteus, are Gram-positive.  
The data shows that amhelin exhibited antimicrobial activity against gram-negative and 
gram-positive bacteria with MICs that are typical of AMPs [172]. On the other hand, the data 
shows negligible lytic activity against human red blood cells, see table 3.1. This confirms 
that amhelin is not toxic to human cells at the studied level of antimicrobial concentrations. 
 
 
 
Figure 3.2: Amhelin biological activity. (A) Average number of stain-dead cells 
incubated with amhelin (blue) and the non-AMP, QIAALEQEIAALEQEIAALQ 
(green), as a function of time. (B) Fluorescence microscopy images of PI-stained 
E. coli cells. Incubation conditions: 10 μM peptide, 30 min, at OD600nm = 0.008. 
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3.2.3   Effect of Amhelin on Bacterial Membranes 
To determine the mechanism by which amhelin attacks the bacterial membrane, atomic 
force microscopy (AFM) was used. AFM was first applied on dried samples – by our 
collaborators at NPL – to image amhelin-treated bacterial cells (Escherichia coli) [159]. The 
images revealed some surface corrugation, but the interpretation of pore-like structures was 
complicated because of the intrinsic roughness of the damaged bacterial surface. 
To circumvent this problem and to facilitate real time AFM imaging, bacterial model 
membranes were used instead of whole bacteria, and the effect of amhelin was imaged on 
these membranes in liquid. Specifically, a supported lipid bilayer was chosen to mimic the 
negatively charged bacterial membrane. As mentioned in chapter 1, the flatness and less 
stickiness of the supported lipid bilayer allow more stable AFM scanning and yield clearer 
images. 
The lipid used is a mixture of DLPC:DLPG, with a mass ratio of (3:1), and the bilayer was 
prepared as explained in chapter 2.  
Once the flat lipid surface was prepared and characterised by AFM, the concentration of 
amhelin peptide to cause a discernible effect on the lipid bilayer was determined by trial and 
Bacterial Strains Minimum Inhibitory Concentration (MIC), µM 
E. coli (K12) 3 
P. aeruginosa (ATCC 27853) 12 
B. subtilis (ATCC 6633) 6 
S. aureus (ATCC 6538) >50 
M. luteus (NCIMB 13267) <12 
Eukaryotic Cells LC50 a 
Human erythrocytes >>600 
Table 3.1: Biological Activity of amhelin. Minimum inhibitory concentration assay for 
amhelin applied on different bacterial strains including Gram-negative bacteria (in 
red) and Gram-positive bacteria (In blue) as well as on human cells. a Median lethal 
concentration 
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error. The challenge was to find the concentration of the peptide at which the kinetics of 
membrane disruption was accessible within the time resolution of AFM imaging. 
Unsurprisingly, the rate at which the peptide attacks the membrane strongly depends on 
concentration and temperature.  
A high peptide concentration will lead to a rapid destruction of the lipid bilayer, and the AFM 
will not be able to track it. A very low concentration of the peptide, on the other hand, will 
lead to a very slow process and the subsequent AFM images will show no significant 
changes. The desired concentration for our mechanism-understanding purpose will lead to 
a relatively gradual and continued disruption of the membrane over the time scale of the 
AFM experiments. 
Figure 3.3 shows an example of an experiment where a high concentration of amhelin was 
applied to the lipid bilayer. It first shows a flat (DLPC:DLPG) negatively charged lipid bilayer 
imaged in buffer before adding any amhelin. The flatness of the bilayer is confirmed by the 
height profile bellow the image, showing only noise of at most a few Å on the vertical (z) 
scale.  At time zero, amhelin was added at a concentration of 0.75 µM. Figure 3.3.B is an 
image of the lipid bilayer after 18 minutes. The image shows a complete disruption of the 
membrane, as also evidenced in the height profile. 
-5 min  
 
18 min 
 
500 nm  
 
2 nm 
 
-2 nm 
 
A 
 
B 
 
Figure 3.3: The effect of high amhelin concentration on bacterial model 
membrane. (A) In liquid AFM Image of flat DLPC:DLPG (3:1 W:W) lipid bilayer. 
(B) Same sample but after incubating with 0.75 µM amhelin. Amhelin was 
injected on the sample at time 0 min. Buffer: 20 mM HEPSE + 150 mM NaCl 
pH≈7.4. 
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The more appropriate concentration of amhelin for AFM imaging was then determined to be 
0.5 µM. 
 
2 min 5 min 8 min 
11 min 14 min 19 min 22 min 
31 min 57 min 111 min 119 min 
145 min 196 min 204 min 
-2 min 
500 nm 
Figure 3.4: Time-lapse AFM images of DLPC:DLPG (3:1 W:W) supported lipid 
bilayer incubated with 0.5 µM amhelin. Amhelin was injected on the sample at 
time 0 min. The first image was acquired before the treatment with amhelin and 
shows a flat bilayer. The sample was prepared in a buffer of 20 mM HEPES 
and 150 mM NaCl, PH≈7.4. The experiment was carried out at room 
temperature 
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To monitor the effect of amhelin, multiple sequential topographical images were recorded 
on the same area of the bacterial model membrane. Figure 3.4 shows time-lapse images of 
the DLPC:DLPG (3:1 mass ratio) lipid bilayer and the degradation process following the 
addition of 0.5 µM amhelin. The first image was taken before the treatment, showing a flat 
lipid bilayer.  
 The effects of amhelin appeared instantly after injecting into the sample at time 0 min. The 
images show roughly circular pores that expand to gradually lead to a nearly complete 
removal of the membrane after about 3 hours. The pore expansion occurred in two ways, 
with single pores expansion in size and with different pores merging. The depth of the pores 
is consistent across the images, at about 3 nm as shown by the height profiles of three 
different pores figure 3.5.B. This pore depth was further confirmed by a heights analysis 
over a complete image of the same sample. Figure 3.5.C. The height histogram shows to 
main peaks corresponding to the two major heights recorded over the sample surface: the 
membrane surface at 0 nm and the substrate surface (pores) at ~ -3 nm. 
 
To interpret these results in terms of a poration mechanism, we have to elaborate on two 
key intrinsic features of amhelin peptide. 
 
Figure 3.5: Pores characterisation from by amhelin in bacterial model membrane. (A) 
AFM topography image of DLPC:DLPG (3:1) supported lipid bilayer incubated with 0.5 
µM amhelin over 5 minutes (taken from figure 3.4). (B) The corresponding cross section 
profiles drown on the image over three different pores showing consistent pores depth 
of ~ 3 nm. (C) Histogram profile of the image heights. Height (0 nm) represents the 
membrane surface while (-3 nm) represents the substrate.. 
500 nm 
 500 nm 
 
A 
B 
C 
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The first feature is the overall positive charge of the peptide, which is attributed to the nine 
lysine residues in its sequence. The isoelectronic point (pI) of lysine is 9.94 meaning that at 
the physiological, neutral pH (~7), lysine residues will be protonated giving the peptide a net 
positive charge of (+9). The second feature is the ability for the peptide to form an 
amphipathic structure caused by the segregation of the hydrophobic and hydrophilic faces. 
To avoid toxicity to human cells, the hydrophobic face, which is attributed to leucine 
residues, was designed narrow comparing with the positive face attributed to lysine with a 
ratio of (1:1.5) (Leucine:lysine) respectively. The haemolytic activities assay confirmed the 
apparent non-toxicity which is common for venom peptides to human cells. These toxic 
peptides normally have broader hydrophobic clusters [79, 173]. To maintain the ratio of 1:1.5 
mentioned above within the amhelin sequence, small alanines and neutral glutamines, 
which do not contribute to membrane binding, were alternately arranged in the polar face as 
a neutral cluster opposite to the hydrophobic face. The resulted secondary structure of the 
peptide helices is then stabilised by inter- and intramolecular forces upon binding to the 
bacterial membrane.  
The positively charged peptides first interact electrostatically with the negatively charged 
bacterial membrane and fold into amphipathic helices. At this state, which we call S-state, 
figure 3.6, amhelin helices remained stable for a time (< few seconds) that is too short to be 
resolved in these AFM experiments. To support this interpretation, molecular dynamics 
simulations were carried out to show that amhelin helices remained stable with slightly tilted 
orientations over timescales of 100 ns [159]. In this S state, the hydrophilic and positively 
charged side of the peptide face the membrane, while the hydrophobic (leucine) side is 
exposed out to the water, implying an energetically unstable state. This is forcing the peptide 
to induce tension on the membrane surface seeking stabilisation.  
 
Figure 3.6: Proposed pore expansion mechanism for amhelin as an 
amphipathic antimicrobial peptide. Amhelin peptides (blue cylinders) first 
bind to the surface of the membrane (S-state), then insert into the lipid 
bilayer forming pores (I-state), which can then expand (E-state).  
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When the tension is large enough, it leads to membrane poration. The first recorded AFM 
image after adding amhelin to the sample was after two minutes, figure 3.4. The image 
shows pores that have already developed to a diameter of around 300 nm. These AFM 
images therefore do not track the pore formation in the very early stage (the first two 
minutes) of the attack. The molecular dynamics simulations, however, showed that the 
poration primarily starts with hexameric and octameric pores constructed in the bilayer, 
which we call (I-state), figure 3.6. The root-mean-square displacement (rmsd), which is a 
measure of differences between values predicted by a model and the values actually 
observed, demonstrates that the expansion of pores double in diameter over timescales of 
order 100 ns [159]. In this state, the peptide helices align together in a bundle and stabilise 
by the intramolecular forces forming almost circular pores which is the lowest energetic state 
possible. The hydrophilic sides are aligned toward the core of the pores, exposed to the 
aqueous medium, while the hydrophobic side is hidden inside toward the hydrophobic fatty 
acid chains of the lipids. The length of the peptide helices is matching the thickness of the 
lipid bilayer (~3nm), making it difficult to identify the peptides themselves in the AFM height 
profiles. However, the edges of larger pores were shown to be lined with helical peptides by 
high-resolution secondary-ion mass spectrometry (SIMS) [159]. In that experiment, amhelin 
which was 15N-labeled at alanine and leucine residues, and attacked the membrane under 
otherwise similar conditions. SIMS images showed a higher signal intensity from regions of 
the surface rich in peptide, which were found at the edges of the pores.  
Finally, our AFM images indicated that these peptide bundles that triggered the pores in I-
state allowed more and more peptides to join making wider pores in a state that we call E-
state figure 3.6. This evolving state is attributed to the fact that the intramolecular forces 
(peptide-peptide and peptide-lipid) are not rigid enough to arrest the initiating pores in I-
state. As the diffusion of peptides across the membrane available, the complete rupture of 
the membrane eventually occurred by either a continued expansion of individual pores or by 
pores merging.  
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3.3   Tilamin Peptide 
3.3.1   Tilamin Design and Structure 
Tilamin was also designed to be a three repeats of the heptad model (PPPHPPH) where (P) 
and (H) are polar and hydrophobic amino acid residues respectively. Tilamin however differs 
from amhelin in the positively charged amino acid used in the sequence. In tilamin, six of 
the positively charged amino acids in the sequence are arginines (R) and only three of them 
are lysines as shown in figure 3.7.A. The aim of this change is to understand whether such 
a small tweak in the amino acid residues will change the structure of the peptide assembly 
under the same conditions as well as its antimicrobial activity and the mechanism of action. 
Similar to amhelin, the amino acid arrangement in tilamin allows the peptide to fold into a ~3 
nm helix when interacting with the bacterial membranes. The folded structure makes a 
segregation of the hydrophobic and the hydrophilic residues along the peptide cylinder 
leading purposely to an amphipathic assembly. The proposed folded secondary structure of 
tilamin is presented schematically in figure 3.7.B. Leucine (L) residues are aligned on one 
side of the peptide cylinder highlighted by the arc while the hydrophilic residues are on the 
other side of the peptide cylinder.  
The helical structure of tilamin was confirmed by CD spectroscopy. In these experiments, 
four different samples were examined to produce a CD spectrum for each shown in figure 
3.7.C. These four samples were; tilamin in phosphate buffer, tilamin mixed with anionic 
unilamellar vesicles (AUVs), tilamin mixed with zwitterionic unilamellar vesicles (ZUVs) and 
a non-AMP peptide mixed with AUVs. Only the spectrum belong to sample 2 (tilamin mixed 
with AUVs ) shows a positive peak at 193 nm and negative ones at 208 and 222 nm which 
are indicative of the alpha helix structure [174]. The other three spectra are nearly 
overlapping and show no such signals indicating disordered peptides structures [174].  
This confirms that tilamin adopts helical structure only when it interacts with the negatively 
charged lipid membrane. Linear dichroism spectroscopy (LD) was also used to investigate 
the orientation of tilamin helices with respect to the lipid membranes [75]  
Four samples were studied, namely; tilamin with AUVs and ZUVs, and a non-AMP control 
peptide with AUVs and ZUVs. Figure 3.7.D shows the spectrum of each sample. The one 
that belong to tilamin in AUVs is clearly distinguished with positive peaks at 190-195 and 
220-230 nm and a vague minimum at 205-210nm. 
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These peaks are indicative of oriented peptides [175]. Comparing with amhelin LD spectrum 
shown in figure 3.1.D, the peaks for tilamin with AUVs are broader. More importantly, the 
peaks here have positive values indicating that tilamin has a more parallel orientation to the 
membrane normal and the direction of the excitation light  [169, 175]. 
3.3.2   Biological Activity of Tilamin  
Tilamin shows an antimicrobial activity against different types of bacteria and with no 
considerable toxicity to human cells under the same conditions.  
Figure 3.7: Tilamin peptide sequence and secondary structure characterisation. 
(A) Tilamin amino-acid linear sequence (Middle) highlighting the polar (P) and 
hydrophobic (H) amino acids residues (lower), and the cationic (C) and neutral 
(N) amino-acids residues (upper). (B) Tilamin peptide as a helical wheel showing 
an amphipathic helix (C) (CD) spectra for tilamin in the DLPC/DLPG (3:1) AUVs 
(solid line), DLPC (dotted line) and phosphate buffer (dash-dotted line) and for 
non-AMP in the DLPC/DLPG (3:1) AUVs (dashed line). Peptides were at 30 µM, 
at lipid/peptide 100 molar ratios. (D) (LD) spectra for tilamin in DLPC/DLPG) (3:1) 
AUVs (solid line) and DLPC (dotted line), and for non-AMP in DLPC/DLPG (3:1) 
AUVs (dashed line) and in DLPC (dash-dotted line). Peptides were at 30 µM, at 
lipid/peptide 100 molar ratios. 
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Table 3.2 compares the minimum inhibitory concentration (MIC) of tilamin with amhelin and 
three other well-known antimicrobials, namely; cecropin B, daptomycin and polymyxin. 
Seven types of gram-positive and gram-negative bacteria were examined in the assay as 
well as the human red blood cells.   
The results show that tilamin is effective in the same concentration ranges when compared 
with the other antimicrobials against all the studied types of bacteria. Tilamin also shows 
less toxicity to human red cells comparing with the other antimicrobials. 
 
 
Cell 
Peptidea 
tilamin amhelin cecropin B daptomycin polymyxin B 
Minimum inhibitory concentrations, µM 
P. aeruginosa 
(ATCC27853) 
4.0 12.3 1.6 >100 <1 
S. aureus 
(ATCC6538) 8.8 
>50 >100 7.7 <50 
E. coli (K12) 
10.2 
3.0 <1 >100 <1 
B. subtilis 
(ATCC6633) 
<1 6.2 >50 7.7 1.5 
S. enterica 
(ATCC700720) 
3.1 
6.2 3.1 >50 <1 
E. faecalis 
(OG1X) 
3.1 6.2 25 >100 >100 
M. luteus 
(ATCC 7468) 
<1 
7.1 <1 15.4 <1 
(LC50)
b, µM 
Human 
erythrocytes 
104 12 x 103 8.3 x 103 103 N/D 
Table 3.2: Minimum inhibitory concentration (MIC) assay indicating the biological activities of 
peptides used in the study. Red, blue and green denote gram-negative, gram-positive and 
gram-variable bacteria respectively. anon-AMP was inactive (>>250 µM). bmedian (50%) lethal 
concentration calculated from the actual percentage of lysed bacteria populations at 500 µM.  
N/D – non-detectable. All tests were done in triplicate. 
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Although the results of MIC assay indicate the amount of the antimicrobials needed to inhibit 
the bacterial growth overnight, it does not give kinetic information about how quick the 
response is against bacteria. To probe this, a live/dead-stain (propidium iodide, PI) assay 
[170] was performed on E coli as a good model for gram-negative bacteria. The fluorescence 
data shows that, at MIC, tilamin is three times quicker in killing bacteria comparing with 
cecropin B and amhelin, figure 3.8. The fluorescence data were compared to a non-
antimicrobial peptide as a reference which shows no impact on bacteria.  
 
3.3.3   Tilamin Mechanism on Bacterial Membrane 
AFM imaging was used to determine the mechanism by which tilamin attacks the bacterial 
membranes and to probe whether it differs from amhelin mechanism. For comparison, AFM 
experiments were performed under similar conditions of those applied for amhelin. Exactly 
the same supported lipid bilayers were prepared as bacterial model membrane using the 
lipid composition of DLPC:DLPG (3:1) mass ratio.  A flat lipid bilayer was reconstituted and 
imaged before adding any tilamin as shown in figure 3.9.  
 
Figure 3.8: Comparison of antimicrobial kinetics of tilamin and other studied 
peptides. (A) Average numbers of stain-dead E. coli cells incubated with tilamin 
(blue), amhelin (orange), cecropin B (grey) at MICs, amhelin at 3xMIC (dark 
blue) and the non-AMP at 10 µM (yellow) as a function of time. The data 
represent mean values ± s. d. (B) Fluorescence microscopy images of PI-
stained E. coli cells. 
84 
 
 
100 nm 
-3 min  30 min  
33 min  36 min  39 min  
42 min  45 min  48 min  
51 min  54 min  57 min  
2 nm  
-2 nm 
27 min  
Figure 3.9: Time-lapse in-liquid AFM images of DLPC:DLPG 
(3:1 W:W) supported lipid bilayer incubated with 1.5µM tilamin. 
Tilamin was injected on the sample at time (0) minutes. The first 
image was taken before the treatment with tilamin and shows a 
flat bilayer. The sample was prepared in buffer of 20 mM 
HEPES and 150 mM NaCl, PH≈7.4 and AFM performed in room 
temperature 
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Tilamin peptide was then added at time 0 min to a total concentration of 1.5 µM in the 
sample. AFM time-lapse imaging was carried out over the same surface for an hour. The 
subsequent images after adding the peptide show that tilamin forms small pores which are 
distributed over the membrane surface. Unlike amhelin, the pores formed by tilamin did not 
develop in size over time. On the other hand, the number of pores has increased.  
The diameter of each pore is constant at about ~15 nm. Zoomed-in images were taken 
shown in figure 3.10. Unlike amhelin, the height profile in figure 3.10 right shows that the 
pores formed by tilamin have depths of about ~1.5 nm. 
In addition, pores could gather in clusters to form bigger compressed membrane areas with 
~1 - 1.5 nm depth. Figure 3.11 shows a bacterial model membrane incubated with 1.8 µM 
tilamin. Figure 3.11.a shows a membrane image captured before injecting tilamin peptide 
which confirms the flatness of the membrane. Once peptides were added, they appeared to 
form clustered pores distributed all over the sample as shown in image 11b. The magnified 
area on image in figure 3.11.b highlighted by the dashed square is shown in figure 3.11.c. It 
shows that the lesions created by tilamin peptides take the form of depressed membranes 
patches with ~ 1.5 nm depth as illustrated in the corresponding height profile on figure 
3.11.d.  
 
40 nm 
 
Figure 3.10: Pores characterisation formed by 1.5 µM tilamin on bacterial 
model membrane. (Left) Zoomed in-liquid AFM topography image taken from 
the area highlighted by the white dashed frame shown on the last image in 
figure 3.9. (Right) the corresponding height profiles of three selected pores 
highlighted by the white dashed lines on the image. The profiles show 
consistent pores depth of ~ 1.5 nm and diameter or ~ 15 nm.  
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The amphipathic assembly and the positive overall charge of tilamin as key antimicrobial 
features are similar to those discussed for amhelin. Changing six of the positively charged 
amino acid, lysine to arginine, however, has influenced the mechanism and results in 
shallower and non-expanding pores 
To understand how helices spanning 3nm (tilamin) drill and stabilise holes of only 1.5 nm 
depth in the membrane, we proposed a mechanism shown in the schematic representation 
in figure 3.12.  
1 µm 
2 nm  
- 2 nm  
500 nm 
500 nm 
a b 
c d 
Figure 3.11: In-liquid AFM images of DLPC:DLPG (3:1) lipid bilayer 
incubated with 1.8 µm tilamin. (a) Image of a flat membrane before treating 
with tilamin peptide. (b) Image of the membrane treated with 1.8 µM tilamin 
showing clustered pores. (c) A magnified image of the area highlighted by 
the dashed square on b. (d) The corresponding cross section profile 
(dashed line on c) showing compered membrane with ~1.5 nm depth. The 
sample was prepared in buffer of 20 mM HEPES and 150 mM NaCl, 
pH≈7.4 and performed under room temperature 
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It shows that tilamin peptides orient with a tilted state to stabilise with a monolayer removal 
of the lipid membrane, compared with the 3 nm deep, bilayer removal for those formed by 
amhelin.  
Tilamin peptides here undergo two stages when interacting with the bacterial membrane. 
The first stage which we call S-state is initiated by the electrostatic interactions between 
positively charged amino-acid residues (arginines and lysines) and the negatively charged 
membrane. This leads tilamin to fold into amphipathic helical structure similar to amhelin.  
The hydrophobic amino-acid residues (Leucines) are then exposed to water which is not 
energetically stable. Hence, tilamin will seek stabilisation by drilling into the membrane to 
hide the leucine residues within the lipid membrane and to interact with the hydrophobic lipid 
tails. 
Arginine however allows extensive H-bonding with its five hydrogen bonds donors to 
stabilise Arginin–lipid headgroups clusters unlike lysine which allows only one hydrogen 
bond [176], figure 3.13. These bonds contribute in holding tilamin back from diffusing freely 
over the lipid surface. In addition, arginine has a pKa of 12.48 comparing with 10.79 for 
A 
Fig 3.12: Proposed interactions and insertion mechanism of tilamin in the 
bacterial membrane. (A) Schematics of pore edges showing depths of insertion 
for proposed monolayer and transmembrane poration mechanisms. For clarity, 
only one peptide (blue cylinder) and one phospholipid per layer are shown 
(aliphatic chains in grey, headgroups in pink). (B) Proposed mechanism for 
antimicrobial monolayer poration. Peptides (blue cylinders) bind to the membrane 
surface – “S”-state (upper), and insert with forming pores in the outer leaflet of 
the bilayer – “M” state (lower). 
B 
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lysine, figure 3.13. This makes 
arginine a stronger base with a more 
stable translocated positive charge on 
the two amine groups under the same 
condition [176, 177]. This supports 
stronger electrostatic interactions 
between tilamin peptides and lipid 
headgroups, compared with amhelin.  
While the hydrophobic interactions 
promote a deeper penetration, the 
electrostatic interactions arrest the 
peptide in the lipid headgroup region [178]. These conflicting forces are compensated in a 
tilted peptide orientation spanning only halfway through the membrane removing only the 
upper leaflet of the lipid bilayer. Such an orientation hides leucine residues from the 
hydrophilic medium and allows electrostatic interactions to lock the peptide from diffusion.  
For such shallow pores to form, however, one would expect that the hydrophobic tails of the 
lower membrane leaflet are exposed to the aqueous medium, which is again not a 
favourable, stable state. This may be true for a real bacterial membrane [22], however, in 
the model membrane conditions, this state could stabilise as the lipids of the lower leaflet 
are bound to the substrate via relatively strong electrostatic interactions. 
3.4   Conclusion 
In conclusion, we have demonstrated that the two peptides amhelin and tilamin show 
effective antimicrobial properties and negligible cytotoxicity. The experimental data indicated 
that both peptides fold into helical amphipathic structure of 3 nm length.  
Atomic force microscopy has revealed a difference in the mechanism by which the two 
peptides attack and disrupt the bacterial model membrane. Amhelin, which has lysines as 
the positive charged amino acid, attacks the bacterial membrane and orients along the 
membrane thickness forming expanding pores until the membrane removal. Tilamin on the 
other hand has six arginine residues. Upon membrane attack, it assumes a tilted 
configuration with respect to the membrane surface, to form shallower static pores, removing 
only parts of the upper leaflet of the membrane bilayer. 
  
Figure 3.13: The chemical structure of Lysine and 
Arginine amino acids with the pKa values. 
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Chapter 4 
Antimicrobial Capsules for Gene Delivery 
4.1   Introduction 
Gene therapy is a promising solution against many genetic diseases. In principle,  genetic 
disorders can be cured by replacing or disrupting defective genes using synthetic nucleic 
acids or analogues [179]. In practice, a main challenge remains in finding  delivery vectors 
that can safely deliver  therapeutic nucleic acids to the targeted human cells [180]. Viruses 
can be developed as transfection vectors and are the most efficient for gene delivery but 
there are safety concerns associated with their use including immune reactions and 
insertional mutagenesis [181]. Synthetic non-viral vectors, on the other hand, still greatly 
lack the required structural integrity. The ideal delivery vector therefore is considered as a 
compromise between viral and synthetic vehicles. This would be a nanoscale device which 
structurally mimics native viruses to efficiently deliver genes, but is directed to do so at the 
designer's whim. 
In addition to the challenge of designing effective and safe delivery vectors, gene delivery 
can be compromised by bacterial infections. This prompts the need for vehicles that are able 
to not only deliver nucleic acids to human cells but also kill pathogens [182]. With the rise of 
antimicrobial resistance, supramolecular chemistry may provide creative solutions to the 
challenge by designing synthetic systems with a dual functionality, i.e., gene delivery and 
antimicrobial activity.  
In this chapter, the design of a synthetic antimicrobial capsule (termed capzip) is discussed, 
as developed by our collaborators at NPL. The results show that the capsules successfully 
and safely deliver siRNA to human cells in addition to being toxic to bacterial cells. As part 
of this PhD research, the antimicrobial attack on the bacterial membranes was monitored by 
atomic force microscopy in real time to elucidate the mechanism of action. 
4.1.1   Antimicrobial Virus Design 
The building block of the devised capsule was inspired by a breast-milk protein lactoferrin 
shown in figure 4.1 [183]. The antimicrobial motif within the protein consists of 6 amino acids 
(RRWQWR) which folds into an amphipathic β-strand which tends to interact with another 
strand (blue and green) via hydrogen bonds, figure 4.2.a [184]. This motif, if isolated from 
the rest of the protein, exhibits negligible antibacterial properties, but does not co-assemble 
into capsules [2].  
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Capsules in nature like in virus capsids employ 
noncovalent interactions between subunits to direct the 
assembly into icosahedral cage architectures [185].  
With such inspiration in mind, we modified the amino 
acid sequence of this natural building block to allow 
particular supramolecular interactions between the 
engineered subunits to co-assemble into capsules.  
First, we have substituted the amino acid glutamine (Q) 
by threonine (T). This change is to copy the well-known 
tryptophan zipper sequence with a characteristic core 
motif WTW. This motif adopts β-sheet conformations 
Figure 4.1: Structure of the 
recombinant N-terminal lobe of 
human lactoferrin determined 
by X-ray crystallography at 2.0 
Å resolution [19] 
Figure 4.2: Capzip design. (a) Antimicrobial lactoferrin peptide (PDB entry 1LFC 
rendered by PyMol [20]) with the RRWQWR motif highlighted in blue (top). The motif 
is converted to a self-complementary RRWTWE β-strand (bottom). (b) Three copies 
of RRWTWE are conjugated into a β-strand triskelion. For clarity only two triskelions 
forming a β-sheet are shown and highlighted in different colours. (c) Triskelions self-
assemble via a β-sheet-formation following a trilateral honeycomb-like symmetry. (d) 
The chemical structure of the triskelion. (e) A β-strand triskelion model with arginine 
and tryptophan residues highlighted by blue and yellow, respectively. The figure was 
reproduced from reference [2]. 
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with cross-strand tryptophan rings packed tightly against one another [186], figure 4.2.a.  
Secondly, we have substituted the positively charged amino acid arginine (R) at the C-
terminal by the negatively charged amino acid glutamic acid (E). This change will increase 
the self-complementary of the β-strands and direct to arrange antiparallel. The self-
complementarity is enhanced from the positive-negative electrostatic interactions arising 
between the amino-acid side chains of opposite termini (R and E), figure 4.2.a.  Finally, we 
can learn from natural virus architecture, which adopts an n-fold rotational symmetry, where 
n is usually 3 or 5 or both [180].Thus, to induce the three dimensional symmetrical self-
assembly, we have linked three of the resulted β-sheet motifs into triskelion figure 4.2.d, 
[185]. The resulted triskel conjugate of RRWTWE is reminiscent of native cage-like subunits 
figure 4.2.b–e. In the triskel conjugate, RRWTWE is prone to fold as a β-turn and pair into a 
β-sheet with another arm of another conjugate [184]. Triskelions are then expected to 
propagate into two-dimensional sheets whose increasing curvature would facilitate the 
formation of a three dimensional capsule. 
4.1.2   Capzip Characterisation  
The capzip assembly conditions were kept constant for reproducibility. As explained in detail 
in chapter 2, the monomers (capsule subunits) were dissolved to a concentration of 100 µM 
in a buffer solution of pH 7. The sample was then incubated over night at room temperature 
to allow time for complete assembly. Various experiments showed that capzip readily 
assembles into morphologically uniform and polydisperse hollow capsules with dominating 
size ranges of 20–200 nm. The assembled structures were confirmed by atomic force 
microscopy (AFM), transmission electron microscopy (TEM) and cryo-scanning electron 
microscopy (SEM) [2]. Figure 4.3.a shows an in-liquid AFM image with capzips in different 
sizes, with diameters typically in the range of 20-100 nm. The cross section profiles in figure 
4.3.b show sizes of the three selected capzips highlighted by the white dashed lines. The 
three measured capzips have almost overlapped cross section profiles with about 60 nm 
width (diameter) and 30 nm height.  Figure 4.3.c shows AFM images of dried samples. 
Circular dichroism (CD) microscopy has confirmed the β-sheet secondary structure of the 
peptides making up the capsules with and without an siRNA cargo. Figure 4.3.d is CD 
spectra of capzip with siRNA (dashed line) and without siRNA (solid line). The CD spectra 
show minima at λ = 200 and λ = 214 nm, which are characteristic to β-turns confirming β-
sheet secondary structure of the subunits within the assembled capsules.  
 
92 
 
  
4.1.3   Gene Delivery and Antimicrobial Property 
To assess the dual functions that are aimed for with this design, capzips were tested for 
their ability to deliver gene to human cells and the antimicrobial responses on bacterial cells. 
For gene delivery, capzip successfully co-assembled with model siRNAs (21 base-pairing 
duplexes) to form structures similar to those assembled in the absence of the cargo 
materials. CD and SAXS data confirmed a successful encapsulation of the cargo [2]. The 
two techniques along with AFM and TEM, all confirmed a consistent structure of capzip with 
and without cargo [2]. The successful gene delivery to human cells and silencing gene 
expression were investigated by florescence microscopy. 
Figure 4.3: Capzip characterisation. (a) In liquid (buffer) AFM topography images of 
capsules on mica. (b) The cross section profiles for the three selected capsules by 
the dashed white lines A, B and C in a. The colour scale is 80nm. (c) In-air AFM 
topography images of capsules (dry samples) on silicon wafer with their 3D 
representations. Colour scales are 20 nm (upper) and 60 nm (lower). (d) CD spectra 
for capzip (solid line) and capzip with siRNA (30 mM, dashed line) 
B 
A 
C 
a c 
b 
d 
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The data shows that capzip delivered fluorescent siRNA to HeLa cells within the first hour 
of incubation [2]. The effect of this transferred gene into HeLa cells was measured by 
monitoring the knockdown of two genes meant to be expressed within the cells. The 
experiments compared knockdown levels of HeLa cells treated in three different ways. 
Firstly, with siRNA alone (without delivery vehicle) as a negative control, secondly; using N-
TER® and Lipofectamine®  which are commercially available vectors as positive controls 
for successful siRNA delivery, and finally using capzip. All samples were treated using the 
same siRNA materials under same conditions. The data were normalised to the first sample 
(negative control) and show that capzips successfully silence mRNA expression in the same 
range of efficiency as for the commercial vector N-TER®. Lipofectamine® however showed 
about 25% more positive result but that was on the expense of substantially reduced cell 
numbers indicating apparent cytotoxicity [2].  
Figure 4.4: Capzip antimicrobial activity. (a) Confocal micrographs of bacterial 
cells after 16 hour incubations with and without capzip, stained with membrane-
permeant SYTO®9. White histogram bars denote total cell counts (%) for 
bacterial colonization with capzip after subtracting background adhesion taken 
as 100%. (b) Biological activity of capzip in comparison with two other known 
antimicrobial agents. The panels were reproduced from Ref. [2]. 
b 
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The antimicrobial property of the capzip was also tested against a range of planktonic cells 
types using fluorescence microscopy and via the minimum inhibitory concentration assay. 
Figure 4.4.a shows dead-stain assays [170] applied on three types of bacterial cells, namely; 
E. coli, P. aeruginosa and S. aureus. The total cell-count was measured using confocal laser 
scanning microscope differentiating between live cells which stain green and dead ones 
which stain red [2]. Capzip shows a 100% efficiency in killing the three tested types of 
bacteria within 16 hours. Figure 4.4.b shows a table comparing the minimum inhibitory 
concentrations [171] of capzip with ampicillin and gramicidin as two well-known 
antimicrobials. The numbers in the table indicate that capzip has values of MIC in same 
range of those for the other agents. The table also shows that capzip, similar to the other 
antimicrobial, does not show toxicity towards Bovine erythrocytes, as verified with a 
haemolysis assay (LC50) [2]. 
4.2   Mechanism of Antimicrobial Attack 
Atomic force microscopy was utilised to image capzip in liquid while attacking the bacterial 
model membranes, showing large membrane disruption. Similar to what was described in 
chapter 3, a supported lipid bilayer was chosen to mimic the negatively charged bacterial 
membrane, facilitating high resolution imaging. The lipid used is a mixture of DLPC:DLPG 
with a mass ratio of (3:1), and the bilayer again was prepared by the same protocol explained 
in chapter 2. 
As usual with these experiments, supported lipid bilayer were used as model membranes, 
and their integrity and flatness were verified before exposing them to capzip as shown in 
figure 4.5.a. The flatness of the surface is confirmed by the cross section profile (right) 
corresponding to the white dashed line in the AFM image. High capzip concentrations (5 
µM) led to a major disruption of the membrane, as illustrated in figure 4.5.b, which shows an 
AFM image of the same area as in figure 4.5.a but after incubation with 5 µM capzip. The 
depth and heights of some features are shown by the cross section profile figure 4.5.b right. 
The profile shows pores with ~3nm depths, which is consistent with the expected lipid bilayer 
thickness. The aggregations however could be lipid vesicles formed from the peeled-off 
lipids or lipid-peptides aggregations. 
After several experiments to optimize measurement protocols, the optimum concentration 
of capzip was found to be ~2 µM (at room temperature). This concentration appeared 
enough for capzip to diffuse across the sample while disrupting the membrane at a time 
scale that was accessible for AFM experiments. 
 
95 
 
 
Figure 4.6 is a time-lapse sequence of AFM images over 17 minutes showing capzips 
attacking the bacterial membrane. The first image shows a flat and clean membrane surface 
acquired two minutes prior to capzip injection. Capzip dosage was injected at time 0 min at 
a concentration of ~ 2 µM.  
The second image was acquired 5 minutes after capzip injection, showing membrane pores 
as well as capsules that are still intact (yellow particles), highlighted by white boxes and 
arrows. Capzip interacted with the bacterial membrane and over time some of them have 
descended in the membrane making pores at their precise landing positions. The pores 
sizes stay constant during the operation time of the experiment (120 minute). 
500 nm 
 
a 
b 
 
Figure 4.5: AFM images in liquid showing the effect of high capzip 
concentration on bacterial reconstituted membranes.  (a) Image of the 
membrane before adding capzip (left). The flatness of the membrane surface 
confirmed with the cross section profile (right) of the area highlighted by the 
white dashed line. (b) Image of the same area after adding 5 µM of capsules 
(left). destruction of the membrane is confirmed by the height profile (right) of 
the area highlighted by the white dashed line. Colour scale is 40 nm. 
Experiment was done under the room temperature. 
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We next analysed the sizes of capsules and membrane pores in the second image of figure 
4.6 (5 minutes after injection). Figure 4.7.a shows the image highlighting the features 
(turquoise colour) that have heights of at least 0.3 nm with respect to the membrane surface. 
The table in figure 4.7.a right shows six features in total (capsules) that have diameters of 
30 ± 3 nm. The pores appearing in the same image were caused by capsules that had 
interacted with the lipid membrane and disassembled in less than 5 minutes. 
Figure 4.7.b shows the depth analysis of the highlighted pores, which have depth of at least 
0.2 nm below the membrane surface. The table in figure 4.7.b right shows that there are 37 
pores counted with a mean depth of 1.2 ± 0.6 nm below the membrane surface. Given the 
small pore size at the scale of this images, the thus observed pore depth values may well 
depend on AFM tip size and the precise surface tracking in the AFM experiment.   
5 min 
 
8 min 
 
11 min 
 
14 min 
 
17 min 
 
-2 min 
 
200 nm  
 
Figure 4.6: AFM time lapse images of a bacterial model membrane incubated with 
capzip at room temperature.  The time stamp refers to the moment of capzip 
injection on the sample happened at time (0) minutes. White boxes and arrows are 
to highlight capzips. The total concentration of capzip in the sample is ~ 2µM.  
Colour scale is 6 nm. The full movie is available online with the supportive 
information of the published paper [2]. 
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To analyse the conversion of an individual capzip into a pore, figure 4.8 shows a sequence 
of magnified AFM images with a capsule that took 14-17 minutes to convert into a membrane 
pore at it precise landing position. From the cross section profiles (dashed white lines) on 
the images, the capsule initially appears with a height of 2 - 2.5 nm. The measured height 
then decreased over time until the capsule completely disappeared and transformed into a 
pore of ~ 2 nm depth. 
 
 
Figure 4.7:  Size analysis of capsules and pores. (a) AFM image of a bacterial 
model membrane incubated with 2 uM capzip for 5 minutes. A mask is set to define 
features that are at least +0.3 nm above the membrane surface. 
Features/capsules with height above 0.3 nm are thus highlighted in blue. The table 
on the right shows size estimates for the highlighted features (capzips on the 
membrane). (b) The same AFM image but with the mask set to define features 
that are at least 0.2 nm below the membrane surface, to highlight membrane 
poration. Table on the right shows sizes of the highlighted features (pores). 
Threshold = above + 0.3 nm 
 
200 nm  
 
a 
 
Threshold = below - 0.2 nm  
 
b 
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4.3   Discussion 
As explained above in the design section, capzip subunits are devised to interact with each 
other to complete the formation of hollow capsules. The stability of capzip structure is 
attributed to the inter-molecular interactions between the subunits’ arms. These interactions 
were probed (by our collaborators) and confirmed by circular dichroism microscopy, FTIR 
and small angle X-ray scattering (SAXS) [2]. However, the pH of the solution is essential to 
maintain these interactions. For example, arginine (R) and glutamic acid (E) are positive and 
negative amino acids, respectively, and the electrostatic interactions between them are part 
of the capzip stability mechanism as explained in the design section of this chapter. The pKa 
and pI values for these two amino acids are, respectively, 13.2 and 10.76 for arginine, and 
4.25 and 3.08 for glutamic acid. In a solution with pH 7 (i.e., neutral and physiological), 
arginine will be protonated and have an overall positive charge, while glutamic acid will be 
deprotonated and have a negative overall charge. Although this has yet to be experimentally 
verified by AFM or laser scattering techniques, having a medium with more acidic or more 
basic pH will affect the balance of the opposite interacting charges which might destabilise 
the capsule structure.   
The AFM data shows that capzip binds to and next collapses on/into the negatively charged 
bacterial model membranes. This is triggered by the electrostatic interactions initiated after 
the first contact between the positively charged arginine within the capzip subunits and the 
negatively charged lipid headgroups.  
Figure 4.8: Time-lapse sequence of AFM images at higher magnification, showing a 
landing capzip on the bacterial model membrane. The time stamp refers to the moment 
of capzip injection into the sample at 0 min. The colour scale is 6 nm. Dashed lines 
highlight the lines for which height profiles are shown in the lower panel. The total 
concentration of the capzip in the sample is 2 µM. The experiment was done at room 
temperature.    
50 nm 
-2 min  5 min  8 min  11 min  14 min  17 min  
99 
 
 
These interactions cause disruption in the membrane and the capzip structure. After some 
time, capzip will disintegrate into either completely discrete and separate subunits or they 
may keep a form of association between their arms. Our data do not allow us to distinguish 
between these two scenarios. That said, as explained above, the subunits arms are β-
strands, which tend to arrange antiparallel with the hydrogen bonds, bridging the backbones 
together as shown in the schematic in figure 4.9.  
In addition to hydrogen bonding, the two strands are further stabilised by interactions 
between side chains of some amino acids, in particular tryptophan- tryptophan (W-W) and 
arginine-glutamic acid (R-E) interactions. This suggests that capzip collapse could happen 
while keeping subunits arms arranged together with some reorientation due to the transition 
from a hollow sphere into an energetically stable pore-forming state within the membrane. 
AFM data confirms that the pores have a depth of ~ 2 nm. This matches the length of the 
subunit arm formed by 6 amino acids as each residue within a β-sheet secondary structure 
spans ~ 0.3 nm [187], figures 4.9 & 4.10.a. It also matches the thickness of one leaflet of 
the lipid membrane, figure 4.10.b. A hypothetical stable pore-state for capzip subunits within 
the bacterial membrane, consistent with our experimental data, is illustrated in figure 4.10.c 
& d. The suggested pore depth of ~ 2 nm is determined by the triskelions arms spanning 
only halfway through the membrane. Each arm is associated with another arm from another 
triskelion. The two associated arms have a hydrophobic side formed by the hydrophobic 
side chains and a hydrophilic side formed by the hydrophilic side chains. The hydrophobic 
side faces and interacts with the hydrophobic tails of the lipids and the hydrophilic side is 
pointing toward the core of the pore to interact with the aqueous medium. 
Figure 4.9: Schematic representation of two β-strands arranged antiparallel with 
hydrogen bonds between the backbones. Coloured circles denote amino acid 
side chains. Each amino acid spans ~ 0.3 nm along the contour of the peptide.  
0.3 nm 
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The bottom of this pore consists of the hydrophobic tails of the lower leaflet of the lipid 
bilayer. This can only be stable as the head groups are bound to mica substrate, which is 
not the case in the real, free-standing bacteria membrane.  In general, it is not energetically 
stable for the hydrophobic tails of the lower leaflets to remain exposed to the aqueous 
medium. This non-stable state could then induce a quick lipid rearrangements leading to 
membrane disruption and cell lysis.   
 
4.4   Conclusion 
In summary, this chapter describes a conceptual design for virus-like capsules with dual 
biological activity. Similar to viruses, the capsules self-assemble from individual subunits 
2nm 
2nm 
a b 
c d 
Figure 4.10: Schematic representation of the proposed stable (meta-)pore-state 
for capzip subunits within the bacterial membrane. (a) Two associated triskelions 
interacting via their arms which span 2nm. (b) Cartoon of a lipid bilayer, 
highlighting the depth of one leaflet. (c) Schematic of a top-down view for the 
pore formed by capzip subunits, highlighting the horizontal arms around the pore 
edges. (d) Schematic showing triskelions forming the walls of the pores within 
the membrane. 
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and promote gene delivery. AFM has confirmed a consistency in the capsule structure with 
a variety in size. This plasticity is an advantageous for ensuring that capsules are not limited 
to hosting only specific sizes of cargo like viruses. Along with other techniques, AFM has 
also confirmed the antimicrobial function of the capsules. The images show capsules 
attacking bacterial model membranes to form pores on their precise landing positions. A 
possible attacking and pore-forming mechanism has been explained.  
To farther elucidate and confirm this mechanism, computational work is needed to quantify 
the interactions arise in between molecules and identify possible transient states. The 
concept holds promise as a structural platform for engineering biologically differential 
nanomaterials and adds to the growing tool kit of nano-defined materials demonstrating the 
versatility of applied chemistry and design. 
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Chapter 5 
Antimicrobial Capsids  
5.1   Introduction 
As discussed in chapter 1, the spread of bacterial resistance to antibiotics stimulates 
antimicrobial discovery. Traditional antimicrobial mechanisms and methods seem 
insufficient to address the challenge of antimicrobial resistance. An alternative and effective 
strategy is to programme membrane-disrupting mechanisms using autonomously functional 
devised biomolecules having subcellular sizes. Here we describe a de novo antimicrobial 
peptide arrangement that – by emulating the virus architecture – assembles into 
antimicrobial capsids. These synthetic capsids destroy bacteria on contact by 
instantaneously porating their membranes. 
Similar to capzip system described in chapter 4, the antimicrobial system explained in this 
chapter is inspired from nature, but in a different way. In capzip, we have started from a β-
strand motif as an initial building block that exists in the natural protein (Lactoferrin) and we 
modified it to assemble into capsules. Here, we next draw inspiration from nature on the 
assembly of virus capsids and we combined this knowledge with our knowledge about 
antimicrobial host-defence peptides to build antimicrobial virus capsids from scratch.   
In programming and building antimicrobial capsids from the very initial building blocks 
(amino-acids), we will first increase our understanding and control over synthetic capsid 
design. Next, this will allow us to further optimise designs for specific applications. The long 
term aim is to programme more sophisticated nano-devised biomolecular assemblies with 
specific functions for targeting specific cells.   
This new capsid system also holds promise for addressing antimicrobial resistance. As 
illustrated in chapter 1, typical antimicrobial peptides disrupt bacterial membranes by 
forming pores, channels or carpets [86]. Every membrane lesion needs multiple peptide 
molecules to act collectively [188].  For this collective effect to happen, peptides have to 
reach a local concentration above a certain threshold, and this threshold is dependent on 
the nature of the peptide and its mechanism of assembly [17]. In contrast, the antimicrobial 
capsids presented in this chapter act like pre-concentrated bactericidal bullets to cause 
membrane poration and disruption instantly on the first contact. Hence these capsids 
present a strategy to apply antimicrobial peptides to bacterial membrane at a high enough 
local concentration to instantly disrupt the membrane.   
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In this chapter, the design of a synthetic viral capsid is discussed, as developed by our 
collaborators at NPL. The results show a good antimicrobial activity of the capsids with no 
apparent toxicity to human cells. As part of this PhD research, capsids have been 
characterised by AFM. In addition, the antimicrobial attack on the bacterial membranes was 
monitored by atomic force microscopy in real time to elucidate the mechanism of action. 
5.2   Virus Capsid Design Principles 
Native virus capsids are self-assembled from natural proteins. The majority of viruses can 
be classified into rodlike or spherical. The capsids of most spherical viruses arranged with 
icosahedral symmetry. The proteins forming such spherical virus architecture follow three 
universal principles for their self-assembly. First, they are packed together forming a 
symmetrical icosahedron. Second, the subunit proteins are positioned in identical chemical 
environments (quasi-equivalent) with respect to each other [189]. And third, they are 
clustered into closed supramolecular networks [190]. The arrangement of these subunits 
tiling a sphere, connected via weak non-specific interactions, suggests that quasi-equivalent 
lattices are the lowest energy possible for these subunits to form icosahedral arrangement 
[19].  
There is large variation in the size and the number of subunits needed to build such a stable 
symmetrical icosahedron. The number of subunits necessary to form the capsid is 
dependent on their n-fold rotational symmetry. This rotational symmetry imposes geometric 
constraints on the allowed folds and interactions of the subunits (proteins). Often a lower n-
fold rotational symmetry implies that more protein subunits are used or needed in a capsid. 
These overall differences are classified on the basis of the quasi-equivalence principle 
proposed by Donald Caspar and Aaron Klug [191].  
For example, figure 5.1.A shows an icosahedron that consists of 20 flat faces of equilateral 
triangles arranged around a sphere. This resulted icosahedron has a 5, 3, and 2 symmetries. 
Such symmetries can be explained by assigning a rotational axis for the icosahedron to see 
how many identical projections can be achieved by rotating the icosahedron around the axis. 
In this particular situation, we could assign three different axes denoted by the black 
pentagon, triangle and the rectangle in figure 5.1.A. Rotating the designed icosahedron 
around the pentagon axis, five identical projections can be achieved, while only three can 
be achieved around the triangle and tow around the rectangle. The number of faces in any 
icosahedron is usually represented by the triangulation number (T-number). This number 
can be calculated graphically from an equilateral triangular net and using a simple equation: 
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T = k2 + k  h + h2, with k and h are the distances (steps) between the successive pentagons 
on the virus surface for each axis, figure 5.1.B.  
 
 
Figure 5.1: The geometry of viral capsids. (A) A schematic representation of an 
equilateral icosahedron. 20 flat triangular faces and 12 vertices are arranged 
around a sphere and related by 5-, 3- and 2-fold axes of rotational symmetry 
(diamond-, triangle- and rectangle, respectively). With each triangular face 
hosting three protein subunits (arrows at the vertices), 60 equivalent subunits 
in total, the icosahedron becomes a T = 1 capsid. (B) An equilateral triangular 
net relating icosahedral and quasi-equivalent symmetries. Each triangulation 
(T) number is calculated from (h, k) and denotes the number of smaller triangles 
arranged around local quasi-6-folds in one triangular icosahedron face. (Right 
inset) The net folded into an icosahedron showing different T numbers in 
individual triangles: (clockwise) 1, 4, 9, 16 and 25 (left). (C) A native virus (T=1) 
capsid unfolded into a triangular net with three identical subunits in each 
triangular face (Vdb 898, PDB 2GSY, reproduced from VIPER 
(http://viperdb.scripps.edu) (9). (D) Two arrangements of a C3-triskelion within 
a triangular unit leading to “starburst” and “honeycomb” propagation modes. In 
the starburst mode, the three equivalent legs of the triskelion serve as the 
altitudes of the triangle (left). Two variations of the honeycomb triskelion 
arrangement, symmetrical and asymmetrical, are given (right). For clarity 
central triskelions are shown in orange. 
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Each triangle (face) can be subdivided into three smaller triangles, facets. In reality, the 
number of these facets represents the number of subunits (proteins) needed to build up the 
capsid. For instance, a capsid with T=1 has 20 triangular faces and each triangle can be 
subdivided into three equal portions each hosting one protein. Figure 5.1.A (right) shows 
that each triangle is subdivided into three identical parts (black arrows).  
 
This means that a total of 60 identical proteins would make up a T=1 capsid as shown in 
figure 5.1.C, where each blue triangle is made up of three identical proteins (blue 
protrusions). However, a capsid with T=2 needs (2x 20 x 3) = 120 subunits (proteins) to be 
built, or if T=3 then it needs (3x20x3) = 180 subunits and so on. The higher the number of 
subunits forming a capsid, the more precise  collective interactions is needed between these 
building blocks to co-assemble together [192]. This level of precision is still challenging to 
achieve with de novo approaches.  
However, to facilitate orthogonal assembly de novo, the same protein or peptide can be 
placed at each vertex of the triangle maintaining the three-fold symmetry around the 
symmetry axis denoted by the black triangle in figure 5.1.A. We have done that by covalently 
connecting three identical peptides together to form a rigid C3-triskelion as shown in figure 
5.1.D (orange triskelions). Each C3-triskelion occupies one triangle which could propagate 
spherically in two different ways; “starburst” and “honeycomb” illustrated in figure 5.1.D. 
These two propagation modes follow the classical 5, 3, 2 symmetries explained above. 
However, as explained in section 5.4, our programmed C3-triskelion design will promote a 
“starburst” arrangement to direct a capsid-like assembly [17]. This is because the 
propagation of the C3-triskelions is induced by engineered hydrophobic interactions 
between cysteine amino acids at their termini. By looking at “starburst” arrangement in figure 
5.1.D, each of these cysteine terminal is in a close distance to other four from adjacent 
triskelions facilitating the hydrophobic interactions among them which lead to a better 
stabilisation. “Honeycomb” propagations, on the other hand, allow only two adjacent 
triskelions termini to interact with each other. In order to stabilise this propagation, these 
interactions have to be strong oblique or orthogonal “sticky” interactions, which often need 
disulfide bridging as an additional stabilisation [193]. These later interactions are not 
facilitated within this presented design.  
Based on these principles, we engineered an antimicrobial protein motif arranged into a C3-
triskelion that assembles into capsid-like shells by clustering with other triskelion copies at 
its leg termini. 
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5.3   Elementary C1-Subunit Design. 
To design the C3-triskelion as a capsid subunit, each leg which we call C1-subunit must be 
rigid and has a rod-like structure. These properties can be achieved by using α-helical 
coiled-coil protein motifs [194]. A coiled coil is a structure of protein bundles in which 2–7 α-
helical motifs are coiled together like the strands of a rope. Figure 5.2 shows an example of 
dimeric and trimeric α-helical coiled-coils. The number of these interdigitated α-helices can 
be tuned and in viruses they are predominantly heterodimeric. The coiled-coils are usually 
stabilised via precise hydrophobic, hydrophilic or electrostatic interactions in between the 
helices. These α-helices making up the coiled coils are characterised by heptad repeats of 
their hydrophobic and polar amino acid residues designated as (abcdefg). The residues at 
positions a and d usually form the hydrophobic interfaces between the bundled α-helices as 
shown in figure 5.3.A, [195]. The average distance between each two hydrophobic residues 
along the α-helix sequence is 3.5 residues, which is less than one complete turn (3.6 
residues) of a monomeric α-helix [194]. As a result, when two α-helices interact to form a 
coiled-coil, these little shifts of the hydrophobic residues along the helices induce a slight 
left-handed twist. This yields left-handed helix-crossing angles in the coiled-coil bundle. In 
addition to the hydrophobic interactions, complementary electrostatic interactions between 
residues at positions e and g help to stabilize the coiled coil. As illustrated in figure 5.3.A, 
this occurs between the successive heptads of partner strands (i.e. g-e' interactions: g of 
one heptad and e' of the following heptad on the other helix) [196]. 
To make the coiled coil antimicrobial, it is necessary to consider the hydrophobic a/d pairs 
in conjunction with the charged g/e' pairs [197]. As antimicrobial peptides or proteins are 
intrinsically positively charged [198], the coiled-coil could be engineered to be a heterodimer 
having an antimicrobial cationic strand and a 
complementary anionic strand. The antimicrobial 
cationic strands will be each arm of the C3-triskelion, 
while the complementary anionic strand will not be 
antimicrobial. However, this anionic strand is 
necessary for the subunits to propagate and form a 
capsid, as will be explained next section.  
To enable an antimicrobial coiled-coil dimer, we 
designed the two positions (a and d) of the repetitive 
heptads in both the cationic and anionic strands to be 
isoleucine and leucine. This is to emulate the native 
leucine-zipper structures. It means that the two 
Figure 5.2: Structures of coiled 
coils. A cartoon presentation of 
a dimeric coiled coil (left) and a 
trimeric coiled coil (right) [8] 
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helices stick to each other via hydrophobic interactions at these two positions. Further 
stabilisation of the dimer is achieved by the electrostatic interactions that arise between the 
complementary g/e' pairs. At these positions, the cationic amino acids (lysines) are used in 
the positive antimicrobial strands, while the anionic amino acids (glutamates) are used in 
the antagonistic strands as illustrated in figure 5.3.A&C. 
 
Figure 5.3: An elementary capsid C1-subunit. (A) The linear sequences of the subunit 
(upper) and configured onto a coiled-coil helical wheel with 3.5 residues per turn 
(lower). Antimicrobial (C1 (+) strand) and antagonist (C1 (-) strand) sequences are 
shown in blue and red, respectively, and are aligned under the coiled-coil heptad 
repeat pattern, gabcdef. The cysteine residue is shown in yellow. Curved double-
headed arrows indicate electrostatic interactions between g and e' (circled) residues. 
Crossed arrows show the hydrophobic interface of the dimeric subunit formed by 
isoleucines and leucines in a and d, respectively. Unengaged positively charged 
lysines are highlighted with “+”. These confer the dimer with an overall positive charge 
facilitating the binding of the subunit to anionic microbial membranes. (B) The linear 
sequence of the C1 (+) strand (upper) and configured onto a monomeric helical wheel 
with 3.6 residues per turn (lower), showing the clustering of amino-acid residues into 
two distinctive polar and hydrophobic faces. Monomeric (i, i+7) and coiled-coil (i, i+3 
and i, i+4) helical spacings are shown, one of each for clarity. (C) A molecular model 
of the coiled coil C1-subunit (PDB entry 4DMD [18] rendered by Macromodel 
Shrödinger). (D) The chemical structure of a dendrimer C3-hub used to make the C3-
triskelion, C3 (+) strand. βA denotes beta-alanine. Figure was reproduced from [17]. 
108 
 
In addition, this arrangement makes the folded C1 (+) strand to follow the typical amphipathic 
structure of antimicrobial peptides explained in chapter 3. The folded helix will have two 
faces, hydrophobic and hydrophilic. Figure 5.3.B is the top-down view of the folded C1 (+) 
strand presented on a wheel-like schematic. The hydrophobic side of the helix is highlighted 
within the acute angle to include the two hydrophobic amino acids (leucine and isoleucine). 
On the other hand, all the hydrophilic amino acids including the positively charged ones are 
on the other side of the helix. 
The hydrophobic positions a and d and the cationic/anionic positions e and g in each helical 
strand have amino acids that are engaged by interactions to stabilise the coiled-coil.  
Additional lysine residues were introduced into the antimicrobial strand at positions c that 
are  not engaged and exposed to solvent as shown in figure 5.3.A. These residues interact 
with the anionic bacterial membrane and facilitate coiled-coil disassembly to boost the 
antimicrobial activity via freeing the other engaged lysine. The other solvent exposed 
positions, b and f, were occupied by alternating neutral polar glutamines and small alanines. 
In the anionic antagonistic strands, however, alternating serine with alanines residues were 
used in b and c positions to promote peptide solubility, with f sites taken up by glutamines.  
The minimum requirement to form stable coiled coils is three contiguous heptads [199]. 
Similarly,  antimicrobial peptides that have sequences of same lengths are reported to be  
significantly strong [200]. For these reasons, the full sequences of the both the negative and 
positive peptides are designed to consist 21 amino-acid residues as shown in figure 5.3.A-
C. This resulted C1-subunit is an antimicrobial dimeric coiled coil (C1 +/C1-) offered an 
elementary rod-shaped anisotropic building block with size of ~ 3.2 nm (length) x 2 nm 
(width).  
Circular dichroism (CD) spectroscopy revealed that when the positive and negative peptide 
monomers are not mixed together, they remain unfolded in solution. However, 90% of 
peptide monomers adopt a helical structure when the cationic and anionic peptides are 
mixed together in (1:1) molar ratio to form a coiled-coil dimer as illustrated in the schematic 
in figure 5.3.C [17].  
The resulting coiled-coil C1-subunits, however, are not expected to propagate or assemble 
into capsids which was confirmed by TEM [17]. To enable each these subunits to be placed 
at the triangular vertices and to endow it with a capsid-like symmetry as discussed in section 
5.2, further modifications were necessary to create what we call C3-subunit. 
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5.4   Capsid C3-Subunit Design 
First of all, three copies of the C1 (+) strand were linked together into a triskelial hub shown 
in figure 5.3.D to form C3 (+). Each leg of the resulting structure folds with the C1 (-) strand 
giving rise to a rigid C3-triskelion as shown in figure 5.4. The three folded legs of the C3-
triskelion are identical carrying a large positive net charge. This positive charge provides 
electrostatic repulsions keeping them away from each other. In addition, the three legs have 
polar faces which are designed to be solvent-exposed with no complementary interactions 
and none of them can facilitate undesired anti-parallel coiled-coil formation [201]. This rigid 
C3-subunit firmly fits into a triangular face with each leg span ~ 4nm as shown in figure 5.4. 
Yet, these C3-subunits cannot propagate into a spherical capsid as verified by TEM [17]. 
To promote the interactions of triskelions termini to propagate and form capsids, we have 
extended the N-terminus of the C1 (-) strand with a cysteine cap highlighted in yellow shown 
in figures 5.3.A&C and 5.4. Cysteine, in both reduced and oxidized forms, has the highest 
hydrophobicity among the proteinogenic amino acids [202]. Therefore it intrinsically tends to 
form secondary structure in aqueous media with the ability to do localised cross-linking [203]. 
For example, unpaired (uncross-linked) cysteines are known to induce particle formation in 
antibodies. This happens through clustered hydrophobic interfaces accompanied with the 
formation of non-native cysteine (more than two interacted cysteines)  [204]. 
 
Figure 5.4: molecular model of the C3-triskelion (PDB entry 
4DMD [18], rendered by Macromodel Schrödinger). Each 
subunit of the triskelion corresponds to the altitude of an 
equilateral triangle. A folded subunit spans ~ 4 nm (three 
coiled-coil heptads extended with the arm of the dendrimer 
hub and the cysteine cap), which makes the side of the 
hosting triangle ~6.1 nm. Figure was reproduced from [17]. 
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Collectively, these factors suggest that C3-triskelions with its three arms capped at the N-
terminal with cysteines should promote hydrophobic clustering at the vertices of triangular 
facets resulting in a capsid-like assembly. 
5.5   Capsid Formation and Characterisation  
As explained in chapter 2, capsids are prepared by mixing C3 (+) and C1 (-) with the molar 
ratio of (1:3) respectively. However, to promote the cysteine clustering explained in the 
previous section, we had to make sure that cysteines in C1 (-) strands exist in their free thiol 
form (not crossed linked/ disulfide). Therefore, (tris(2-carboxyethyl)phosphine) (TCEP) was 
added as a reducing agent to protect thiol groups from oxidation. The assembly takes place 
in a buffer solution of pH 7 to be close to the natural conditions and to maintain the balance 
of charged amino acids within the two strands. 
AFM images and high resolution TEM revealed broadly uniform paracrystalline assemblies 
with an average diameter of 18 nm. Figure 5.5.A shows AFM images of capsids in solution. 
The height mask is set to be 2 nm (image on the left) and thus all assemblies having 2 nm 
height or more are highlighted by the pink colour. Another larger scale image is in figure 
5.5.A (right) showing capsids (white dots) spread all over the substrate. 
The colour scale for both images is 4 nm. The size analysis of the assemblies demonstrates 
that the majority of them have a diameter in the range of 15-20 nm, figure 5.5.A (lower right). 
Consistent with this, high resolution TEM micrographs show capsids deposited across the 
substrate. 
The four highlighted capsids with the white squares are magnified to reveal some structural 
details. The average diameter of capsids is 18 nm as shown by the size distribution 
histogram, figure 5.5.C (right). 
 In our design, each leg of the folded triskelion (from the centre of the dendrimer hub to the 
acetylated N-terminus of C1 (-) strand) spans approximately 4 nm, figure 5.4. This makes 
the side of an equilateral triangle ~6.1 nm. The capsid assembly with T = 1 is believed to be 
unstable option as geometrically dis-favoured. This is because the triskelions are not able 
to orient around six-fold axes in this capsid, figure 5.1.D. Therefore, smaller assemblies are 
more likely to be observed. 
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Since the triskelions can only pack into equilateral triangular facets, the next possible 
assembly, in which triskelia termini cluster into clearly defined six- and five-fold symmetries, 
is a T = 4 capsid of ~20 nm in diameter shown in figure 5.6.A.  Triskelions readily fit into this 
capsid, figure 5.6.B, which is amply complemented by the most abundant diameters 
observed by AFM and TEM. 
 
 
Figure 5.5: Capsid-like assembly characterisations of the C3-subunit. (A) in-
water (buffer) AFM images of assembled capsids on mica. Colour scale bar 
(height) is 4 nm. The histogram is the capsids size analysis with height mask is 
set to be 2 nm. (B) In-air AFM images of assembled capsids on silicon recorded 
by a colleague in NPL. Colour scale bar (height) is 15 nm. (C) High resolution 
electron micrographs for C3 (+) strand (100 µM) assembled with C1 (-) strand at 
1:3 molar ratio, with individual structures highlighted by white squares. (Right) 
diameter distributions of the assembled capsids with corresponding sizes 
calculated for the triskelion fitted into a triangular facet (C3) and T capsids.) EM 
data was acquired by a colleague in NPL. Figure reproduced from [17]. 
C 
A 
200 nm  
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5.6   Antimicrobial Activity and Mechanism of C3-Capsids  
The antimicrobial activity of capsids as discussed is expected for the positively charged C3 
(+) triskelions. In contrast, C1 (-) is not expected to show any toxicity against bacterial cells. 
In addition, both peptide strands should not show any toxicity against eukaryotic cells. 
To probe this, CD spectroscopy was used to monitor the patterns of structural folding for C3 
(+) and C1 (-) strands when mixing with negatively charged and neutral lipid vesicles. The 
peaks that indicate helicity of peptides shown by the CD spectra means that the peptide 
interacts with these vesicles and induce folding. These interactions indicate that the peptide 
is toxic toward cells that have membranes composed of similar lipids [73, 159]. 
As discussed, bacterial cell membranes were mimicked by the anionic unilamellar vesicles 
(AUVs) formed by the lipid mixture of either (DLPC:DLPG) or (POPC:POPG) with the mass 
ratios (3:1) respectively. However, mammalian membranes were modelled by forming 
zwitterionic unilamellar vesicles (ZUVs) using either DLPC or POPC lipids. of similar lipids 
[73, 159].  
The CD spectrum of  C3 (+) mixed with AUVs shows negative peaks at 209 nm. This typically 
indicates that the C3 (+) peptide folds into a helical structure upon binding to the negatively 
charged membrane implying toxicity toward it. However, the spectrum does not show such 
folding behaviour when mixing C3 (+) with the ZUVs indicating no toxicity toward human 
A B 
Figure 5.6: Capsid Icosahedron model with T=4. (A) A T = 4 icosahedron with four 
facets in each triangular face with each accommodating one triskelion. For clarity, 
only a partial network of triskelions in the icosahedron is shown. Five- and six-fold 
axes are highlighted by yellow diamonds. The diameter of the icosahedron and the 
side of its triangular face are calculated based on the triskelion dimensions shown in 
(Fig 4). (B) A model of a T = 4 capsid assembled from the C3-subunit with matching 
those from (A) and (Fig 4). For clarity, only one of five- and six-fold axes each is shown 
in colour. Figure was reproduced from the published paper. 
113 
 
cells.  The CD data also indicates that C1 (-) does not interact and fold with both types of 
lipid vesicles, and no toxicity is expected toward them [17]. 
In addition, the antimicrobial activities of capsids were tested on bacterial cells via MIC 
assays [171] and their haemolytic activities were tested on human erythrocytes via LC50 
assays. These activities were then compared with those for C3 (+) triskelions and the other 
known antimicrobials as listed in table 5.1.  
 
 
Cell 
Peptidea 
C3 (+)  C3-capsid cecropin B daptomycin polymyxin          
B 
gramicidin                  
S 
Minimum inhibitory concentrations, µM 
P. aeruginosa 
(ATCC27853) 
3 12 <2 >100 <1 ≥40 
S. aureus 
(ATCC6538) 50 
>100 >100 7.7 <50 >20 
E. coli (K12) 1.5 3 <1 >100 <1 >20 
B. subtilis 
(ATCC6633) 
1.5 3 >50 7.7 1.5 ≥40 
S. enterica 
(ATCC700720) 
3 
3 3 >50 <1 <10 
E. faecalis 
(OG1X) 
50 >50 ≥25 >100 >100 ND 
K. pneumoniae 
(NCTC 5055) 
>12 
<25 <1 >50 <1 ND 
(LC50)
b, µM 
Human 
erythrocytes 
>150c >150 >150c >150c N/D >20 
 
 
Table 5.1: Biological activities of peptides used in the study a: C1 (-) strand was 
inactive (>250 µM); b: median (50%) cell death compared with untreated cells. c: 
haemolysis of 3-10% observed at higher concentrations. Gram negative and 
Gram positive are highlighted in red and blue, respectively. N/D – not determined. 
All tests were done in triplicate. 
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The table shows that C3-capsids and C3 (+) triskelion exhibit strong antimicrobial effects 
with no apparent haemolytic activities at micro-molar concentrations. MIC values for C3-
capdis and C3 (+) triskelions were typical of polypeptide antibiotics within the phenotypic 
tolerance of bacteria to antibiotics [205]. In comparison, the C3-capsids have shown higher 
MIC values of MIC over the C3 (+) triskelion, indicating a smaller antimicrobial effect. This 
could be as a result of the coiled coil formed with the negatively charged strand that prevent 
C3 (+) from binding to the membrane. 
This effect was minimised, however, by having extra lysine residues exposed to liquid in the 
C3 (+) strand sequence which initiate binding to the negative membranes. These then will 
trigger the disassembly of capsids. On the other hand, C1 (-) strand was found biologically 
inactive, table 5.1.  
Consistent with the biological results, AFM images showed that C1 (-) did not interact or 
disrupt negatively charged lipid bilayers. Figure 5.7 is a time-lapse AFM imaging of 
negatively charged membrane. The first image (-3 minutes) was acquired before injecting 
C1 (–) peptide, showing a flat membrane surface as a reference. At time (0) minutes, 1 µM 
of C1 (–) peptides was injected on the sample. Next, AFM imaging was carried out on the 
same area for 56 minutes with a speed of 4 minutes per frame. As expected, the membrane 
remained intact (images 4-56 minutes) and no effect of C1 (-) on the bacterial membrane 
was probed. As a control, 0.5 µM of C3 (+) peptide was injected to the same sample at 61 
minutes. 
Consequently, the next image (65 minutes) shows that C3 (+) disrupted the membrane 
confirming that the membrane is responsive to antimicrobial peptides. 
Next, the effect of C3 (+) peptide on bacterial model membrane was monitored in real time 
by AFM. Figure 5.8.A shows time lapse AFM imaging of bacteria model membrane 
incubated with C3 (+). The first image, (-3 minutes) was acquired before injecting the 
peptide, showing a flat membrane surface as a reference. The flatness of the surface is 
demonstrated by the cross-section profile shown in figure 5.7.B1 for the corresponding area 
marked by the white dashed line.  
The subsequent images (3-21 minutes) shown in figure 5.8.A, are all acquired after adding 
0.5 µM C3 (+) peptide. Small pores appeared shortly after peptide injection, which continued 
expanding over the time of the experiment. 
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Figure 5.8.B2&B3 shows the cross-section profiles of expanding pores at the areas 
highlighted by the white dashed lines of the corresponding images. The profiles demonstrate 
that the pores have depths of ~ 3 nm matching the thickness of the lipid bilayer and the 
length of C3 (+) arms. 
Figure 5.7: C1(-) effect on bacterial model membrane. In water AFM topography 
imaging of supported lipid bilayers incubated with 1 µM C1 (-) peptide for images (4 
-56 minutes) and with 0.5 µM C3 (+) for image (65 minutes). Image (-3 minute) is 
before adding any peptide (control).  Scanning rate is 4 minutes per frame. The time 
stamp corresponds to the final line of each AFM scan, referenced to the time (00:00) 
of C1 (-) peptide injection. The final image (65 min is captured after injecting 0.5 µM 
of C3 (+) peptide showing a big disruption of the membrane. Colour scale is 10 nm. 
1 µm 
-3 min 8 min 12 min 
16 min 20 min 24 min 28 min 
40 min 32 min 36 min 44 min 
56 min 52 min 48 min 
4 min + 1 µM 
C1 (-) 
65 min + 0.5 µM 
C3 (+) 
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Noticeably, there are aggregations (yellow blobs) developed on the edges of the pores over 
the time of experiment. The sizes of these aggregations vary and could reach up to 20 nm 
in height as shown in the cross-section profile in figure 5.8.B4. 
1 µm 
-3 min 3 min 6 min 9 min 
21 min 18 min 15 min 12 min 
1 2 
3 4 
1 2 
3 
4 
A 
B 
Figure 5.8:  C3 (+) effect on bacterial model membrane. Time-lapse AFM images 
of bactewrial model membrane incubated with C3 (+) and pores characterisation. 
(A) In water AFM topography imaging of supported lipid bilayers incubated with 
0.5 µM C3 (+) peptide for images (3 -21 minutes). Image (-3 minute) is before 
peptide injection (control).  Scanning rate is 3 minutes per frame. The time stamp 
corresponds to the final line of each AFM scan, referenced to the time (00:00) of 
C3 (+) peptide injection. Colour scale is 10 nm. (B) Cross section profiles of areas 
highlighted by the white dashed lined on the images. 
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The effect of the assembled C3-capsids on the bacterial model membrane was also 
monitored by AFM. The aim is to track the attacking process of intact capsids followed by a 
gradual disassembly during the poration process within the bacterial membrane, similar to 
what illustrated for capzip in chapter 4. The samples of C3-capsids were prepared following 
the same protocol explained in section 2.  
1 µm 
-2 min 5 min 10 min 
15 min 20 min 25 min 
30 min 35 min 40 min 
Figure 5.9 In water time lapse AFM imaging of ~ 1 µM C3-capsids porating bacterial 
model membranes. Topography (height) images, captured at 5 minutes per frame, 
are shown. The time stamp corresponds to the final line of each AFM scan, 
referenced to the time (00:00) of capsid injection. The first image (-2 minutes) was 
captured before capsids injections. Colour scale is 10 nm.  
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Figure 5.9 shows time-lapse AFM images of bacterial model membrane incubated with 
assembled C3-capsids. As usual, the first image (-2 minutes) was captured before the 
injection of any capsids, showing a flat membrane as a reference. At time (0 minutes), 1 µM 
of assembled C3-capsids were injected into the sample.  
The subsequent images show expanding pores that start to form immediately after injections 
of the capsids. Given the time resolution of these AFM experiments (5 minutes per frame), 
earlier stages of pore formation could not be observed.  
Since the first recorded image (5 minutes) did not show intact or dis-assembling capsids, it 
is assumed that capsids were completely disassembled before acquiring the first image.  
As expected, the pores formed by the capsids have a depth of 3 nm, matching the thickness 
of the lipid bilayer and the length of C3 (+) triskelion arm. Figure 5.10 shows the cross-
sectional profile of the line drawn in the second image in Figure 5.9. Here, and similar to 
what was observed in Figure 5.8, aggregation is noticed on the edges of the pores (yellow 
blobs). 
 Since similar aggregations appeared when membrane is attacked by capsids and by C3 (+) 
monomers, this demonstrates that the aggregation happens between the C3 (+) triskelion 
and membrane components.  
 
Figure 5.10: Pores sizes formed by C3-capsids in bacterial model membrane. (Left) is 
in liquid AFM image taken from figure (9), after 5 minutes of capsids injections. C3-
capsids concentration is ~ 1 µM. (right), the cross section profile representing the area 
highlighted by the white dashed line on the image. Colour scale is 10 nm.  
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Since capsids disassembly take place during the first 5 minutes of the attack, we next 
improved the time resolution to image the early stages of the process, with at best 13 
seconds per frame. As mentioned in chapter 2, we used a modified AFM head designed for 
the photothermal actuation of miniaturised cantilevers (REFS) [156].   
Figure 5.11.A shows time-lapse fast-scan AFM images of bacterial membrane incubated 
with 3 µM capsids. Upon the addition of the capsids on the flat membrane (at 0 seconds), 
poration became apparent within seconds. This indicates that capsids instantaneously 
disassemble on the membranes. Even with the ability to acquire a frame every 13 second, 
intact capsids could not be imaged on the membrane. The formed pores grew in size and 
merged, resulting in the complete removal of the phospholipid matrix within 5 min after 
exposure to the C3-capsids. The depths of the pores as shown in figure 5.10.B were 
consistently ~3 nm, consistent with C1 (+) strands spanning the bilayer. 
Figure 5.11: C3-capsids porating phospholipid bilayers. (A) In-liquid high speed 
AFM imaging of supported lipid bilayers treated with C3-capsids (~ 3 µM total 
capsid). Topography (height) images, captured at 13 seconds per frame, are 
shown. The time stamp corresponds to the middle line of each AFM scan, 
referenced to the time (00:00) of capsid injection. White arrowheads indicate 
the AFM scan direction. (B) Cross-sections along the lines marked in (A, -00:13 
and 01:57) before (left) and after (right) the addition of capsids 
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5.7   Discussion  
The capsid design has two main characteristics that each support a specific function. Firstly, 
the assembly is stable in solution as well as in the presence of mammalian cell membranes. 
This is important as the antimicrobial capsid may effectively target intracellular pathogens 
via the ability to traverse mammalian membranes and reach the cytoplasm without 
cytotoxicity.  
Secondly, the capsids bind to microbial membranes followed by an immediate disassembly 
into their independent components, which does appear at the target membrane at a high 
local concentration. These components are the antimicrobial C3 (+) triskelions that fold and 
porate the microbial phospholipid membrane, and the anionic antagonist C1 (-) strands that 
convert into random coil and stay in solution. 
Because all three legs in the C3 (+) triskelion are identical, each has the same ability to bind 
and insert in the bacterial membrane. As the length of each strand matches the thickness of 
the phospholipid bilayers (3-4 nm), each arm of the triskelion (C1 (+)) is designed to insert 
in the bilayers in a transmembrane manner. Finally, since all the strands would have the 
same orientational preference in the membrane, for which they compete, this non- balanced 
energetic state of triskelions induces them to move and diffuse to generate wider pores and 
disruption of the membrane until the complete removal.  
Figure 5.12 is a schematic representation of the C3 (+) triskelions and possible orientations 
of their arms within the environment of bacterial membranes. As explained in the result 
section, the length of the folded arm matches the thickness of the lipid bilayer.  
 
Figure 5.12: Schematic representation of pore edges 
with the thickness of the SLB (3-4 nm). For clarity, only 
one C3 (-) strand with three C1 (-) strands (blue 
cylinders) and one phospholipid per layer are shown 
(aliphatic chains in grey, headgroups in pink). 
121 
 
When interacting with the negatively charged lipids, all arms are expected to adopt helical 
structure spanning 3-4 nm. The geometric constraints make the existence of three arms 
inserted in the lipid bilayer improbable. The more likely scenario however is that the three 
arms compete with the same probability to get in the membrane and when the one of them 
get in the other two stay out.  The inserted arms in the membrane (arms a in figure 5.12) 
can stablise by the same mechanism explained for the helical antimicrobial peptide 
(amhelin) in chapter 3. The amphipathic structure of the helix induces a transmembrane 
orientation in which the peptide hydrophobic side hides within the hydrophobic tails of the 
lipid chains while the hydrophilic side stays exposed toward the pore where the aqueous 
medium is.  
The other two arms, if folded and not inserted, will still be amphipathic helices seeking 
stabilization, possibly in a way that leads to the aggregation observed on the edges of the 
pores, figures 5.8.A, 5.9 and 5.11. One may speculate that the lipids chains stack on these 
exposed arms, hiding the hydrophobic sides of the peptides from the aqueous medium. The 
positive and hydrophilic side preferably interact with the lipid headgroups or the aqueous 
solution.  
5.8   Conclusion 
In this chapter, a concept of a platform for engineering antimicrobial capsids is 
demonstrated. Capsids can be assembled from relatively short amino-acid sequences. 
Given that there are thousands of antimicrobial peptides reported in the literature [66], each 
of these may be used to construct a self-assembling capsid protomer. 
Atomic force microscopy has the ability of imaging and tracking the process of antimicrobial 
attack on the bacterial model membranes at high resolution.  The presented AFM data is 
consistent with the data of other techniques applied in studying the capsid system (e.g., CD 
and TEM). 
Further experiments that could be done are imaging the effect of capsids on the human cell 
membranes by AFM. This could be achieved by using DLPC or POPC lipids. These 
experiments will not provide new information but could confirm the biological data of negative 
cytotoxicity of capsids which was also observed by the CD. In addition, resolving the 
orientation mechanism of the three arms within the membrane as well as the dynamic 
equilibrium could be achieved via further experiments employing linear dichroism or NMR 
techniques. 
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Chapter 6 
Next Steps towards Commercialisation  
6.1   Overview  
As explained in chapter 1, antimicrobial resistance is considered a global challenge in the 
21st century. One contributing factor to this problem is the low interest showed by the 
pharmaceutical companies over the last five decades to invest in developing new antibiotics. 
One reason is that it is as costly a development as that for other types of medicines but with 
a higher risk: The antibiotic market is not stable and predictable. The global demands on 
antibiotics fluctuate with the waves of the bacterial infections attacking particular areas at 
particular times. Hence, pharmaceutical industry prefers to invest in developing drugs for 
chronic diseases that require long term treatments [27, 29]. The demand for such drugs can 
be better estimated and the financial studies for such investments including, revenue, costs 
and profits forecasts are achievable. 
Unfortunately, regardless the humanitarian need for certain drugs, investment in drug 
developments from the perspective of business is normally evaluated based on the profit. 
Investors usually have many proposed business opportunities that are run through an 
evaluation process to finally invest in those having the lowest risk and the highest expected 
profit. 
In fact, since 2000, more than 20 new antibiotics have been produced and distributed to 
markets and more than 40 other drugs are now in active clinical development [206]. 
However, only few antimicrobial peptides (AMPs) are being developed and reached clinical 
trials [207]. This antibiotic development move is due to the recent pressure that government 
bodies are putting on big pharma to invest in this field [207]. In addition, governments provide 
support and incentives to stimulate such investments as they are in the interest of the 
national security.  
Entrepreneurs try hard to reduce the risk of any new businesses to become more attractive 
opportunity for investors. Therefore, one should aim to reduce the investment risk for 
developing AMPs.  
This chapter sheds light on how investment in developing AMPs could be a successful 
business opportunity. It includes a detailed business plan for an application of AMPs which 
is antimicrobial wound dressing business.  
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6.1.1   AMPs Possible Commercial Applications 
As mentioned in chapter 1, AMPs could be considered as the next generation of antibiotics. 
However, this does not mean that medicine is the only application possible. In fact, there 
are many other possible and feasible applications which have big steady markets. For 
instance, it could be used for active packaging which requires an antimicrobial packaging 
system for food products to extend the products shelf life. AMPs can also be used in 
personal care & cosmetics products as preservatives and to deter skin pathogens. In 
addition, AMPs are suitable for agricultural applications as plants protection agents as well 
as additives within the animal nutrition system. Finally, AMPs can be used for wound 
management as cream and ointment or it could be embedded within the wound dressings 
to protect the wound from infections and accelerate healing. The last application is the one 
studied in detail in this commercialisation chapter.  
6.1.2   Antimicrobial Wound Dressings 
Unlike the pharmaceutical applications of AMPs as medicines, the market of antimicrobial 
wound dressings is considerably more stable and predictable. Every person and pet has a 
risk of being physically wounded especially during surgical operations or during heavy 
activities. Wounds can range from acute to chronic. Chronic wounds are those that do not 
heal in an orderly set of stages and in a predictable amount of time and often remain in the 
inflammatory stage for too long. Open wounds have to be managed in order to accelerate 
healing. Such management can be achieved via different methods including applying special 
dressings to cover the wound. There are many types of wound dressings available in the 
market and each is preferred for particular wound situation [208, 209]. Open wounds are 
usually vulnerable to bacterial infections, and therefore it is recommended in some case and 
necessary in other to protect the wound from bacteria during the healing time.  
Wound infection increases exudate to distressing levels, causes inflammation, pain and 
odour, and can result in further surgical interventions for debridement or excision [210]. Yet, 
modern dressings and best-practice techniques can reduce wound infection from its current, 
unacceptably high base.  
Hence, antimicrobial wound dressings are available and take up to 11% of the wound 
management market according to study in 2013 [211]. Such dressings are usually used 
frequently as consumables at hospitals, clinics and the related industries. 
In addition to being a relatively stable market, the development of antimicrobial wound 
dressings is easier than developing a drug from the perspective of regulations. This is 
because such application is considered topical and cosmetic leading to fewer and quicker 
124 
 
steps required for clinical approvals. According to FDA, wound dressings require “510(k)” 
approval which is designed for class 2 medical devices [212]. This rather simpler regulatory 
pathway reduces the R&D costs and the overall risk of the investment. 
More importantly, developing AMPs for wound dressing application will pave the way for the 
next steps, which could be antibiotic drug development. With similar but longer regulatory 
steps required for a new drug, AMPs could enter the clinical trials with lower risks from 
investment and safety perspectives.   
Based on these rationales, we have persuaded a company to develop such new technology. 
The company, which is not mentioned anywhere in this thesis for reasons of confidentiality, 
has signed an R&D deal with the National Physical Laboratory (NPL) to develop 
antimicrobial wound dressings using AMPs as the active ingredient.  
Here, I am presenting a business plan for such investment. The plan starts from a market 
study including the market evaluation and growth forecasts, the available products and the 
market gap. Next, I explain our product and its unique value propositions (UVPs). Then, the 
products development and milestones are outlined. Next, the plans for manufacturing, 
marketing and selling are described. Finally, I present the financial study of the project 
including an estimation of the investment needed, risks register and exit plans. 
6.2   Wound Dressings Market  
Current estimates indicate that wounds account for almost 4% of total health system costs 
[213]. The breakdown of wound costs in the acute setting, 15-20% material costs, 30-35% 
nurse time and >50% hospitalisation [213]. In a typical hospital setting today, between 25% 
and 40% of beds will be occupied by patients with wounds. In addition, in the community, 
management of wounds takes up over half of all resources [214]. 
A wound is defined as a disruption in the continuity of the skin or mucosa due to physical or 
thermal damage, or an underlying medical condition [215]. Wound healing is a complex, 
dynamic, and multistep process which occurs after skin damage leading to tissue repair. 
Although the skin normally undergoes repair after a disruption, the healing process can be 
affected in different conditions such as diabetes mellitus, infections, venous/arterial 
insufficiency, among others.  
Disease states such as diabetes have a surprisingly high association with wounds. In 
Europe, diabetes already affects 20.2 million people, a figure predicted to rise by 37% over 
the next two decades [216]. 
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 To enhance healing, a wide range of wound dressings are available. However, a thorough 
wound assessment (e.g., wound type, size, depth, or colour) is required to choose the 
appropriate dressing. The emergence of new dressings has brought a new perspective of 
wound healing, but there is no superior product yet to treat acute and/or chronic wounds 
[215].  
6.2.1   Market Size & Growth  
Global  
According to a market research report by Technavio, the global wound care market was 
valued at $10.9 billion in 2016. However, other studies have estimated this to be only $6.7 
billion worldwide [217]. Antimicrobial dressings comprise around 11% of the wound care 
market. Thus, the global market size for antimicrobial dressings was $990 million in 2015, 
predicted to reach $1.37 billion by 2020, representing a compound annual growth rate CAGR 
of 6.65%. Based on this ratio, the estimated market size for 2017 is at $1.126 billion. 
North America Market Share & Revenue  
North America accounts for 35% of the global wound dressing market [218]. This is resulting 
in annual spending for antimicrobial dressing around $ 494 million in 2017. 
Europe Market Share & Revenue  
The Europe wound management market in 2016 was valued at $2.22 billion [219]. 
Therefore, Europe controls around 20.37% of the global wound care market. Assuming this 
percentage is consistent across the wound care products including antimicrobial dressings, 
then the size of Europe's antimicrobial dressing market is approximately $228.5 million in 
2017.  
England Market Share & Revenue  
Antimicrobial dressings accounts for about £110 million per year in primary care in England, 
with more than £20 million spent on silver dressings alone [220]. 
6.2.2   Antimicrobial Dressings Available in the Market  
Antimicrobial dressings can be categorised based on the active antimicrobial material used 
in the product. The most known materials are; honey, silver, iodine, activated carbon cloth, 
chlorhexidine, dialkylcarbamoyl chloride (DACC) and polyhexamethylene biguanide 
(PHMB). Silver antimicrobial dressings are still the most common type. This is because 
several pathogenic bacteria have developed resistance against various antibiotics leading 
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to the re-emergence of silver after it has been avoided due to the associated toxicity [221]. 
Antimicrobial dressings can also be categorised based on their functions and the wound 
type. 
Tables 6.1 and 6.2 include lists of the available types of antimicrobial dressings, brand 
names, manufacturers’ names categorised according to their function and the active 
antimicrobial material used respectively. 
6.2.3   Competitive Landscape  
The ideal wound dressing is usually chosen based on the wound type: The dressing should 
be made of a suitable material (textile carrier). However, there are general criteria all wound 
dressings should comply with. These are the ability to: 
a) Provide or maintain moist environment. b) Enhance epidermal migration. c) Promote 
angiogenesis and connective tissue synthesis. d) Allow gas exchange between wounded 
tissue and environment. e) Maintain appropriate tissue temperature to improve the blood 
flow to the wound bed and enhances epidermal migration. f) Provide protection against 
bacterial infection. g) Should be non-adherent to the wound and easy to remove after 
healing. h) Must provide debridement action to enhance leucocytes migration and support 
the accumulation of enzyme. i) Must be sterile, non-toxic and non-allergic [222]. 
To practically compare the available dressings at the market, we set six measurable features 
listed below:   
1- How long the wound takes to heal 
2- The efficiency in protecting the wound from bacterial infection and how frequent the 
dressing should be changed 
3- The ability to protect the wound from the resistant bacteria 
4- Any toxicities or allergies to the patient 
5- How easy it can be applied on the wound 
6- The price 
Tables 6.3 to 6.10 compare eight known brands of antimicrobial wound dressings. The 
comparison includes the advantages, the disadvantages, the efficiency, the toxicity and the 
price of each product. This information was taken from commercial websites and the safety 
datasheets of the products. 
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Types Brand Name Manufacturer 
Bacterial Binding 
Actisorb KCI - An Acelity Company 
Bioguard Derma Sciences, Inc. 
Cutimed BSN medical, Inc. 
KoCarbonAg Equinox Medical, LLC 
Leukomed BSN medical, Inc. 
RTD Keneric Healthcare 
Sorbact IHT 
Suprasorb L&R USA, Inc. 
Zorflex Calgon Carbon 
Bacterial Trapping 
Aquacel ConvaTec 
RTD Keneric Healthcare 
Suprasorb L&R USA, Inc. 
Zorflex Calgon Carbon 
Bactericidal 
Iodofoam Progressive Wound Care Technologies 
Promogran 
Prisma 
KCI - An Acelity Company 
Silvercel KCI - An Acelity Company 
Acticoat Smith & Nephew, Inc. 
Actisorb KCI - An Acelity Company 
Algicell Derma Sciences, Inc. 
Allevyn Smith & Nephew, Inc. 
Anaspet Anacapa Technologies, Inc. 
Aquacel ConvaTec 
Bacteriostatic 
Dextrosan MPP Group LLC 
Aquacel ConvaTec 
Curity Medtronic 
Excilon Medtronic 
Kendall Medtronic 
Kerlix Medtronic 
Simpurity Safe n' Simple 
Suprasorb L&R USA, Inc. 
Fungicidal Anaspet Anacapa Technologies, Inc. 
Microbicidal Sorbact IHT 
Sporicidal Anaspet Anacapa Technologies, Inc. 
Virucidal Anaspet Anacapa Technologies, Inc. 
Table 6.1: Wound dressings sorted based on their function 
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Types Brand Name Manufacturer 
Honey Dressing 
Actilite Advancis Medical 
Activon Advancis Medical 
Algivon Advancis Medical 
Medihoney Derma Sciences, Inc. 
Silver Dressing 
Tegagerm 3M Healthcare 
Aquacel ConvaTec 
Safetac Mepilex Molnlycke Healthcare Us LLC 
Polymem Ferris 
Biopatch Johnson & Johnson 
SilverIon Argentum Medical 
InterDry AG Coloplast Corp 
Durafiber AG Smith & Nephew, Inc. 
Acticoat Smith & Nephew, Inc. 
Algicell Derma Sciences, Inc. 
Algisite Smith & Nephew, Inc. 
Askina B.Braun Hospicare Ltd. 
Promogran Prisma KCI - An Acelity Company 
Iodine dressing 
Inadine Johnson & Johnson Medical Ltd 
Iodoflex Smith & Nephew, Inc. 
Povitulle CD Medical 
Activated carbon 
cloth 
Zorflex Calgon Carbon 
Chlorhexidine Bactigras Smith & Nephew, Inc. 
Dialkylcarbamoyl 
chloride (DACC) 
Cutimed BSN medical, Inc. 
Polyhexamethylene 
biguanide (PHMB) 
ActivHeal Advanced Medical Solutions 
CelluDress Medicareplus International 
Excilon Medtronic 
Kendall Medtronic 
Kerlix Medtronic 
Table 6.2: Wound dressings based on types of active antimicrobial materials 
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Product 1 Actilite 
Advantages Manuka honey dressings have anti-bacterial properties. It also 
eliminates any odours. The combination of Manuka honey & Manuka 
oil has shown to be effective against major bacteria like MRSA, VRE, 
MSSA. The dressings are available in larger sizes, including 30x60cm. 
Shorter treatment periods with honey dressings are noticed as it can 
clear infections faster. 
Disadvantages Non-adhesive. Some people experience discomfort with honey 
dressings. Can be ineffective if not applied properly, as not enough 
honey comes into contact with the wound. 
Length of effectiveness Unspecified. Single use only. Honey dressings overall are usually 
changed once a day, though with heavily infected wounds, up to 3x 
per day may be appropriate. 
Pricing [$ 2.6/100 cm2] 
Toxicity profile Monitor patients with diabetes. Do not use on patients who are allergic 
to bee venom. 
Type of textile carrier Light viscose net dressing 
Table 6.3: Actilite wound dressing details including advantages, disadvantages, 
effectiveness, toxicity profile, price and type of carrier used. 
 
 
Product 2 Medihoney 
Advantages "Comes in both adhesive and non-adhesive varieties. Uses 63% 
Maukua honey in a hydrogel dressing. Promotes removal of necrotic 
tissue, so appropriate for patients with advanced wounds. Good for 
light to moderately exuding wounds. Ideal for diabetes patients. 
Adhesive version does not require secondary dressing." 
Disadvantages Less economic 
Length of effectiveness Unspecified. Frequency of change determined by medical provider. 
Pricing [$ 89/100 cm2] 
Toxicity profile Not appropriate for 3rd degree burns or those with allergy to honey, 
algae or seaweed. 
Type of textile carrier Super Absorbent Polymer 
Table 6.4: Medihoney wound dressing details including advantages, disadvantages, 
effectiveness, toxicity profile, price and type of carrier used. 
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Product 3 Aquacel 
Advantages "Extra strong and extra absorbant. Lasts longer than other dressing 
with a controlled, slow release of ionic silver yet absorbing wound 
exudate at the same time. Offers adhesive and non-adhesive 
varieties. Comes in both ribbons and pads for all types of wounds." 
Disadvantages Some associated toxicity 
Length of effectiveness 14 days 
Pricing [$ 69.5/ 100 cm2] 
Toxicity profile No known contraidications, but not ideal for very dry wounds or those 
covered in black, necrotic tissue. Obviously not for use on patients 
allergic to the dressing's components. 
Type of textile carrier "Hydrofiber™ Technology is a soft, absorbent material that transforms 
into a gel on contact with wound fluid" 
Table 6.5: Aquacel wound dressing details including advantages, disadvantages, effectiveness, 
toxicity profile, price and type of carrier used. 
 
 
Product 4 Inadine 
Advantages "Color changes when ready to change. Non-adhesive imbedded with 
10% povidone-iodine. Effective against bacteria, viruses, funghi and 
protezoa. " 
Disadvantages Iodine dressings come with many contraindications. 
Length of effectiveness Likely not to contain antimicrobial activity longer than 2 days. Some 
wounds might need changing daily or more often depending on 
exubance. 
Pricing [$30.7/100 cm2] 
Toxicity profile Should not be used where there is a known iodine hypersensitivity; 
before and after the use of radio-iodine (until permanent healing); if 
the patient is being treated for kidney problems, is pregnant or 
breastfeeding; in cases of Duhring's herpetiform dermatitis (a rare skin 
disease). Must be used under medical supervision: in patients with any 
thyroid diseases; in newborn babies and infants up to the age of 6 
months as povidone-iodine may be absorbed through unbroken skin; 
when treating deep ulcerative wounds, burns or large injuries. 
Type of textile carrier Knitted viscose fabric 
Table 6.6: Inadine wound dressing details including advantages, disadvantages, effectiveness, 
toxicity profile, price and type of carrier used. 
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Product 6 Iodoflex 
Advantages Changes color to indicate when ready to change. Biodegradable. 
Highly absorbant, deslougher, range of antimicrobial action. Odor 
control. 
Disadvantages Iodine dressings come with many contraidications. More expensive 
than other iodine offerings as 
Length of effectiveness Effective for around 1/3 a week. 
Pricing [$ 9.1/100 cm2] 
Toxicity profile Iodine is absorbed systemically especially when applied to large 
wounds and therefore Iodoflex should be used with care on patients 
who have a history of thyroid disorders. Iodoflex should not be used 
on children and as iodine can cross the placental barrier and is 
secreted into milk Iodoflex should not be applied to pregnant women 
or lactating mothers. 
There is a potential interaction of iodine with lithium and therefore co-
administration is not recommended. Iodoflex should not be used 
concomitantly with mercurial antiseptics, e.g. mercurochrome and 
thiomersal, or taurolidine. 
A single application should not exceed 50 grams and not more than 
150 grams of Iodoflex should be applied during the course of one 
week. A single course of treatment with Iodoflex should not exceed 3 
months. Iodoflex should not be used on dry wounds. 
Type of textile carrier Gauze fabric 
Table 6.8: Iodoflex wound dressing details including advantages, disadvantages, effectiveness, 
toxicity profile, price and type of carrier used. 
 
Product 5 InterDry AG 
Advantages "Provides moisture management to skin. Prevent and manage 
intertrigo (where skin touches skin creating moisture and friction that 
causes, redness, itching, burning, odour and/or maceration) in skin 
fold areas(ie: groin, abdomen, axilla, toes, fingers, buttock).  May be 
used under compression wraps, braces or splints as well. " 
Disadvantages Not used on wounds. 
Length of effectiveness Up to 5 days 
Pricing [$ 11/100 cm2] 
Toxicity profile Some patients might have sensitivity or allergy to silver 
Type of textile carrier Knitted polyester textile impregnated with silver. 
Table 6.7:   InterDry AG wound dressing details including advantages, disadvantages, 
effectiveness, toxicity profile, price and type of carrier used. 
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Product 7 Durafiber 
Advantages "Effective against infection. High integral wet strength allowing easy 
one piece removal. Allows fluid retention under compression and 
minimises lateral wicking of fluid, thus reducing the potential for 
maceration of peri-wound skin.Provides broad spectrum antimicrobial 
activity at 4 hours against pathogens" 
Disadvantages Not to use on infected wounds. 
Length of effectiveness 7 days 
Pricing [$ 71.5/100 cm2] 
Toxicity profile Not intended to be used as a surgical sponge in heavily bleeding 
wounds, Not compatible with oil-based products such as petrolatum. 
Type of textile carrier Absorbent, non-woven silver containing antimicrobial dressing 
composed of cellulose ethyl sulphonate fibers. 
 
Table 6.9: Durafiber wound dressing details including advantages, disadvantages, effectiveness, 
toxicity profile, price and type of carrier used. 
 
 
Product 8 Celludress – PHMB 
Advantages Can be used at different stages of healing to promote granulation, 
while providing antimicrobial protection and effective exudate 
management. It can also be used under compression. 
Disadvantages Can't be used where bone tissue is exposed, where there is cartilage 
damage or there is known hypersensitivity to one of the ingredients 
Length of effectiveness Not specified but shouldn't be left for more than 3 days. Daily change 
is recommended for PHMB dressings. 
Pricing [$ 5.9/100 cm2] 
Toxicity profile Should not be used for clients with known sensitivity or allergy to 
PHMB. 
Type of textile carrier Non-woven polyester/viscose fleece impregnated with PHMB. 
Table 6.10: Celludress – PHMB wound dressing details including advantages, disadvantages, 
effectiveness, toxicity profile, price and type of carrier used. 
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6.2.4   The Main Players  
There are many companies operating in the antimicrobial dressings market. The top ones 
include 3M Healthcare, Medtronic Plc, Smith & Nephew Plc, Medline Industries, Inc., 
ConvaTec, Inc., Organogenesis, Inc., Molnlycke Health Care AB, Paul Hartmann AG, Urgo 
Medical, Derma Sciences and Inc. J & J. 
6.2.5   The Gap in the Market 
Based on the market study, the gap in the market is defined from the six measurable features 
mentioned in the previous section. The data shows that there are contradictory reports about 
the efficiency of the available products. Based on conducted clinical studies for the available 
products, there are claims confirming the ability of the dressings to accelerate wound healing 
and other suggesting the ability to prevent bacterial infection. Silver dressings toxicity was 
reported [223, 224] and the ability to accelerate wound healing was doubted [225].  
Surgeons who were consulted for this study advised that the most effective dressings 
available in the market can only be left on the wound for a maximum of three days and 
usually have to be changed daily. Their replacement causes pain and discomfort to the 
patient. Finally, the relatively high price of the current products accompanied with the low 
efficiency makes wounds treatment expensive. The Telegraph newspaper reported in 2010 
that millions of pounds are being wasted by the NHS on wound dressings that contain silver 
amid doubts over their effectiveness. 
6.3   The Product (AMP-based Wound Dressings)  
For a new developed product to have a potential in the market, it has to provide an added 
value over the available ones. The more added values are provided, the more appealing the 
product will be for the market. We are proposing new antimicrobial dressings which fill a 
current gap in the market. The products are developed using AMPs as active agents to 
protect wounds from bacterial infections.  
Similar to the available products, the new ones are going to be developed to suit different 
wounds types and sizes. There will be adhesive and non-adhesive dressings made by 
different textile carriers (woven or unwoven). In additions, many sizes of each product will 
be available with some special ones designed to cover tricky areas of the human body.  
Although it has to be demonstrated during the development that these products will have 
added values over the current products. First, they are expected to be able to protect wounds 
from the resistant bacteria. In addition, the dressings will be more efficient as we expect 
them to last on the wound a 30 to 50 % longer comparing with the silver dressings with no 
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associated toxicity. Finally, our products will be more cost effective solution for wound 
management.  
6.3.1   Unique Value Propositions (UVP) 
The points below summarise the UVPs of the products 
1- No toxicity. 
2- Effective against the resistant bacteria. 
3- The dressings last 30% longer on the wound than the usual dressings which is less 
pain to the patient. 
4- Cost effective wound management. 
5- Products are available at different shapes and sizes. 
6- Different textile types to suit many types of wounds. 
6.4   Product Development 
The proposed products are going to be developed in three parts: The development of AMPs, 
the development of the textile carriers and the dressings design and finally the development 
of the coating technology (applying the AMPs on the textile carrier).  
6.4.1   Translation Cycle 
According to classic medicinal products, the development is expected to pass through 
clinical study, regulatory assessment and process validation before sale and distribution. 
The current state of the dressing development is in the proof of concept, figure 6.1. The 
transitional steps for antimicrobial dressings is expected as for topical and cosmetics 
applications and not as a drug. This makes the development quicker and less subject to 
intense safety regulations. 
6.4.2   Basic Discovery and Proof of Concept 
The product idea has immerged from the successful “in vitro” results of AMPs as explained 
in chapters 3, 4 and 5. These results show principle of antimicrobial active materials we 
intend to use in our dressings products. However, the effect of such peptides was not tested 
while they are incorporated within the dressing materials. Thus, in this stage we have to 
assess in vitro the efficiency of antimicrobial dressing using an AMP model.   
6.4.3   Preclinical Development 
The focus of preclinical testing is to assess whether the dressing product is safe for human 
volunteers and whether it exhibits pharmacological activity to merit further investigation. 
Such investigations could be in vitro and in vivo studies. Usually, preclinical studies are not 
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very large. However, these studies must provide detailed information on dosing and toxicity 
levels. If the investigation meets the criteria, the company files an investigational new 
product application with the FDA/EMA to pursue clinical testing on humans. We could also 
initiate patent fillings at this stage.  
 
 
6.4.4   Clinical Testing in Human Volunteers 
Potential new drugs must undergo extensive study in human volunteers in order to 
demonstrate safety and efficacy to the regularity bodies. Clinical trials comprise the most 
lengthy and costly portion of the R&D process. The clinical trials process occurs in several 
phases and takes many years. However, for the topical cosmetic applications, clinical trials 
are significantly quicker and should cost less than a typical drug. Biopharmaceutical industry 
sponsored clinical trials are conducted around the country and in a variety of settings, 
including academic medical centres, dedicated clinical trial testing centres, and physician 
offices. 
From enrolment to completion, these trials take many years to complete and can cost 
millions of pounds. These randomized, controlled trials generate large amounts of data to 
support submission to the regulatory bodies for approval. 
Product Delivery
Knowledge Managment
Products Assessment
Clinical Phase 3
Clinical Phase 1/2
Clinical Phase 0
Preclinical Development
Proof of Concept
Basic + Discovery Research
Figure 6.1: Expected development stages for drugs or medical devices. 
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Clinical trials are viewed in several distinct phases as outlined below: 
Phase I clinical trials typically are conducted with a small number of healthy volunteers, 
typically less than 100, to determine the safety, tolerability, and pharmacokinetics and 
pharmacodynamics of the wound dressing (i.e., researchers assess how the dressing 
behaves on the body and relationship between its components’ molecular structure and their 
effects on volunteers).  
Phase II clinical trials begin if the drug successfully passes Phase I testing. This phase 
generally involves between 100 and 500 human volunteers to assess the efficacy and dose 
response of the investigational dressing in development, including identification of common, 
short-term potential side effects.  
Phase III clinical trials are initiated if the potential new dressing is found to be both safe 
and efficacious through Phases I and II testing. Phase III trials may enrol 1,000 to 5,000 
patients or more across numerous clinical trials sites across the country and around the 
world. 
6.4.5   Product Assessment 
This involves the assessment of the products by surgeons. The assessment aim to analyse 
feedbacks from surgeons and practitioners about the product design, packaging and how 
easy it is to use under the clinic conditions. It also aims to assess the best storage conditions 
of the products.  
6.4.6   Knowledge Management 
For the dressing products, knowledge management includes: standardized manufacturing 
process and clinical practice guidelines.  
6.4.7   Healthcare Delivery 
Health care delivery system for the wound dressings includes educational and training 
sessions for surgeons and practitioners if necessary. It also involves finding the right 
distribution channels for the products to reach the target hospitals, clinics and the related 
industries. 
6.5   Manufacturing and Operation 
6.5.1   Peptides Production 
Peptides production can be done via contract manufacturing with companies specialised in 
this industry. We evaluate such partnership based on three principles; first, the quality of the 
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peptides produced in a form of powder or concentrated liquid, second, the company 
reliability and quality consistency, and finally the price.  
Generally, peptides could be either produced chemically or via recombinant methods. 
Although each of these production methods has its advantages, it does not matter as long 
as the final product meets the criteria. Hence the choice will be based on the added value 
provided by either of these two manufacturing methods whether a cheaper price or a better 
quality.   
6.5.2   Textile Carriers Production  
Wound dressings are manufactured using different textile materials. The dressing can be as 
simple as a strip of plain textile, or as complex as an engineered composite that contains 
layers of different geometries and reactive materials, including medicines. A number of 
polymeric materials are used as films, fibres and other structures for developing wound-
dressing products. Some of the primary materials employed are cotton, rayon, polyester, 
nylon, polyolefins, acrylic, polyurethan, chitosan and alginate. The textile made by such 
fibres could be woven and non-woven and both have application in wound dressings [226]. 
As explained in competitive landscape section, textiles used to produce wound dressings 
have to meet specific criteria in order to do the job. 
Similar to peptide production, textile production can also be outsourced via a contract 
manufacturing. Textile manufacturing companies can produce according to our specific 
requirements. However, textile carriers could also be produced in house within an integrated 
production line including the AMPs coating stage. This will save time and cost as well as 
maintain a protected manufacturing environment needed for medical dressings.   
6.5.3   Coating Process and Packaging 
Textile coating is the process of absorbing materials onto the textile. Whether it is chemical 
or pharmaceutical nano or micro-material, the suitable coating technology should be applied 
based on the textile nature and coating material. The suitable technology should be efficient 
in absorbing the material that could be expensive such as AMPs. In fact, AMPs coating onto 
textile has been reported but not yet commercially invested [227]. AMPs coating technology 
can of course be developed in labs and then scaled up for industry. 
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6.6   Sales and Marketing Strategy  
6.6.1   Who Are the Customers 
Wound dressings are distributed and sold globally. With the rise of antimicrobial resistance, 
a new technology employing AMPs to protect wounds from resistant pathogens will be of 
interest to hospitals and clinics all over the world.  For a start-up company however, it is 
usually difficult to set sales and marketing plans to cover the global market. In fact, we aim 
here to specify the sales channels in the UK and how to reach them and supply them. This 
plan could be replicated in each country and performed either directly by the manufacturing 
company or, more practically, via exclusive agents.   
Hospitals and surgical clinics consume the majority of the antimicrobial dressings. According 
to the National Health Services (NHS) data, there are in England: 209 clinical commissioning 
groups, 135 acute non-specialist trusts, 17 acute specialist trusts, 54 mental health trusts, 
35 community providers, 10 ambulance trusts, 7,454 GP practices, 853 for-profit and not-
for-profit independent sector organisations. Although not all these health care providers 
consume antimicrobial dressings, it is necessary to gradually educate all of them about the 
new products. This will make the product widely known and acceptable within the industry.  
Usually when a new product is launched, hospitals trustees are invited to a sponsored lunch 
to include products pitching. Such events are organised to show the advantages of the new 
products comparing with the existing ones. In fact, with the recent cut of the NHS funding, 
trustees are looking for cheaper alternatives especially for consumables. If proven to be 
overall a cheaper wound management option, AMPs based dressings will be attractive 
products for NHS hospitals. Negotiations with hospitals trustees take long time and might 
be mediated by brokers who understand their need and could have direct connections with 
the decisions makers. These events for pitching the new products can be performed not only 
for UK NHS hospitals but also for private sector hospitals which usually are more fixable in 
making decisions to stock new products. 
In addition to selling to hospitals, wound dressings can be sold directly to pharmacies and 
healthcare shops. These could be reached via healthcare distribution companies.  
Building a brand name is not an easy job for start-up companies. In order to do so, 
conferences and exhibitions that are related to the industry have to be attended. The trust 
for the company and the new products can be gradually built by exposing them to surgeons, 
nurses and practitioners who apply such dressings to the patients.  
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6.7   Financial Model 
6.7.1   Estimated Costs for Products Development  
The cost of each stage along the development is estimated and presented in the table below 
in thousands (£ 1000).  
 
6.7.2   Gross Profit Margin 
The calculations of the products net costs are very difficult at this stage as they are not fully 
developed yet. Thus the precise calculation of the profit margin is not possible. However 
according to the market study, medical dressings producers expect a gross profit margin of 
50 -70%. Hence, we assume that the minimum gross profit margin for our products is 50%.  
 
6.7.3   Sales Assumptions 
We assume that the sale will increase gradually each month till reaching in sales 20 % of 
the antimicrobial dressing market in the UK by the end of the third year. The amount of 
estimated sales is divided equally over 5 products. The table below shows the revenue 
presented in thousands (£1000) generated from each product each year and the estimated 
gross profit. 
 
 
 
Development Stage Expected Duration (Months) Cost 
Proof of concept 3 £ 100 
Preclinical  6 £ 200 
Clinical phase 1/2 9 £ 500 
Clinical Phase 3 9 £ 500 
Product Assessment 6 £ 50 
Knowledge Management 3 £ 10 
Total 36 months £ 1,360 
Table 6.11: Expected time and cost in thousands (X £1000) for each stage of the products 
development 
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                    Year 
Product 
2021 2022 2023 
Product 1 £780 £2,220 £3,660 
Product 2 £780 £2,220 £3,660 
Product 3 £780 £2,220 £3,660 
Product 4 £780 £2,220 £3,660 
Product 5 £780 £2,220 £3,660 
Total sales (revenue) £3,900 £11,100 £18,300 
Total gross Profit (50%) £1,950 £5,550 £9,150 
Table 6.12: Sales assumptions and revenue in thousands (X £1000) over three years 
2021-2023 
6.7.4   Estimated Operational Cost & Overheads 
The table below shows the overhead costs estimated presented in thousands (£ 1000). We 
assume that peptide production and all the logistics and delivery forces are out-sourced.  
 
 
 2021 2022 2023 
Total Salaries (Incl NI) £250 £375 £500 
Manufacturing site rent £25 £70 £90 
Marketing £200 £300 £400 
Heat & Light £10 £20 £25 
Travel £50 £75 £10 
Accounting £2 £4 £6 
Annual Other Misc Costs £10 £15 £20 
Quality Control £100 £150 £200 
R&D £200 £400 £600 
# Employees at Year End 10 15 20 
Average Salary £25 £25 £25 
Table 6.13:  Estimated operational costs in thousands (X £ 1000) and overheads over 3 
years 2021-2023 
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6.7.5   Capital Equipment: 
The company must purchase a production line to include machinery items for the two 
production stages; textile production and peptide coating. In addition, offices equipment and 
hardware items are needed for the management staff. The cost of these are estimated in 
the table below presented in thousands (£ 1000).  
Machinery and equipment Purchase £1,000 
Computer Hardware £34  
Depreciation Period (Years)  5  
  
6.7.6   Three Year Profit and Loss Estimated Account 
 
 
 
 
 
 
Figure 6.2: Annual sales and net profit forecast in thousands (x £1000) 
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6.7.7   Three Year Cash Flow Forecast  
This cash flow account starts by January 2021 when the production starts. It does not include 
all the money invested for the products developments in the first 3 years. 
 
 
 
6.7.8   Investment Requirements 
Year Start 2018 2019 2020 2021 Total 
Amount x £ 1000 £ 500 £ 860 £ 500 £ 1,000 £ 2,860 
Table 6.14: Estimated investment required over 4 years 2018-2021 
 
6.7.9   Estimated Payback Time 
Based on the financial study, the payback time of all the investment (2,860 K) is estimated 
to be after four and a half years. This includes the 3 years period spent on the product 
development.  
 
 
Figure 6.3: Cashflow forecast for three years in thousands (x £1000) 
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6.8   SWOT Analysis 
Strengths  Weakness 
 Novel technology, no competition 
 Long term development is possible 
 Very big global market 
 Gradual investment over the 
development  
 Easy and available exits strategy in 
each development stage 
 No negative effects  
 Large scale production is possible  
  New technology, could face 
unexpected problems 
 Clinical trials could show the need 
for further optimisations 
 High cost of peptide production 
 Peptides stability could be an 
issue  
 The difficulty to patent peptides 
sequence as they easily can be 
copied with little modifications  
Opportunities  Threats 
 Ability to open new applications 
using the same AMPs 
 The ability to licensing the use of 
the peptide for other industries 
  Competition from other 
companies 
 Clinical trials not approved  
 Bacteria acquire resistance 
against peptides 
6.9   Exit Strategies 
There are ways for investors to exit this investment. This could happen at the end of this 
plan, i.e., by the end of 2023 or it could happen after any stage of the development. Each 
stage of the products development is a milestone and if was done successfully, it will be an 
added value to the project which will be translated into a rise in the shares price.  
For example, the evaluation of the company after passing the phase 1 of clinical trials is 
certainly higher than that before passing it. This means that the investors will most likely get 
their money back if not making any profit.  
Potential new investors in this company will be all the big companies performing in the 
wound management sector. In addition, this innovative company could be made as a public 
company. This will give the opportunity for everybody to invest in the company especially as 
it could be looked at as one of the future solutions for the antimicrobial resistance  
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6.10   Risk Register 
Every business has a risk and usually the amount of risk is proportion to the expected 
outcome of the business. Start-up businesses, for example, are usually risker than older 
running businesses. This is why investors expect a higher return when investing in a start 
up company comparing with investing in an old structured company.  
However, studying the potential risks, minimising it and having contingency plans is very 
recommended for entrepreneur to be included in the business plan to be more sound to 
investors.  
Appendix 2 shows a list of potential risks associated with this business highlighted as low 
(L), medium (M) and high (H). There are three high risk items within the list. First, a regulatory 
issue of not approving the products as safe to be marketed.  This off course could be as a 
result of unexpected toxicity or allergy reactions during the clinical trials. This risk can’t be 
completely eliminated, however, going through the gradual development cycle, such 
reactions will appear much earlier and before investing in clinical trials. In addition, the 
screening process during clinical trial is very important to carefully being set to exclude those 
who have high potential to react to peptide treatment.  
Second, the potential of having unforeseen cost. This is very common when it comes to 
study costs well in advance of actually starting the project. In order to minimise this, the 
study has already included 20% extra costs in order to have enough margin for such 
expenses.  
Finally, as this is a cutting edge innovative company, it is always of a worry for entrepreneur 
to lose his experienced staff. This could happen either when another company hunted them 
in better positions, or staff can find it possible to spin off again to found their own company. 
This problem can always be accommodated with strong leadership. When the experienced 
staff are engaged enough in the project, i.e. have shares in the company and feeling the 
businesses as it their own, then they won’t think of fleeing.   
6.11   Conclusion 
In conclusion,  this chapter has demonstrated a plan for a spin off business based on the 
antimicrobial peptide technology. As the idea has a lower risk comparing with developing 
drugs and promises a stable market, investors could find it attractive. Although the 
investment involves research and development, which is considered risky, it actually was 
segmented into parts to minimise this risk. In addition, the business can fit under the 
government’s priorities and concerns which facilitate funds and incentives. Finally, the 
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success in this emerging product will open the doors to many other products using the same 
peptide technology with massive market opportunity across the world. 
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Chapter 7 
Conclusion  
In a conclusion, the work in this thesis has contributed to elucidating membrane attack 
mechanism employed by antimicrobial peptides (AMPs), with the long-term potential to 
address the global challenge of increasing antimicrobial resistance. Much previous work 
was done on characterising and understanding the mechanisms of these natural powerful 
agents. However, we de novo designed new peptides and tested their antimicrobial 
properties and mechanism of actions. The atomic force microscopy (AFM) data in this thesis 
have enabled us to better understand structure-function relationships, with the possibility of 
controlling and changing these structures for optimum antibacterial results. 
In particular, four de novo AMPs have been compared in terms of structure, biological 
activities and the proposed antibacterial mechanisms to kill bacteria. As these peptides were 
meant to kill bacteria via interacting with the bacterial membrane followed by poration or/and 
disruption its intactness, atomic force microscopy (AFM) was a tool to image this process as 
it happens. 
All the methods employed and used in this study were explained in the chapter 2. This 
includes peptides synthesis, sample preparations and AFM operations.   
In chapter 3, two helical peptides were compared to conclude that a change in the amino 
acid cationic residues has led to a change in the membrane disruption mechanism. A 
substitution of six cationic amino acids, lysine (K) to arginine (R), led to a change from 
perpendicular spanning of the helices to form expanding pores within the bacterial 
membrane into, instead, a tilted orientation to form shallower static pores.   
In chapter 4, a de novo triskelion with three arms of antimicrobial β-sheet peptide motifs 
inspired from the breast-milk protein (lactoferrin) was explained. The design was meant to 
co-assemble to form hollow antimicrobial capsules that can act as vehicles for gene delivery 
with bactericidal properties. Time-lapse AFM was used to image the capsules while 
attacking the membrane. The results showed that capsules descended in the membrane 
followed by the disassembly to form static pores on their precise landing positions.  
In chapter 5, another de novo peptides design was explained. Two peptide monomers were 
devised to co-assemble and form antimicrobial hollow capsids inspired by the natural viral 
capsids. One monomer is a triskelion with three arms of helical cationic antimicrobial peptide 
motifs. The other is anionic non-antimicrobial helical peptide designed to interact with the 
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positive one and facilitate the co-assembly. Time-lapse AFM showed that this system 
attacks bacterial membranes and disassemble in a much quicker time-span compared with 
the capsule system explained in chapter 4. The disassembled cationic monomers were 
shown to disrupt the bacterial membrane via expanding pores until a complete removal.  
These AMPs hold a promise to be feasibly transferred towards medical applications. Some 
of these applications were explained in chapter 6 with a complete business plan for 
antimicrobial wound dressings as a potential application of the AMPs studied within the 
framework of this thesis. 
However, medical products including drugs have to go through lengthy and costly regulatory 
investigations to demonstrate their safety and suitability for humans. Although the concept 
of synthetically produced antimicrobial peptides has been sufficiently demonstrated, 
additional work on the same peptides could help to gain further understanding and to 
facilitate the path to medical applications. For example, the methods of AFM imaging can 
be improved to enable imaging the attacking mechanism on live bacteria instead of model 
membranes. In addition, to confirm the non-cytotoxicity probed by the other employed 
techniques, AFM can be used to image mammalian cell membranes as a negative control. 
Furthermore, improving the resolution of imaging and sample preparations could enable 
resolving the fine details of the assembly for the capsules and capsids explained in chapter 
4&5 respectively. 
Yet, these demonstrated in vitro experiments as a proof of concept are only the first step for 
moving towards commercial application. Further in vivo validation would involve testing the 
AMPs on animals, followed by extensive clinical testing on human volunteers to demonstrate 
the safety and efficacy to the regularity bodies.  
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Appendices  
Appendix 1—Amino Acids 
 
  
Amino acids structures prepared by Dan Cojocari working at Princess Margaret Cancer 
Centre, University of Toronto. Source: Wikipedia. 
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Appendix 2—Risk Register 
Risk Area Risk Description Likelihood Impact Risk 
Score 
Mitigation Strategies 
Manufacturing  Manufacturing bottleneck leads to 
short distribution capacity. 
L H L  Expanding the company if the 
manufacturing model was successful. 
 Out-source from more than one 
company  
Manufacturing Dependence on quality control of 
suppliers could end up with low 
quality products. 
L H L 
 
 Dealing only with trusted companies 
which perform GMP. 
 Safety and quality control checks 
before accepting materials into the 
production line 
Manufacturing/ 
Market 
Staff may be poached by 
competitors  
M H M  Pay bonuses based on performance. 
 Include perks such as providing health 
insurance. 
 Have back-up trained staffs for critical 
roles 
Manufacturing/ 
Market 
Staff may leave to pursue 
different/competing projects 
M H H  Provide staff with company shares. 
 Implement strong contracts with 
confidentiality agreements. 
Market Advances in other wound 
treatment therapy 
L M L  The key challenge is the bacterial 
resistance which is not likely to be 
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overcome easily with other therapy in 
a period of 5 years. 
Regulatory Regulatory issues (Clinical phase 2 
and on-going FDA check during the 
manufacturing) 
H H H  Have an experienced QC team and 
Chief medical officer to mitigate 
problems and ensure maintaining 
high standards. 
 Follow all guidelines established by 
regulatory agencies. 
 Collaborate with consultant 
companies. 
Finance Unforeseen cost H M H  Allocate a budget in business plan for 
unforeseen costs. 
 
Finance Insufficient funding M H M  Adjust the size of spinning company. 
 Make a thorough business and 
economy plan. 
 Get multiple funding cooperation. 
Finance Misuse of available cash 
 
H M M  Filing documents of other quotes for 
all purchases. 
 Hiring experienced financial team and 
accountants. 
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